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ABBREVIATIONS 
 
ABC    ATP-binding cassette 
BBM    brush-border membrane 
BCRP/ABCG2*  breast cancer resistance protein  
BLM    basolateral membrane 
BSA    bovine serum albumin 
CAR    constitutive androstane receptor 
calcein-AM   calcein-acetoxymethylester 
cAMP/cGMP  cyclicAMP/cyclicGMP 
CDNB   chlorodinitrobenzene 
DMEM   Dulbecco’s Modified Eagle’s Medium 
dsRNA   double-stranded RNA 
EDTA    ethylenediaminetetraacetic acid 
EHBR    Eisai hyperbilirubinemic rat (Mrp2-deficient rat) 
ET    endothelin 
EYFP    enhanced yellow fluorescent protein 
FL-MTX   fluorescein methotrexate 
FXR    farnesoid xenobiotic receptor 
GERP    immortalized rat proximal tubule cell line 
GFP    green fluorescent protein 
GR    glucocorticoid receptor 
GS-B    glutathione-S-bimane 
GS-DNP   S-(2,4-dinitrophenyl)glutathione  
GSH    glutathione 
GY  Groningen yellow Wistar rat (Mrp2-deficient rat) 
HBSS    Hanks’ balanced salt solution 
IEC-6    intestinal epithelial cell line derived from rat 
IL    interleukin 
L-NMMA   NG-methyl-L-arginine 
LPS    lipopolysaccharide 
LTC4    leukotriene C4 
MCB    monochlorobimane 
MDR1/Pgp/ABCB1* multidrug resistance 1/P-glycoprotein 
MRP/ABCC*  multidrug resistance protein 
NEM-GS   N-ethylmaleimide glutathione  
NO    nitric oxide 
NOS    nitric oxide synthase 
Abbreviations 9
NRK-52E   normal rat kidney epithelial cell line 
ODN    oligodeoxynucleotide 
OAT    organic anion transporter 
OATP   organic anion-transporting polypeptide 
OCT    organic cation transporter 
PAH    p-aminohippurate 
PGE1    prostaglandin E1 
PBS    phosphate-buffered saline 
PKC    protein kinase C 
PPARα   peroxisome proliferator activated receptor α 
PSC-833   valspodar 
PXR    pregnane xenobiotic receptor 
qRT-PCR quantitative reverse transcriptase-polymerase chain 
reaction 
RU-486   mifepristone 
RXR    retinoid xenobiotic receptor  
siRNA   short interfering RNA 
SLC    solute carrier 
TBS-T   Tris-buffered saline supplemented with Tween-20 
TNFα    tumor necrosis factor α 
TR-    transport deficient Wistar rat (Mrp2-deficient rat) 
Tris    tris(hydroxymethyl)-aminomethane 
TRITC   tetramethyl rhodamine isothiocyanate 
VSV-G protein  vesicular stomatitis virus G protein 
WH    Wistar Hannover 
 
*: for non-human variants only the first letter is capitalized 
 10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
hapter 1
General introduction
Chapter 1 12
GENERAL INTRODUCTION 
 
Endothelins (ETs) belong to a family of 21-amino acid peptides with potent 
vasoconstrictive properties. The ET-1 isoform was discovered in 1988, followed by 
the identification of two additional ET-peptides, ET-2 and ET-3 (Inoue et al., 1989; 
Yanagisawa et al., 1988). Nevertheless, ET-1 seems to be responsible for the 
overwhelming portion of actions. ETs are produced from their biologically inactive 
precursors (prepro-ET), which are enzymatically cleaved into their intermediates 
(big-ET or pro-ET), and finally converted by the ET converting enzyme into 
mature, biologically active peptides. ETs interact with two molecularly and 
pharmacologically distinct receptors; the ET-A and ET-B receptor. The first 
receptor displays a preferential affinity for ET-1 and ET-2 over ET-3, while the 
latter exhibits an equal affinity for all three isoforms (Arai et al., 1990; Lin et al., 
1991; Sakurai et al., 1990).  
In mammalian kidney, ET-1 is, in addition to the endothelium, produced by all 
tubular segments of the nephron (Moridaira et al., 2003). Here, it can exert its 
actions by binding to the ET-A receptor, which is mainly present in the vascular 
system and glomeruli, or the ET-B receptor, primarily expressed in the inner 
medullary collecting ducts, glomeruli, and to a lesser extent in the proximal tubules 
(Hori et al., 1992; Terada et al., 1992; Yamamoto et al., 1998). The ET-1 peptide is 
an important regulator of kidney functioning by controlling renal blood flow, 
glomerular hemodynamics, and sodium and water homeostasis. Additionally, ET-1 
plays a role in several renal disorders, including radiocontrast agent-induced 
nephropathy, transplant rejection, and acute and chronic renal failure (Kohan, 
1997; Naicker et al., 2001).  
Previously, our group discovered a novel function for ET-1, namely the 
regulation of ATP-driven drug transport in the renal proximal tubule (Masereeuw 
et al., 2000). In this segment of the nephron, multiple plasma membrane 
transporters excrete a wide variety of potentially toxic xenobiotics, xenobiotic 
metabolites, and metabolic waste products from blood to urine. Among the 
proteins implicated in this process are the multidrug resistance protein 2 
(MRP2/ABCC2) and the multidrug resistance 1/P-glycoprotein 
(MDR1/Pgp/ABCB1). Both transporters are members of the ATP-binding cassette 
superfamily of membrane transporters and are expressed in the luminal membrane 
of proximal tubule cells (Schaub et al., 1997; Thiebaut et al., 1987). In general, 
MRP2 transports anionic compounds into the urine, whereas Pgp handles 
uncharged and cationic compounds.  
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In killifish proximal tubules, ET-1 was shown to regulate the transport activity 
of Mrp2 and Pgp. Exposure to ET-1 rapidly (within 30 min) reduced cell-to-tubular 
lumen transport of fluorescent Mrp2 and Pgp substrates, while tubular uptake was 
not affected (Masereeuw et al., 2000). Signaling took place by binding of ET-1 to 
the ET-B receptor, subsequent production of nitric oxide (NO) by NO synthase, 
cyclicGMP release by soluble guanylyl cyclase, and activation of protein kinase C, 
finally leading to an inhibition of transport activity (Masereeuw et al., 2000; 
Notenboom et al., 2002; Notenboom et al., 2004). Exposure to nephrotoxic agents, 
including heavy metal salts, aminoglycoside antibiotics, and radiocontrast agents, 
triggered ET-1 release in a calcium-dependent manner, causing a similar sequence 
of events (Terlouw et al., 2001; Terlouw et al., 2002). In contrast, a 24 hour 
exposure or 30 min exposure followed by a 24 hour recovery period induced 
transport activity (Notenboom et al., 2005; Terlouw et al., 2002).  
The induction of renal ET-1 synthesis and rapid inhibition of ATP-driven drug 
excretion observed after exposure to nephrotoxic agents is in support of a role for 
ET-1 in the progression of renal injury. By rapidly inhibiting transport activity, 
potentially toxic compounds may accumulate in the renal proximal tubule and 
cause injury. Therefore, we hypothesized that inhibition of ET-1 production after a 
toxic insult in renal proximal tubules may protect against drug-induced injury. The 
aim of this thesis was to develop in vitro and in vivo models in which this 
hypothesis could be tested. ET-1 production can be inhibited using antisense 
oligodeoxynucleotides (ODNs) or short interfering RNA (siRNA). Both techniques 
have advantages over the use of a classical pharmacological approach by using ET-
receptor antagonists. In particular the kidney proximal tubule provides a unique 
site for directed gene silencing to prevent ET-1 signaling and injury. In vivo studies 
showed that systemically administered antisense ODNs spontaneously accumulate 
in renal proximal tubule cells at concentrations much higher than in other organs 
(Bijsterbosch et al., 1997; Carome et al., 1997; Oberbauer et al., 1995). Uptake in 
proximal tubule cells takes place through endocytosis via the brush-border 
membrane after glomerular filtration, as well as via scavenger receptors on both 
sites of the proximal tubule cells (Rappaport et al., 1995; Sawai et al., 1996).  
During the course of this project, siRNA became available for mammalian cells 
(Elbashir et al., 2001). Although the in vivo behavior of this novel method is still 
largely unexplored, siRNA has many advantages over the use of antisense ODNs. 
Duplexes of siRNA seem to be more stable against degradation and more potent 
and specific in silencing gene expression (Bertrand et al., 2002; Grunweller et al., 
2003). Furthermore, DNA vectors expressing siRNA are available, enabling stable 
transfection and induction or repression of siRNA expression (Brummelkamp et al., 
2002). Figure 1.1 summarizes the proposed mechanism by which gene silencing 
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could prevent ET-1 release upon nephrotoxicant exposure. In accordance with 
antisense ODNs, we speculate that siRNA duplexes accumulate in proximal tubule 
cells after intravenous administration. Within the tubular cell, antisense ODNs or 
siRNA duplexes may inhibit prepro-ET-1 and, subsequently, ET-1 generation by 
preventing protein translation. The ET-1 signaling cascade (presented in a 
simplified way in figure 1.1) will not be activated, and inhibition of MRP2- and 
Pgp-mediated transport may be prevented. An advantage of this approach over the 
use of ET-receptor antagonists is that fewer side effects, like vasoconstriction as a 
result of excessive ET-1 production, are to be expected.  
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Figure 1.1 
Proposed mechanism of an antisense or siRNA treatment against ET-1 production. After intravenous 
administration and glomerular filtration, antisense ODNs or siRNA duplexes will accumulate in renal proximal 
tubule cells through endocytosis. Within the cells, they inhibit prepro-ET-1 and, subsequently, ET-1 production 
by preventing protein translation. The ET-1 signaling cascade, here presented in a simplified way, will not be 
activated, and an inhibition of MRP2- and Pgp-mediated transport by ET-1 signaling after nephrotoxicant 
exposure is prevented. In addition, vascular side effects, like vasoconstriction, are circumvented by using this 
approach. Adapted from Terlouw et al. (2001).  
 
 
AIM AND OUTLINE OF THIS THESIS 
 
The aim of this thesis was to develop in vitro and in vivo models, in which the 
hypothesis could be tested, that inhibition of ET-1 production after a toxic insult in 
renal proximal tubules may protect against drug-induced injury. For this purpose, 
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different aspects regarding ET-1 expression and excretion, transport activity, 
regulation of drug transport, and gene silencing by antisense and siRNA in diverse 
experimental models are addressed in this thesis. Rat cell lines, isolated killifish 
proximal tubules, and an in vivo rat model were used as experimental models.  
In chapter 2, an overview of the current knowledge on the function and 
regulation of the expression and transport activity of MRP/ABCC transporters in 
the renal elimination of organic anions is given. Chapter 3 describes the 
characterization of two renal and one intestinal rat epithelial cell line used for 
investigating ET-1 and ET-receptor expression, as well as the inducibility of ET-1 
expression and excretion by inflammatory cytokines. The cell lines express ET-1 
and its receptors, and two cell lines excrete measurable amounts of ET-1. Excretion 
of ET-1 is induced after exposure to tumor necrosis factor α and interleukin-1β. In 
chapter 4, a first attempt to silence ET-1 expression in vitro is given. Several gene 
silencing approaches, using antisense or siRNA expressing vectors, and different 
transfection methods were tested for their effects on ET-1 excretion. This chapter 
shows the complexity of silencing ET-1 expression in vitro and discusses the 
different factors that are important for successful gene silencing. Chapter 5 
addresses the characterization of drug transporter expression and activity in the 
three rat epithelial cell lines. The cell lines investigated show Pgp and Mrp 
expression and transport activity. In chapter 6, we describe the regulation of renal 
Mrp2 in killifish proximal tubules by dexamethasone. Under the conditions tested, 
Mrp2 expression and transport activity is most likely regulated by signaling via the 
glucocorticoid receptor, rather than through the nuclear pregnane xenobiotic 
receptor or farnesoid xenobiotic receptor. Chapter 7 describes the, till recently 
unexplored, effects of siRNA duplexes in vivo. Biodistribution studies show an 
accumulation of siRNA in kidney after intravenous injection, where it specifically 
silences gene function in the proximal tubule. The thesis is concluded with a 
general discussion and a summary in chapter 8 and 9, respectively.  
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ABSTRACT 
 
The reabsorptive and excretory capacity of the kidney has an important 
influence on the systemic concentration of drugs. Multidrug resistance proteins 
(MRP/ABCC) expressed in the kidney play a critical role in the tubular efflux of a 
wide variety of drugs and toxicants, and, in particular, of their negatively charged 
phase II metabolites. Nine structurally and functionally related MRP family 
members have been identified (MRP1-9), which differ from each other by their 
localization, expression levels, and substrate specificity. During altered 
physiological circumstances, adaptations in these transporters are required to avoid 
systemic toxicity as well as renal tubular damage. Key players in these events are 
hormones, protein kinases, nuclear receptors, and disease conditions, which all 
may affect transporter protein expression levels. This review discusses the current 
knowledge on the renal characteristics of MRP1-9, with specific focus on their 
regulation.  
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INTRODUCTION 
 
Once administered, drugs are absorbed, distributed, and often metabolized 
before they are excreted. The liver is a main site of metabolism, and from there, 
drugs can be excreted into bile or transported back into the systemic circulation to 
be eliminated by the kidney, unaltered or as metabolites. Concerning renal drug 
clearance, an interplay of secretory and reabsorptive processes in the tubular 
system in addition to glomerular filtration determine overall urinary excretion. 
The proximal tubule of the kidney is the predominant site of carrier-mediated 
excretion, in which several primary, secondary, and tertiary active transporters are 
involved. Roughly two excretory mechanisms exist: one for anionic compounds 
and a mechanism driving organic cations into urine. Concerning the transport 
mechanisms for organic cations, the reader is referred to excellent recent reviews 
(Koepsell, 2004; Wright et al., 2004). This paper will focus on the organic anion 
drug efflux system, in particular, the multidrug resistance protein (MRP/ABCC) 
family.  
 
 
RENAL ANIONIC DRUG HANDLING 
 
The interaction with the renal organic anion efflux system determines the 
effectivity and toxicity of many clinically important drugs. Examples include 
antibiotics, chemotherapeutics, diuretics, nonsteroidal anti-inflammatory drugs 
(NSAIDs), angiotensin-converting enzyme inhibitors, radiocontrast agents, 
cytostatics, drug metabolites (especially glutathione, glucuronide, glycine, sulfate, 
and acetate conjugates), but also toxicants and their metabolites, like mycotoxins, 
herbicides, plasticizers, glutathione S-conjugates of polyhaloalkanes, 
hydroquinones, and aminophenols. The proximal tubule is often a target for 
toxicity, because of its rich transport function and concentrative capacity. Efficient 
tubular efflux mechanisms are, therefore, crucial for the kidney to protect itself 
against toxic injury.  
Anionic drugs are translocated mostly by ‘polyspecific’ transporters, i.e., 
transport proteins that accept anionic compounds of different sizes and molecular 
structures. Two large transporter families are involved in renal anionic drug 
transport: the solute carrier family (SLC), and the ATP-binding cassette (ABC) 
superfamily, including the MRPs. Knowledge of the molecular identity of these 
transporters has increased considerably the past few years (Hediger et al., 2004; 
Mizuno et al., 2003; Russel et al., 2002; Schinkel et al., 2003; Wright et al., 2004), 
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and observations on their presence in proximal tubules and membrane localization 
has led to the depicted model of renal anionic drug transport (figure 2.1).  
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Figure 2.1 
Organic anion transporters expressed in human proximal tubules. Uptake of anionic drugs (OA-) into 
proximal tubular cells occurs both from the basolateral and the apical side against a steep electrochemical 
gradient, and is mediated by members of the multispecific organic anion transporter family (OAT1/3/4; 
SLC22A6/8/9) in exchange with dicarboxylates (mostly α-ketoglutarate; α-KG2-), the peptide carriers PEPT1 
(SLC15A1) and PEPT2 (SLC15A2), or the organic anion transporting polypeptide, OATP-H (SLCO4C1). 
Organic anion-transporting polypeptides implicated in anionic drug efflux are expressed at the luminal 
membrane and include NPT1 (SLC17A1) and URAT1 (SLC22A12). Multidrug resistance proteins are all efflux 
carriers and are localized to either the basolateral membrane (MRP6; ABCC6) or apical membrane (MRP2/4; 
ABCC2/4). Intracellularly, OA-s may accumulate in mitochondria and in, not yet further identified, vesicles.  
 
 
Transporters of the SLC family are exchangers or cotransporters for which 
substrate transport is driven by gradients of endogenous (organic) ions across the 
basolateral and apical membrane. Although by nature bidirectional, the direction 
of the transmembrane driving gradients favors tubular uptake rather than efflux of 
organic anions. ABC transporters are primarily active and ATP-hydrolysis directly 
drives substrate efflux. These transporters have been intensively studied over the 
past decades as potential mediators of multidrug resistance, with P-glycoprotein 
(MDR1/ABCB1) as the first discovered and prototypic example. Overexpression of 
members of the MRP/ABCC family and breast cancer resistance protein 
(BCRP/ABCG2) has also been implicated in multidrug resistance, but there is 
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ample evidence suggesting an important role for ABC transporters in physiology, 
pharmacology, and toxicology. Of these transporters, members of the ABCC and 
ABCG families function in the efflux of anionic drugs (Schinkel et al., 2003). 
Concerning the ABCG family, member 2 (ABCG2 or BCRP) mediates the efflux of 
anionic chemotherapeutic drugs (Schinkel et al., 2003). Hence, its expression in 
human kidney is very low, in contrast to renal tubular expression levels in mice, 
therefore, in human, its role in renal drug efflux seems minor (Doyle et al., 2003). 
Members of the ABCC subfamily have a more important role in renal drug efflux. 
Twelve members of this ABCC subfamily have been identified, of which nine are 
multidrug resistance proteins (MRPs) (table 2.1). This review focuses on the role 
that these MRPs play in renal anionic drug efflux, with a special reference to their 
regulation.  
 
 
Table 2.1 
Transporters of the ABCC family involved in renal drug efflux in humans 
 
Gene symbol Gene product Chromosome 
localization 
Nephron 
distribution 
Membrane 
localization 
ABCC1 MRP1 16p13.1 CCD BLM 
ABCC2 MRP2 10q24 PT BBM 
ABCC3 MRP3 17q21.3 DT BLM 
ABCC4 MRP4 13q32 PT BBM 
ABCC5 MRP5 3q27 ? BLM 
ABCC6 MRP6 16p13.1 PT BLM 
ABCC10 MRP7 6p21 ? ? 
ABCC11 MRP8 16q12.1 ? ? 
ABCC12 MRP9 16q12 ? ? 
Abbreviations: BBM: brush-border membrane; BLM: basolateral membrane; CCD: cortical collecting duct; DT: distal 
tubule; PT: proximal tubule.  
 
 
MULTIDRUG RESISTANCE PROTEINS 
 
The MRPs are associated with the efflux of a broad range of anionic compounds, 
and nine structurally and functionally related family members have been 
identified. However, they differ from each other by their localization, expression 
levels, and substrate specificity (Kruh et al., 2003). Current knowledge on nephron 
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distribution and membrane localization of MRP expression in human kidney is 
given in figure 2.2.  
 
PT
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CD
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Figure 2.2 
Nephron distribution and membrane 
localization of human multidrug resistance 
proteins. The human kidney contains 
approximately one million functional units, called 
nephrons. Multidrug resistance proteins (MRPs) 
are distributed along this functional unit. PT: 
proximal tubule, TAL: thick ascending loop of 
Henle, DT: distal tubule, CD: collecting duct.  
 
 
 
 
MRP1 (ABCC1) 
 
MRP1 was originally identified in a lung cancer cell line (Cole et al., 1992), but 
it is also expressed in many tissues with a detoxification function, like epithelial 
cells of the kidney, lung, intestine, brain, testis, heart muscle cells, and 
macrophages and, in lower levels, liver cells (Cherrington et al., 2002; Flens et al., 
1996; Peng et al., 1999; Wijnholds et al., 1998). In the kidney, expression of MRP1 
is localized to the basolateral membranes of cells lining the limb of Henle, and the 
distal and collecting duct tubule cells, but not in proximal tubule cells (Peng et al., 
1999; Wijnholds et al., 1998). MRP1 mediates the transport of oxidized 
glutathione, different glutathione conjugates, glucuronide conjugates, and bile salt 
conjugates (Jedlitschky et al., 1996; Jedlitschky et al., 1997; Leier et al., 1994; Leier 
et al., 1996; Loe et al., 1996a; Muller et al., 1994). Besides these conjugates, MRP1 
transports unconjugated anionic compounds, like vincristine and aflatoxin B1 
together with glutathione (GSH) (Loe et al., 1996b; Loe et al., 1997). Because a 
number of compounds need to be conjugated to become a substrate of MRP1 and 
some unconjugated substrates are transported together with glutathione, enzymes 
involved in glutathione production and conjugation reactions may act 
synergistically with MRP1 to drive effective drug excretion. For example, the 
expressions of MRP1 and γ-glutamylcysteine synthetase, an enzyme that catalyzes 
the rate-limiting step in glutathione synthesis, were co-induced by different toxic 
compounds, thereby enabling the effective elimination of these compounds 
(Ishikawa et al., 1996).  
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The expression pattern of MRP1 in the kidney and its transport capacity suggest 
that MRP1 functions to protect the distal parts of the nephron from toxic drug 
accumulation, which may occur together with water reabsorption. This function 
for MRP1 was strengthened by the finding that Mrp1-deficient mice after exposure 
to etoposide developed polyuria and acquired nephrogenic diabetes insipidus 
(Wijnholds et al., 1998). It was proposed that Mrp1 deficiency in the urinary 
collecting duct results in cell damage or changes in the presence or function of the 
vasopressin receptors in the basolateral membrane of the collecting duct. This may 
lead to a reduced responsiveness to vasopressin and diminished water reabsorption.  
 
 
MRP2 (ABCC2) 
 
MRP2 was cloned from rat liver, as the canalicular multispecific organic anion 
transporter (cMOAT) (Paulusma et al., 1996), and rabbit kidney (van Kuijck et al., 
1996). Besides its expression in liver hepatocytes and renal proximal tubule cells, 
MRP2 is expressed in the enterocytes of the intestine, and in all these epithelial 
cell layers, the transport protein is expressed at the apical membrane (Buchler et 
al., 1996; Mottino et al., 2000; Paulusma et al., 1996; Schaub et al., 1999; van Aubel 
et al., 2000a). MRP2 functions as a transporter of a broad range of organic anionic 
substrates and has been studied extensively. A defect in MRP2 was found in 
patients with the Dubin-Johnson syndrome and in two different rat strains, the 
Eisai hyperbilirubinemic Sprague-Dawley rat (EHBR) and the Groningen 
yellow/transport deficient Wistar rat GY/TR- rat (Buchler et al., 1996; Ito et al., 
1997; Kartenbeck et al., 1996; Paulusma et al., 1996; Paulusma et al., 1997). These 
patients and rat strains exhibit an impaired canalicular secretion of glutathione, 
glutathione conjugates, and bilirubin glucuronides, indicating that MRP2 functions 
in the secretion of these conjugates. In addition, the renal efflux of some bulky 
MRP2 substrates (MW>600 kD) was impaired in GY/TR- rat as well (Masereeuw et 
al., 2003). In consistence with a high amino-acid homology, the substrate 
specificity of MRP2 shows considerable overlap with that of MRP1 and MRP3. The 
transporter was found to mediate the efflux of glutathione conjugates like 
leukotriene C4 (LTC4), S-(2,4-dinitrophenyl)glutathione (GS-DNP), and N-
ethylmaleimide glutathione (NEM-GS), as well as glutathione (Bakos et al., 2000; 
Elferink et al., 1989; Madon et al., 1997; Paulusma et al., 1999). In addition, 
glucuronide conjugates are transported by MRP2 (Jedlitschky et al., 1997; 
Morikawa et al., 2000; van Aubel et al., 1998). Different phase II conjugating 
enzymes, UDP-glucuronosyltransferase and glutathione S-transferase, show a 
similar distribution with MRP2 (Catania et al., 2004), suggesting that metabolism 
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and the subsequent efflux of organic anion conjugates act coordinately. Besides 
conjugated drugs, MRP2 is involved in the excretion of sulfated bile salts (Akita et 
al., 2001), nonconjugated compounds (Bakos et al., 2000; Evers et al., 1998; van 
Aubel et al., 1998), and cytotoxic agents, including etoposide, vinblastine, cisplatin, 
doxorubicin, and epirubicin (Cui et al., 1999; Kawabe et al., 1999; Koike et al., 
1997; van Aubel et al., 1999). A number of these drugs, especially of cationic 
nature, are only translocated by MRP2 in presence of, or in cotransport with, 
reduced glutathione.  
Transport studies in proximal tubules of a teleost fish (killifish; Fundulus 
Heteroclitus) led to the identification of the antiviral, acyclic nucleoside 
phosphonates adefovir and cidofovir (Miller, 2001), and the HIV protease 
inhibitors saquinavir and ritonavir as potential substrates of MRP2 (Gutmann et al., 
1999). Also, fluorescein methotrexate (FL-MTX) was identified as an Mrp2 
substrate in killifish (Masereeuw et al., 1996). In addition, studies in MRP2-
transfected Sf9 vesicles showed that this compound is transported by both the 
rabbit (Terlouw et al., 2002) and human (Smeets et al., unpublished data) isoform. 
Furthermore, findings by our group and others showed that p-aminohippurate 
(PAH), the classic substrate for the characterization of organic anion transport in 
renal proximal tubules, is a low affinity substrate for MRP2 (Leier et al., 2000; van 
Aubel et al., 2000b). However, in isolated perfused kidneys from wild-type and 
Mrp2-deficient (GY/TR-) rats, renal PAH excretion was not significantly different. 
The high expression levels and affinity of PAH for MRP4 suggest that this 
transporter may compensate for an impaired MRP2 function (Smeets et al., 2004). 
Comparable results were found for the MPR2 substrates lucifer yellow and 
glutathione-S-bimane (Masereeuw et al., 2003; Terlouw et al., 2001b; van de Water 
et al., 2004).  
 
 
MRP3 (ABCC3) 
 
Of the different human MRPs, MRP3 is with an amino acid identity of 58% 
most closely related to MRP1 (Konig et al., 1999b). MRP3 has been identified in 
liver, gall bladder, small intestine, colon, pancreas, adrenal gland, and kidney 
(Kiuchi et al., 1998; Konig et al., 1999b; Kool et al., 1997; Scheffer et al., 2002b). 
Like MRP1, MRP3 is localized to the basolateral membrane of epithelial cells and 
transports a broad range of compounds from the cell into the blood (Konig et al., 
1999b; Kool et al., 1999b; Rost et al., 2002; Scheffer et al., 2002b). In human 
kidney, MRP3 is expressed in the basolateral membranes of the distal convoluted 
tubule and, possibly, the thick ascending loop of Henle (Scheffer et al., 2002b). In 
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rat kidney, Mrp3 was also found to be expressed in basolateral membrane of 
proximal tubule cells (Kuroda et al., 2004).  
Substrates are, among others, a wide range of bile salts (Hirohashi et al., 2000; 
Zeng et al., 2000), glutathione conjugates, glucuronides, and methotrexate, 
although with a lower affinity (Hirohashi et al., 1999; Kool et al., 1999b; Zelcer et 
al., 2001; Zeng et al., 2000). In patients with the Dubin-Johnson syndrome, who 
are deficient in MRP2, MRP3 is expressed at higher levels (Konig et al., 1999b). In 
addition, Mrp3 expression is upregulated in the kidney and liver of Mrp2-deficient 
EHBR rats (Kuroda et al., 2004). This suggests that upregulation of Mrp3 expression 
may function as a compensatory mechanism to reduce injury to hepatocytes from 
cytotoxic materials that accumulate in Mrp2 deficiency. 
 
 
MRP4 (ABCC4) 
 
MRP4 represents the shortest family member and is expressed in several tissues 
with high expression levels in kidney and prostate, while the expression levels of 
MRP4 in liver are low (Chen et al., 2004; Lee et al., 1998). In the tubuloacinar cells 
of the prostate and in hepatocytes of the liver, MRP4 is localized to the basolateral 
membrane (Denk et al., 2004; Lee et al., 2000; Rius et al., 2003). In contrast, MRP4 
is expressed at the apical membrane of renal proximal tubule cells (Denk et al., 
2004; van Aubel et al., 2002). MRP4 appears to be involved in the efflux of cyclic 
nucleotides and nucleoside analogs. Different groups showed that MRP4 is capable 
of transporting the cyclic nucleotides cyclic GMP (cGMP) and cyclic AMP (cAMP) 
(Chen et al., 2001; Lai et al., 2002; van Aubel et al., 2002; Wielinga et al., 2003). 
Furthermore, MRP4 supports the efflux of the nucleoside analogs 9-(2-
phosphonylmethoxyethyl)adenine (PMEA), 6-thioguanine, 6-mercaptopurine, and 
azidothymidine monophosphate (Chen et al., 2001; Lai et al., 2002; Reid et al., 
2003a; Schuetz et al., 1999). Overexpression of MRP4 severely impairs the antiviral 
or chemotherapeutic efficacy of these nucleoside analogs.  
Besides the cyclic nucleotides and nucleoside analogs, more substrates of MRP4 
were identified. MRP4 was also found to transport methotrexate, folates, and 
prostaglandins (Chen et al., 2002; Reid et al., 2003b; van Aubel et al., 2002). Also, 
several anionic conjugates like GS-DNP and estradiol-17β-D-glucuronide were 
identified as substrates for MRP4 (Bai et al., 2004; Chen et al., 2001; van Aubel et 
al., 2002). The transport of estradiol-17β-D-glucuronide was inhibited by bile salts, 
especially by sulfated derivatives and by cholestatic estrogens. Inhibition by 
estradiol 3,17-disulphate and taurocholate 3-sulphate was competitive, suggesting 
that MRP4 functions in the transport of bile salts (Zelcer et al., 2003). Monoanionic 
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bile salts are cotransported with GSH by MRP4, whereas transport was negligible 
in absence of GSH (Rius et al., 2003). The basolateral localization of MRP4 in 
hepatocytes and apical localization in proximal tubule cells of the kidney is 
compatible with a role as an alternative elimination pathway under conditions of 
impaired canalicular bile salt excretion.  
Recent findings from our group added two important renal organic anions to the 
growing list of MRP4 substrates, viz. urate and p-aminohippurate. In HEK293 cells 
overexpressing MRP4, it was shown that MRP4 mediates the efflux of urate, the 
end product of human purine metabolism. ATP-dependent uptake of urate in 
MRP4 enriched membrane vesicles occurred via a positive cooperative mechanism, 
and a complex allosteric interaction pattern was observed with methotrexate, 
cAMP, and cGMP. MRP4 may be a candidate transporter for urinary urate 
excretion and may also mediate hepatic export of urate into the circulation, 
because of its basolateral expression in the liver (van Aubel et al., 2005). 
Furthermore, MRP4 was identified as a novel PAH transporter that has higher 
affinity for PAH and is expressed more highly in human kidney than MRP2 and 
may, therefore, be more important in renal PAH efflux (Smeets et al., 2004).  
 
 
MRP5 (ABCC5) 
 
The human MRP5 gene is most closely related to MRP4. The MRP5 protein is 
ubiquitously expressed (Kool et al., 1997), and, in polarized epithelial cells, it is 
routed to the basolateral membrane (Wijnholds et al., 2000). To date, nothing is 
known about the expression levels of MRP5 along the nephron. One important 
function of MRP5, together with MRP4, is the cellular export of cyclic nucleotides 
(Jedlitschky et al., 2000). Classical inhibitors of organic anion transport, as well as 
prostaglandin A(1) and progesterone inhibited this cyclic nucleotide efflux 
(Wielinga et al., 2003). By transporting cyclic nucleotides, MRP5 and MRP4 may, 
in addition to degradation by phosphodiesterases, represent an important 
elimination pathway for these signaling molecules. In addition to these cyclic 
nucleotides, some base and nucleoside analogs used in chemotherapy of cancer and 
viral infections and several other anionic compounds are substrates for MRP5 (Reid 
et al., 2003a; Wijnholds et al., 2000) (table 2.2). Furthermore, MRP5 transfected 
cells were resistant to thiopurine anticancer drugs (Wielinga et al., 2002; 
Wijnholds et al., 2000).  
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Table 2.2  
Substrate specificity of human multidrug resistance transporters 
 
Name Substrates Inhibitors References 
    
MRP1 LTC4;  E217ßG; GS-DNP; bilirubin-
glucuronide; GSSG; AFB1-SG; PGA1-
SG; PGA2-SG ; etoposide-glucuronide; 
S-(ethacrynic acid)-glutathione; GSH; 
PAH ; MTX ; NEM-GS; daunorubicin 
Probenecid; MK571; cyclosporin 
A; PSC833; S-(decyl)-
glutathione; sulfinpyrazone; V-
104; indomethacin 
(Bakos et al., 2000; 
Evers et al., 2000; 
Konig et al., 1999a; 
Leier et al., 1994) 
MRP2 LTC4; E217ßG; GS-DNP; PGA1-SG; 
bilirubin-glucuronide; S-(ethacrynic 
acid)-glutathione; GSH; MTX; PAH; 
ochratoxin A; NEM-GS; vinblastine 
MK571; indomethacin; 
furosemide; benzbromarone; 
probenecid 
(Bakos et al., 2000; 
Evers et al., 1998; 
Evers et al., 2000; 
Konig et al., 1999a; 
Leier et al., 2000) 
MRP3 LTC4; GS-DNP; E217ßG; MTX; 
glycocholate; etoposide; etoposide-
glucuronide 
 (Kool et al., 1999b; 
Zelcer et al., 2001; 
Zeng et al., 2000) 
MRP4 PMEA; PMEG; AZTMP; MTX; E217ßG; 
cAMP; cGMP; 6-thioguanine; 6-MP; 
folic acid; N(5)-formyltetrahydrofolic 
acid; DHEAS; GS-B; GSH; S-methyl-
glutathione; cholyltaurine; cholylglycine; 
cholate; prostaglandins; urate; PAH; 
ADP 
Probenecid; α-naphthyl-β-D-
glucuronide; p-nitrophenyl-
glucuronide; GS-DNP; NAc-
DNP-Cys; dipyridamole; 
estradiol 3,17-disulphate; 
taurolithocholate 3-sulphate; 
benzbromarone; verapamil; 
indomethacin; CDNB; MK571; 
sulfinpyrazone 
(Bai et al., 2004; Chen et 
al., 2001; Chen et al., 
2002; Jedlitschky et al., 
2004; Reid et al., 
2003b; Rius et al., 
2003; Schuetz et al., 
1999; Smeets et al., 
2004; van Aubel et al., 
2002; van Aubel et al., 
2005; Zelcer et al., 
2003) 
MRP5 GS-DNP; PMEA; 6-MP; cAMP; cGMP; 
GSH; CMFDA; BCECF; FDA; d4TMP; 
alanilyl-d4TMP 
Probenecid; sulfinpyrazone; FDA; 
8-bromo-cGMP; zaprinast; 
trequinsin; sildenafil 
(Jedlitschky et al., 2000; 
McAleer et al., 1999; 
Reid et al., 2003a; 
Wielinga et al., 2002; 
Wijnholds et al., 2000) 
MRP6 LTC4; NEM-GS; GS-DNP, BQ123 Probenecid, benzbromarone, 
indomethacin 
(Belinsky et al., 2002; 
Ilias et al., 2002) 
MRP7 E217ßG; LTC4 Glycolithocholate 3-sulfate; 
MK571; cyclosporine A 
(Chen et al., 2003b) 
MRP8 cAMP;  cGMP; PMEA; 5’-fluoro-2’-
deoxyuridine monophosphate; LTC4; 
GS-DNP; DHEAS; estrone 3-sulfate; 
E217ßG; glycocholate; taurocholate; 
MTX 
 (Chen et al., 2005; Guo 
et al., 2003) 
MRP9 Not determined   
Abbreviations: ADP, adenosine diphosphate; AFB1-SG, S-(aflatoxin B1)-glutathione; (alanilyl)-d4TMP, (alanilyl)-2’,3’-
dideoxynucleoside 2’,3’-didehydro-2’,3’-dideoxythymidine 5’-monophosphate; AZTMP, azidothymidine monophosphate; 
BCECF, 2', 7'-bis-(2-carboxyethyl)-5 (and-6)-carboxyfluorescein acetoxymethyl ester; BQ123, (cyclo [Trp-Asp-Pro-Val-
Leu]); CDNB, 1-chloro-2,4-dinitrobenzene; CMFDA, 5-chloromethylfluorescein; DHEAS, dehydroepiandrosterone-
3sulphate; E217βG, estradiol-17β-D-glucuronide; FDA, fluorescein-diacetate; GS-B, glutathione-S-bimane; GS-DNP, S-
(dinitrophenyl)-glutathione; GSH, reduced glutathione; GSSG, oxidized glutathione; LTC4, leukotriene C4; 6-MP, 6-
mercaptopurine; MTX, methotrexate; NAc-DNP-Cys, N-acetyl 2,4-dinitrophenyl cysteine; NEM-GS, N-ethylmaleimide 
glutathione; PAH, p-amminohippurate; PGA1/2-SG, S-(prostaglandin A1/2)-glutathione; PMEA/PMEG, 
9-(2-phosphonylmethoxyethyl)adenine/-guanine. 
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MRP6 (ABCC6) 
 
MRP6 is notably expressed in liver and kidney and to a lower extent in other 
tissues (Kool et al., 1999a). In murine and human kidney, MRP6 is found in the 
proximal tubule cells and, to a lesser extent, in murine distal tubule cells (Beck et 
al., 2003; Scheffer et al., 2002a). In the kidney proximal tubule as well as in 
MDCKII cells transfected with MRP6, the protein was localized to the basolateral 
plasma membrane (Beck et al., 2003; Scheffer et al., 2002a; Sinko et al., 2003). 
Mutations in the gene are associated with the heditary disease Pseudoxanthoma 
elasticum (PXE), which is a connective tissue disorder characterized by 
calcification of elastic fibres in the skin, arteries, and retina, resulting in skin 
lesions, arterial insufficiency, and visual field loss (Bergen et al., 2000; Le Saux et 
al., 2000; Ringpfeil et al., 2000). To date, the molecular mechanisms by which 
mutations in the MRP6 gene cause the clinical manifestations of PXE are 
unknown.  
A few substrates for MRP6 were identified, including the endothelin receptor 
antagonist BQ-123 (Madon et al., 2000) and the glutathione conjugates LTC4, 
NEM-GS, and GS-DNP (Belinsky et al., 2002; Ilias et al., 2002; Madon et al., 2000). 
The transport of NEM-GS was inhibited by probenecid, benzbromarone, and 
indomethacin (Ilias et al., 2002). Furthermore, MRP6 showed low levels of 
resistance to etoposide, teniposide, doxorubicin, and daunorubicin (Belinsky et al., 
2002). The higher expression levels of MRP6 in kidney and liver might suggest a 
role in detoxification, but apparently only for a limited number of compounds, 
considering the small range of substrates that are transported.  
 
 
MRP7 (ABCC10) 
 
In mice, the Mrp7 transcripts are expressed in various tissues, including liver, 
brain, and kidney. The Mrp7B splice variant is expressed at higher levels in the 
kidney than the Mrp7A variant (Kao et al., 2002). In human, MRP7 transcripts are 
also expressed at low levels in various tissues, with highest expression levels in 
colon, skin, and testis (Hopper et al., 2001). Functional studies showed that MRP7 
may be involved in the cellular extrusion of lipophilic anions (Chen et al., 2003b). 
Furthermore, MRP7 exhibits resistance towards docetaxel and in lower levels 
towards paclitaxel, vincristine, and vinblastine (Hopper-Borge et al., 2004). The 
exact localization in the kidney, as well as its importance in drug efflux need to be 
defined further.  
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MRP8 (ABCC11) 
 
The human MRP8 gene was identified by different groups (Bera et al., 2001; 
Tammur et al., 2001; Yabuuchi et al., 2001). Alternative splice variants of this gene 
exist, and the gene product shows a high similarity to MRP5. It is expressed in 
various tissues, including the liver and kidney (Yabuuchi et al., 2001), although 
others did not find expression in kidney (Tammur et al., 2001). Furthermore, the 
gene is highly expressed in breast cancer cells (Bera et al., 2001). One functional 
study showed that MRP8 is an amphipathic anion transporter that is able to efflux 
cAMP and cGMP and to function as a resistance factor for commonly employed 
purine and pyrimidine nucleotide analogs (Guo et al., 2003). Furthermore, MRP8 
transports glutathione conjugates, steroid sulfates, glucuronides, monoanionic bile 
salts, and methotrexate (Chen et al., 2005). No data are yet available on a role, if 
any, for MRP8 in the kidney. 
 
 
MRP9 (ABCC12) 
 
To date, human and mouse MRP9 were cloned (Shimizu et al., 2003; Tammur et 
al., 2001; Yabuuchi et al., 2001). Different splice variants of the gene were found, 
and the predicted amino acid sequence showed a high similarity with MRP5. In 
human, MRP9 was detected in various tissues. Although Tammur et al. (2001) did 
not find MRP9 gene expression in kidney, others showed its presence in renal 
tissue (Yabuuchi et al., 2001). Furthermore, Bera et al. (2002) showed that one of 
the two major different transcripts of the MRP9 gene is highly expressed in breast 
cancer cells. Studies on the functions of MRP9 have not yet been performed.  
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REGULATION OF MULTIDRUG RESISTANCE PROTEINS 
 
The reabsorptive and excretory capacity of the kidney can influence systemic 
drug concentrations to a great extent. To avoid toxicity and cellular damage, 
adaptations in renal drug transport may be required during altered physiological 
circumstances. The expression levels and functionality of transporters are 
influenced by polymorphisms in the transporter gene, sex differences, and species 
differences, but also physiological and pathological circumstances can regulate 
their expression and activity. This takes place on the level of gene transcription, 
mRNA stability, mRNA translation, or by post-translational control. Key players in 
these events are hormones and drugs, protein kinases, nuclear receptors, and 
disease conditions, subsequently discussed below and summarized in table 2.3.  
 
 
Hormones 
 
Regulation by steroid hormones 
Steroid hormones can have a strong influence on the expression of multidrug 
resistance transporters. For example, treatment of rat liver cells with ethinyl 
estradiol increases the amount of Mrp2 mRNA, which is associated with an 
enhanced Mrp2 promoter activity. However, Mrp2 protein levels decrease, 
probably through a post-transcriptional mechanism (Kauffmann et al., 1998). 
Mottino et al. (2005) showed that estradiol-17β-D-glucuronide induces a marked 
but reversible inhibition of bile flow in the rat, together with an endocytic 
retrieval of Mrp2 from the canalicular membrane to intracellular structures.  
Also, gender differences were described in the membrane transport of 
endogenous and exogenous compounds (Morris et al., 2003). For example, the renal 
organic anion transporting polypeptide (Oatp) mRNA expression is about 20 times 
higher in male than in female rat kidney, which was shown to be under control of 
androgens (Lu et al., 1996). Regarding the MRP transporters, there is only little 
information available on gender differences in transporter expression levels and 
activity. One report showed that Mrp4 is expressed at higher levels in male rat 
kidney than in female (Chen et al., 2004). The circulating hormones may influence 
MRP expression levels via activation of nuclear steroid hormone receptors (see 
Nuclear receptors).  
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Regulation by dexamethasone 
Mrp2 expression was also found to be regulated by the synthetic glucocorticoid, 
dexamethasone. Dexamethasone increased Mrp2 protein expression in rat kidney 
(Demeule et al., 1999) and induced Mrp2 mRNA (Courtois et al., 1999; Kubitz et 
al., 1999a) and protein (Demeule et al., 1999; Kubitz et al., 1999a) expression in the 
liver after long-term exposure. Treatment of sandwich-cultured rat hepatocytes 
with dexamethasone also increased Mrp2 expression, while Mrp3 expression was 
not altered (Turncliff et al., 2004). Analysis of the 5’-flanking region of the Mrp2 
gene showed that this region contains several glucocorticoid–responsive elements 
(Kauffmann et al., 1998). This is in line with the finding that dexamethasone 
regulates Mrp2 expression, possibly via binding to the glucocorticoid receptor, 
although in contrast with others who found an Mrp2 upregulation independent of 
binding of dexamethasone to the glucocorticoid receptor (Courtois et al., 1999), 
possibly explained by activation of the pregnane xenobiotic receptor (PXR, see 
Nuclear receptors) (Kast et al., 2002; Kliewer et al., 1998). Recent experiments by 
us in killifish renal tubules are in line with a role of PXR in the regulation of Mrp2 
expression, which seems to occur independently of dexamethasone binding to the 
glucocorticoid receptor (van de Water et al., unpublished data).  
 
Regulation by endothelin-1 
Using killifish renal proximal tubules, we identified a new signaling pathway for 
Mrp2 through the vasoactive hormone endothelin (ET-1) (figure 2.3). After short-
term exposure (30 min) to ET-1, Mrp2-mediated transport is inhibited by a 
pathway in which ET-1 signaling takes place by binding to the ET-B receptor, 
leading to nitric oxide (NO) production by nitric oxide synthase (NOS), activation 
of guanylyl cyclase, cGMP generation, and protein kinase C (PKC) activation 
(Masereeuw et al., 2000; Notenboom et al., 2002; Notenboom et al., 2004b). The 
signaling pathway is triggered by nephrotoxicants like the radiocontrast agents 
iohexol and diatrizoate, the aminoglycosides gentamicin and amikacin, and the 
heavy metal salts CdCl2 and HgCl2 (Terlouw et al., 2001a). After short-term 
exposure (30 min), Mrp2-mediated transport was reduced, while after long-term 
exposure (6 to 24 hours) to the two heavy metal salts, transport activity and 
immunostaining of Mrp2 at the luminal membrane of the proximal tubule cells 
were increased (Terlouw et al., 2002). These data show that exposure of renal 
proximal tubule cells to heavy metal salts initially reduces Mrp2 function, which is 
followed by an induction in transport activity. Long-term induction of Mrp2 may 
function as a compensatory mechanism for the initially reduced efflux of 
potentially toxic compounds. Long-term induction of Mrp2 also results from short-
term exposure to gentamicin or ET-1. When killifish proximal tubules were 
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exposed for 30 min to gentamicin or ET-1, Mrp2-mediated transport was still 
decreased after 90 min of recovery. However, after 24 hours of recovery, 
expression and transport activity of Mrp2 were increased. This upregulation was 
prevented by inhibitors of the ET-1 signaling pathway, indicating the involvement 
of ET-1 signaling, even in the long-term consequences of exposure to nephrotoxic 
agents (Notenboom et al., 2004a). In contrast, expression of Mrp4 remained 
unchanged.  
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Figure 2.3  
Endothelin signaling pathway in renal proximal tubules. Short-term exposure to nephrotoxic compounds (30 
min) causes an increase in intracellular calcium by opening calcium channels. This stimulates the release of 
endothelin, which activates the basolateral endothelin-B receptor, nitric oxide synthase (NOS), guanylyl cyclase 
(GC), and PKC, finally leading to a reduction in Mrp2-mediated transport. In the long-term (6 to 24 hours), 
exposure to nephrotoxicants or endothelin results in an upregulation of Mrp2, in which at least activation of NOS 
and GC are involved.  
 
 
The long-term effects on Mrp2 in killifish renal tubules were also observed in a 
mammalian cell line, MDCKII, transfected with hMRP2. After 24 hours exposure 
to gentamicin, as well as after 1 hour exposure to gentamicin followed by a 
recovery period of 24 hours, MRP2 protein expression in the apical membrane and 
transport activity were enhanced. However, total MRP2 protein expression was not 
induced, suggesting an effect of gentamicin on the shuttling of MRP2 to the apical 
membrane (Notenboom et al., 2004c). In addition, in humans, high ET-1 levels in 
kidney are associated with several renal disorders, like acute ischemic renal failure 
and nephrotoxicity induced by cylcosporin, cisplatin, and radiocontrast agents 
(Bruzzi et al., 1997; Clavell et al., 1994; Hocher et al., 1997). Furthermore, ET-B 
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receptor expression in proximal tubule cells enables ET-1 binding and subsequent 
signaling. These data indicate that also in humans, gentamicin exposure, followed 
by ET-1 signaling, might have implications for renal MRP2 expression and 
function. In addition, the ET-1 signaling pathway was also described in rat blood-
brain barrier, where expression of the multidrug transporter P-glycoprotein (Mdr1; 
ABCB1) was regulated by endothelin (Hartz et al., 2004), similar to that observed 
earlier in the kidney (Masereeuw et al., 2000).  
 
 
Protein kinases 
 
Cellular responses triggered by hormones are often produced through the 
activation of protein kinases. These enzymes are involved in the phosphorylation 
of specific proteins, which can lead to an activation or inhibition of specific 
proteins or to the activation of the transcription of specific genes. Protein kinases 
were also found to be involved in intracellular signaling leading to the regulation 
of MRPs. Activation of protein kinase C (PKC) was found to down-regulate Mrp2 
in killifish proximal tubules (Masereeuw et al., 2000). Also, in the rat liver, Mrp2-
mediated transport is regulated by PKC, although in an opposite direction 
(Roelofsen et al., 1991). Direct Mrp2 phosphorylation does not seem to have 
functional implications. An indirect regulation of Mrp2 by PKC appears more 
likely, as it was shown that insertion of Mrp2 in the canalicular membrane is 
enhanced by bile acid treatment with a parallel induction in PKC-α and -ε. 
Treatment with a PKC-selective inhibitor reversed functional Mrp2 induction, 
suggesting that PKC activation precedes Mrp2 insertion (Beuers et al., 2001).  
In contrast to PKC, protein kinase A (PKA), which is activated by cAMP, did 
not seem to be involved in the regulation of Mrp2 expression in kidney 
(Masereeuw et al., 2000) and liver (Roelofsen et al., 1991). However, long-term 
exposure of isolated hepatocyte couplets to the cAMP analog, dibutyrylcAMP, 
stimulated the sorting of Mrp2-containing vesicles to the canalicular membrane 
and increased Mrp2-mediated efflux (Roelofsen et al., 1998).  
Protein kinase G (PKG) was also implicated in the regulation of Mrp2-mediated 
transport. To date, no direct regulation of Mrp2 by PKG was shown, but guanylyl 
cyclase and the generation of cGMP were found to reduce Mrp2 activity in renal 
proximal tubule (Notenboom et al., 2004b).  
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Nuclear receptors 
 
As mentioned above, endogenous and synthetic compounds may act through 
nuclear receptors in affecting MRP activity. The superfamily of nuclear receptors 
consists of various transcriptional regulators, involved in widely diverse 
physiological functions. Some members of the nuclear receptor family act as 
ligand-inducible transcription factors, while a large number of them have no 
defined ligand and are, therefore, called ‘orphan’ receptors. The ligand-activated 
nuclear receptors are triggered by either xenobiotics or endogenous, most often 
lipophilic, substances. The natural ligands of the nuclear steroid hormone receptors 
are endogenous steroid hormones, which act by binding DNA as a homodimer. 
Examples are the glucocorticoid receptor (GR; NR3C1), mineralocorticoid receptor 
(MR; NR3C2), estrogen receptor (ER; NR3A), androgen receptor (AR; NR3C4), and 
the progesterone receptor (PR; NR3C3) (Bai et al., 2003). Gender differences in 
transporter expression and function may be explained by binding of circulating sex 
hormones to these receptors (see Regulation by steroid hormones). Other members 
of the nuclear receptor superfamily bind DNA as heterodimers with the retinoid 
xenobiotic receptor α (RXRα; NR2B1). Examples are the farnesoid xenobiotic 
receptor (FXR; NR1H4), the human steroid xenobiotic receptor or rodent pregnane 
xenobiotic receptor (SXR/PXR; NR1I2), the constitutive androstane receptor (CAR; 
NR1I3), and the peroxisome proliferator activated receptor α (PPARα; NR1C1). 
These last members of the nuclear receptor superfamily were found to be 
important regulators of detoxifying enzymes, like the cytochrome P450 enzymes, 
and of transport systems, like MRPs, in liver, intestine, and kidney (Chen et al., 
2003a; Kullak-Ublick et al., 2003; Nuclear Receptors Nomenclature Committee, 
1999).  
Regulation of MRPs by these receptors was studied most abundantly in the liver. 
Because of an overlap in transporter expression between liver and kidney, the 
activity of renal transporters may be regulated by the same mechanisms as 
observed in the liver. On the other hand, one should be aware of species and tissue 
differences. For example, in humans and mice, PXR is predominantly expressed in 
liver and intestine, while its expression in kidney is very low or even absent 
(Kliewer et al., 1998; Lehmann et al., 1998). In contrast, PXR expression is high in 
rat kidney (Zhang et al., 1999).  
Up to now, little research has been performed on the regulation of MRP 
expression by nuclear receptors. Exposure of the porcine kidney cell line LLC-PK1 
to rifampicine increased the mRNA expression of Mrp1, but no effects were 
detectable on the protein level (Magnarin et al., 2004). Because rifampicine is a 
ligand of the nuclear receptor PXR, the induction of Mrp1 mRNA expression may 
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be mediated by PXR. Regulation of MRP2 by nuclear receptors is rather 
complicated. Activation of PXR increased Mrp2 protein expression, possibly post-
transcriptionally (Johnson et al., 2002), although regulation on the level of 
transcription was also reported (Kast et al., 2002; Magnarin et al., 2004). Kast et al. 
(2002) showed that besides the nuclear receptor PXR, the expression of Mrp2 may 
also be regulated by FXR and CAR. In addition, Mrp2 protein expression in rat 
liver was reduced after treatment with inducers of PPARα. This regulation takes 
place on a post-transcriptional level (Johnson et al., 2002). MRP3 was also found to 
be under the regulatory control of PXR and CAR (Staudinger et al., 2003). Selective 
activation of the nuclear receptor CAR in rat induces hepatic Mrp3 expression, 
although in kidney and large intestine, Mrp3 was not affected (Cherrington et al., 
2002). These findings correspond with the fact that CAR is predominantly 
expressed in liver (Baes et al., 1994; Choi et al., 1997). PXR and CAR also affect the 
expression of MRP4. Treatment of rats with the PXR ligands pregnenolone-16α-
carbonitrile (PCN), spironolactone, and dexamethasone decreased the renal 
expression of Mrp4, suggesting a negative regulation of Mrp4 by PXR (Chen et al., 
2004). Furthermore, activation of the nuclear receptor CAR results in an induction 
of Mrp4 mRNA and protein expression in the liver (Assem et al., 2004). Research 
on the regulation of Mrp5-9 by nuclear receptors was not yet performed.  
 
 
Disease conditions 
 
Chronic renal failure 
Chronic renal failure is often associated with systemic accumulation of various 
toxins, which may result from impaired renal uptake or excretion into urine.  
During chronic renal failure, induced by subtotal nephrectomy, protein and mRNA 
expression of Mrp2 in the kidney were strongly elevated (Laouari et al., 2001), 
suggesting impaired uptake into proximal tubule. After a longer period of chronic 
renal failure, Mrp2 expression was also induced in the liver (Laouari et al., 2001). 
This specific overexpression of Mrp2 in kidney and liver during chronic renal 
failure is possibly an adaptative response to elevated levels of circulating toxins.  
 
Inflammation 
A commonly used disease model to study the role of infection and inflammation 
on the regulation of biotransformation enzymes and transporters is endotoxin- or 
sepsis-induced cholestasis. Systemic exposure to the endotoxin lipopolysaccharide 
(LPS) activates the liver Kupffer cells and triggers the secretion of cytokines like 
interleukin (IL)-1, tumor necrosis factor α (TNFα), and IL-6 (Nakamura et al., 
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1999). The released cytokines initiate a complex pathway of signal transduction 
reactions, hereby influencing the expression levels of biotransformation enzymes 
and transporters in the liver and other organs, like the kidney. Changes in 
expression levels of the different transporters may either contribute to endotoxin-
induced cholestasis, or function as an adaptive response. Upon treatment with LPS, 
Mrp2 expression levels in liver decrease, which contributes to cholestasis (Kubitz 
et al., 1999b; Trauner et al., 1997; Vos et al., 1998). LPS initially induced retrieval 
of Mrp2 from the canalicular membrane into intracellular vesicles, whereas down-
regulation of Mrp2 mRNA was a later event (Hartmann et al., 2002; Kubitz et al., 
1999b; Nakamura et al., 1999). Also, the nuclear receptor PXR was found to be 
involved in down-regulation of several hepatic proteins during inflammation (Teng 
et al., 2005). In contrast, Mrp1 and Mrp3 expression in rat liver increase after 
treatment with LPS, suggesting a compensatory role for these transporters during 
endotoxin-induced cholestasis (Cherrington et al., 2004; Donner et al., 2004; Vos et 
al., 1998). Controversy exists about the effects on hepatic Mrp5 and Mrp6 
expression (Cherrington et al., 2004; Donner et al., 2004).  
Inflammation also has consequences for the expression of MRPs in the kidney. 
To date, our preliminary studies showed that intraperitoneal injection of Wistar 
Hannover rats with LPS induces iNOS and Mrp2 expression in the kidney 
(Heemskerk et al., 2004). Upregulation of renal Mrp2 may function as a 
compensatory elimination mechanism to reduce enhanced levels of circulating bile 
salts caused by endotoxin-induced cholestasis, or to protect proximal tubular cells 
against the higher exposure via primary urine.  
 
Liver failure/obstructive cholestasis 
Cholestatic liver disorders have important implications for the expression and 
functionality of different transporters in the liver and in the kidney. A decreased 
activity of transporters may result in an accumulation of bile salts in the liver, 
thereby contributing to cholestasis, while upregulation of other transporters may 
result in an adaptive response to limit injury as observed after LPS treatment, 
described above. Another experimental model used to study the in vivo effects of 
cholestasis is bile duct ligation, after which Mrp2 mRNA and protein expression in 
the liver of rats were found to be down-regulated (Tanaka et al., 2002; Trauner et 
al., 1997). This resulted probably through an upregulation of IL-1β and down-
regulation of the nuclear receptor heteromer RARα:RXRα, which is associated 
with a repressed Mrp2 promoter activity (Denson et al., 2002). However, Paulusma 
et al. (2000) found a reduction of Mrp2 protein expression solely, indicating 
regulation on a post-transcritional level. In contrast to Mrp2, expression of the 
basolateral Mrp1, Mrp3, and Mrp4 proteins in the liver were induced after bile 
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duct ligation (Bohan et al., 2003; Denk et al., 2004; Donner et al., 2001; Pei et al., 
2002; Soroka et al., 2001; Tanaka et al., 2002). Consistent with the large substrate 
overlay of the MRPs, it seems likely that Mrp1, Mrp3, and Mrp4 function as 
compensatory mechanisms for the loss of Mrp2 function in cholestasis.  
In kidney tissue, Mrp2 expression levels were upregulated during cholestasis 
(Lee et al., 2001; Tanaka et al., 2002). Mrp1 immunostaining was also enhanced in 
epithelia of some renal tubules (Pei et al., 2002). In contrast to the Mrp2 levels, 
Mrp4 protein levels in rat kidney were decreased during cholestasis. No changes of 
Mrp4 mRNA were found, suggesting a post-transcriptional regulation of Mrp4 
expression (Denk et al., 2004).  
 
 
CONCLUSIONS 
 
Multidrug resistance proteins play an important role in the absorption, 
distribution, and excretion of endogenous compounds, drugs, and their metabolites. 
Interplay of these transporters in intestine, liver, and kidney is necessary for 
effective elimination of toxic compounds and metabolites and for the conservation 
of essential compounds. Although animal knockout models exist for the most 
important MRPs, their specific role in renal anionic drug excretion is still poorly 
understood. Because of the high redundancy of the renal organic anion transport 
system, and adaptive changes therein, it is difficult to elucidate the relative 
contribution of a single transporter to the overall clearance of specific anionic 
compounds. Marked adaptations are also observed during altered physiological 
circumstances and environmental influences. Hormones, local mediators, nuclear 
receptors, protein kinases, and disease conditions influence the expression levels 
and activities of the MRPs to a great extent.  
Renal MRPs are regulated by comparable mechanisms as in liver. For example, 
in both organs, activation of nuclear receptors may lead to down- or upregulation 
of MRPs. However, when extrapolating findings in liver to kidney, the 
physiological roles and interplay of these two organs should be taken into 
consideration. In the in vivo situation, MRP subcellular localization, expression 
levels, and activity may differ between liver and kidney. For example, in the case 
of cholestasis, the normal canalicular excretion of bile salts is impaired, and Mrp2 
expression in the liver is diminished. As a response, the expression levels of the 
basolateral Mrp1, Mrp3, and Mrp4 transporter in liver and apical Mrp2 and Mrp4 
in kidney are enhanced, offering an alternative elimination route for accumulating 
bile salts and reducing potential toxicity.  
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Besides adaptational changes under altered physiological conditions, 
interindividual expression levels and activities of the MRPs may differ due to 
genetic variation. A large number of single nucleotide polyporphisms (SNPs) were 
found in each of the MRP/ABCC genes (Ito et al., 2001; Saito et al., 2002). 
Polymorphisms in certain regions of these genes, like binding sites of transcription 
factors or regions being responsible for substrate binding and transport, might 
affect expression or functionality of these tranporters. However, little information 
on functional changes as a result of these SNPs is available, and currently, there are 
no examples of clinically relevant variations and their possible implications for 
renal drug elimination. Some studies showed that several frequently observed 
polymorphisms in MRP1 and MRP2 did not alter protein expression levels or 
function (Hirouchi et al., 2004; Moriya et al., 2002). Furthermore, due to overlap in 
substrate specificity, the functional effects of certain polymorphisms may be 
masked by compensation for transport by other MRPs.  
Taken together, MRP transporters in the kidney are involved in the renal 
excretion of a broad range of organic anions. The expression and transport activity 
of these MRPs are highly regulated by signals like circulating hormones, activation 
of protein kinases and nuclear receptors, and disease conditions, enabling the 
kidney to adapt to altered physiological conditions. The adaptive capacity of the 
kidney contributes to an effective elimination of endogenous compounds, 
xenobiotics, and their metabolites, thereby reducing their potential toxicity.  
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ABSTRACT 
 
The hormone endothelin-1 (ET-1) is involved in many functions of the kidney 
and intestine. In addition to its vasoactive and proliferative effects, ET-1 is 
involved in the maintenance of water and salt balance and in drug excretion by 
influencing the activity of different transporters in the epithelial cells of these two 
organs. To study ET-1 function and its role in pathophysiological processes in 
epithelial cells in vitro, we investigated ET-1 and ET-receptor expression and 
inducibility of ET-1 excretion by cytokines in three rat cell lines of intestinal (IEC-
6) and renal (NRK-52E and GERP) origin.  
Immunocytochemistry showed that all three cell lines express ET-1 and the ET-
A and ET-B receptor. ET-1 was expressed intracellularly, and also the ET-A 
receptor showed a punctate intracellular staining pattern. The ET-B receptor was 
localized in the membrane, which was confirmed by Western blot analysis. 
Quantitative RT-PCR and ELISA showed that exposure of IEC-6 cells to the 
cytokines, interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα), induced ET-
1 mRNA expression and excretion, while IL-2 was ineffective. In NRK-52E cells, 
IL-1β and TNFα induced ET-1 excretion as well. In GERP cells, adequate 
measurement of cytokine effects on ET-1 excretion was not possible, since ET-1 
excretion under non-stimulated conditions was around the lowest level of 
detection.  
In conclusion, we showed ET-1 and ET-receptor expression, and inducibility of 
ET-1 by cytokines in IEC-6, NRK-52E, and GERP cells. These rat intestinal and 
renal cell lines appear to be suitable for further characterization of ET-1 function 
and its role in pathophysiological processes in epithelial cells.  
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INTRODUCTION 
 
In 1988, endothelin-1 (ET-1), a 21-amino acid peptide, was first isolated from 
cultured porcine aortic endothelial cells and identified as a potent vasoconstrictor 
(Yanagisawa et al., 1988). ET-1 is synthesized by proteolytic cleavage of its 
precursor, prepro-ET-1, into ‘big-ET-1’ or ‘pro-ET-1’ and, subsequently, cleaved 
into ET-1 by the endothelin converting enzyme. The rate-limiting step in the 
synthesis of ET-1 is thought to be at the level of transcription (Yanagisawa et al., 
1988). After secretion from the cell, ET-1 exerts its actions by binding and 
activating the ET-A or the ET-B receptor.  
ET-1 is an important regulator of renal and intestinal function. In the kidney, it 
increases the vascular resistance, resulting in a decrease in renal blood flow and 
glomerular filtration rate (Badr et al., 1989). In addition, mesangial cell 
proliferation and matrix production are regulated by ET-1 (Gomez-Garre et al., 
1996; Simonson et al., 1989). In the various parts of the gastrointestinal tract, ET-1 
has distinct functions, like stimulation of smooth muscle contraction in the colon 
and small intestine, and regulation of hemodynamics in the submucosal 
microcirculation of the small intestine by reducing the terminal vessel flow and 
increasing the microvascular permeability (King-VanVlack et al., 2003; Moummi et 
al., 1992; Takahashi et al., 1990).  
In both organs, ET-1 exerts additional functions, such as the control of the 
activity of many transporters. In the kidney, ET-1 maintains sodium and water 
homeostasis by influencing the activity of ion transporters in different parts of the 
nephron. For example, the transport activities of the luminal Na+/H+ exchanger and 
Na+/Pi cotransporter in the rat proximal tubule are induced by low levels of ET-1, 
while higher ET-1 concentrations inhibit their activities (Eiam-Ong et al., 1992; 
Guntupalli et al., 1994). Ion transport by the basolateral Na+/Ca2+ exchanger, the 
Na+/HCO3- cotransporter and Na+/K+-ATPase is regulated by ET-1 as well (Eiam-
Ong et al., 1992; Kita et al., 2004; Zeidel et al., 1989). Besides its effects on ion 
transport, the vasoactive hormone controls urinary drug excretion. Exposure of 
killifish proximal tubules to ET-1 rapidly decreases the transport activity of the 
multidrug resistance 1 gene product, P-glycoprotein (MDR1/Pgp), and the 
multidrug resistance protein 2 (Mrp2/Abcc2) (Masereeuw et al., 2000). On the 
other hand, 30 min exposure to ET-1 followed by a recovery of 24 hours resulted in 
an increase in Mrp2 (Notenboom et al., 2005). In the small intestine, ET-1 reduces 
sodium and glucose reabsorption by inhibiting the apical Na+/glucose cotransporter 
(Kuhn et al., 1997; Moummi et al., 1992). Moreover, ET-1 stimulates chloride 
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secretion across the intestinal mucosa in the small intestine and colon (Kuhn et al., 
1997; Moummi et al., 1992).  
In addition to its physiological function, many pathological conditions in the 
kidney and intestine are associated with altered ET-1 levels (Kohan, 1997; Miura et 
al., 1996; Naicker et al., 2001; Wolfard et al., 2002). Factors involved in processes 
like hypoxia, ischemia, and inflammation induce ET-1 production, resulting in an 
enhanced ET-1 plasma level (Luscher et al., 1995). Compared to its vascular effects, 
much less is known about the effects of enhanced concentrations on epithelial cell 
function. Altered ET-1 levels may disturb the activity of epithelial cell transporters 
and contribute to renal and intestinal dysfunction and disease. In the present study, 
we characterized three rat epithelial cell lines of intestinal (IEC-6) and renal (NRK-
52E and GERP) origin for ET-1 and ET-receptor expression. In future, these cell 
lines may be useful in the study to ET-1-mediated processes in altered 
physiological states of the cells.  
 
 
MATERIALS AND METHODS 
 
Cell culture 
 
IEC-6 and NRK-52E cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). NRK-52E cells are of proximal tubular origin 
derived from rat kidney (de Larco et al., 1978). IEC-6 cells are of intestinal origin 
and have the characteristics of undifferentiated small intestinal crypt cells 
(Quaroni et al., 1979). IEC-6 cells (passage 9-52) and NRK-52E cells (passage 8-57) 
were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 
glutamax (DMEM-glutamax; Invitrogen, Breda, The Netherlands) and with 5% 
fetal bovine serum (MP Biomedicals, Irvine, CA, USA). The GERP cell line, a 
spontaneously immortalized epithelial cell line isolated from the rat kidney 
proximal tubule by Dr. G. Schaaf, was a kind gift of the department of Veterinary 
Pharmacology, Pharmacy and Toxicology of the University of Utrecht, The 
Netherlands. These cells (passage 51-89) were cultured in collagen-coated culture 
flasks in DMEM-glutamax supplemented with 5% fetal bovine serum and 10 mg/l 
insulin, 5.5 mg/l transferrin, and 67.0 μg/l selenium (Invitrogen, Breda, The 
Netherlands). All cells were grown in a humidified atmosphere of 5% CO2 and 
37°C.  
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Immunocytochemistry 
 
IEC-6, GERP, and NRK-52E cells were cultured on glass slides, and confluent 
cell monolayers were fixed with 3.7% formaldehyde in phosphate-buffered saline 
(PBS) at room temperature for 20 min. Subsequently, cells were washed twice in 
PBS/0.1% triton X-100 on ice for 5 min and in PBS supplemented with 1.5 mg/ml 
glycine and 5 mg/ml bovine serum albumin (BSA) for 15 min. Thereafter, cells 
were incubated with a monoclonal antibody against ET-1 (Sigma, St. Louis, MO, 
USA), the ET-A (Alomone Labs, Jerusalem, Israel), or the ET-B receptor diluted in 
PBS with glycine and BSA at room temperature for 90 min. For ET-B 
immunostaining, antibodies of Alomone Labs (Jerusalem, Israel), Abcam 
(Cambridge, UK), as well as Calbiochem (San Diego, CA, USA) were tested. After 
incubation, the washing steps were repeated, and cells were incubated with an 
Alexa Fluor 488-labeled goat anti-mouse, goat anti-rabbit IgG (Molecular Probes, 
Eugene, OR, USA), or fluorescein isothiocyanate-labeled donkey anti-sheep 
(Sigma, St. Louis, MO, USA) for another 90 min at room temperature. For 
counterstaining, an Alexa Fluor 594-labeled lectin GS-II marker (Molecular Probes, 
Eugene, OR, USA) was used. After staining, cells were washed again with 
PBS/0.1% triton X-100 and PBS and mounted in Vectashield medium (Vector 
Laboratories, Burlingame, CA, USA). Slides were analyzed using a confocal laser 
scanning microscope (MRC1024, Bio-Rad Laboratories, Hercules, CA, USA).  
 
 
Immunoblot analysis 
 
For the determination of ET-B receptor expression using Western blot analysis, 
total membrane fractions were isolated from IEC-6, GERP, and NRK-52E cells. 
Briefly, cells were lyzed for 60 min in 0.5 mM sodium phosphate, 0.1 mM 
ethylenediaminetetraacetic acid (pH=7.0) supplemented with protease inhibitors 
(0.1 mM phenylmethylsulfonylfluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin, and 
1 μg/ml pepstatin) and centrifuged for 5 min at 200g. The supernatant was ultra-
centrifuged at 100,000g for 60 min to pellet the total membrane fraction. This 
fraction was dissolved in 10 mM tris(hydroymethyl)-aminomethane (Tris), 250 
mM sucrose buffer (pH=7.4).  
After total membrane isolation, protein concentrations were determined using 
the Bio-Rad protein assay (Bio-Rad Laboratories, Munich, Germany), and 50 μg of 
protein was solubilized in Laemmli’s sample buffer supplemented with 100 mM 
dithiothreitol. After heating for 10 min at 65°C, proteins were separated on a 10% 
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SDS-polyacrylamide gel. Separated proteins were transferred to a Hybond-C pure 
nitrocellulose membrane (Amersham, Buckinghamshire, UK), and transfer of 
proteins was confirmed by the reversible staining of the membrane with Ponceau 
Red. Subsequently, the blot was blocked for 60 min with 5% non-fat dry milk 
powder in Tris-buffered saline supplemented with 0.3% Tween-20 (TBS-T). The 
membrane was incubated at 4°C for 16 hours with an antibody against the ET-B 
receptor (Alomone Labs, Jerusalem, Israel). For a negative control, the blot was 
incubated with the antibody together with an ET-B control peptide, provided by 
the manufacturer. After washing twice with TBST for 10 min, the membrane was 
blocked for 30 min as described above and incubated at room temperature with an 
affinity-purified horseradish peroxidase-conjugated goat anti-rabbit antibody for 60 
min (Sigma, St. Louis, MO, USA). Finally, the blot was washed twice in TBS-T for 
10 min and proteins were visualized using enhanced chemiluminescence (Pierce, 
Rockford, IL, USA).  
 
 
RT-PCR and quantitative RT-PCR analysis 
 
Total RNA was extracted from cultured cells using TRIzol reagent according to 
the manufacturers’ instructions (Invitrogen, Breda, The Netherlands). For the 
analysis of the effects of different cytokines on ET-1 expression, IEC-6 cells were 
exposed to 10 U/ml interleukin-2 (IL-2), 10 ng/ml tumor necrosis factor α (TNFα), 
or 10 ng/ml interleukin-1β (IL-1β) prior to RNA isolation. All cytokines were 
purchased from Sigma (Zwijndrecht, The Netherlands). Concentrations of isolated 
total RNA were measured with the GeneQuant pro (Amersham International, 
Little Chalfont, UK) and RNA integrity was checked under UV light by 
visualization of 28S- and 18S-rRNA bands on a 1.5% agarose gel containing 
ethidium bromide. For quantitative RT-PCR (qRT-PCR) analysis, RNA samples 
were treated with DNase before reverse transcription, according to the 
manufacturers’ instructions (Promega, Madison, WI, USA). Total intact RNA was 
reverse transcribed using M-MLV reverse transcriptase and a random oligo dT 
primer (pd(T)12J18; sodium salt) for RT-PCR analysis or a pd(N)6 random hexamer 
primer (Amersham International, Little Chalfont, UK) for qRT-PCR analysis 
(Invitrogen, Breda, The Netherlands). Transcription reactions without the reverse 
transcriptase enzyme were performed for negative controls in subsequent PCR-
reactions.  
For the analysis of ET-1 mRNA expression in the three cell lines, PCR 
amplification was performed in a reaction mixture containing cDNA sample, 200 
nM of each primer, 1.25 U Taq DNA polymerase, 200 μM dATP, 200 μM dGTP, 
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200 μM dCTP, 200 μM dTTP, and 1.5 mM MgCl2 (Invitrogen, Breda, The 
Netherlands). The reaction mixture was heated at 94°C for 5 min followed by 35 
cycles, each consisting of incubation for 1 min at 94°C, 1 min at 50°C, and 1 min at 
72°C. After termination of the last cycle, the samples were incubated at 72°C for 4 
min and chilled at 4°C. Specific primers were used for the amplification of rat ET-1 
(sense: 5’-tgagttccatttgcaaccgag-3’; antisense: 5’-aattccagcacttcttgtctt-3’), resulting 
in an amplified product of 443 base pairs. The amplified PCR products were 
electrophoresed on a 1.5% agarose gel containing ethidium bromide. The products 
were visualized under UV light and images were saved digitally with the Gel DocTM 
2000 Gel Documentation System (Bio-Rad Laboratories, Hercules, CA, USA).  
To analyze the effects of cytokines on ET-1 mRNA expression in IEC-6 cells, 
qRT-PCR amplification was performed in a reaction mixture containing cDNA, 600 
nM of each primer, and Sybr Green PCR master mix (Applied Biosystems, Forster 
City, CA, USA). The primers used were specific for the detection of ET-1 (sense: 5’-
gttttgcattgagttccatttgc-3’; antisense: 5’-gaaagccacaaacagcagagaga-3’) and for the 
housekeeping gene β-actin (sense: 5’-ctatgagctgcctgacggtc-3’; antisense: 5’-
agtttcatggatgccacagg-3’). Amplification and Sybr Green detection were performed 
on the ABI PRISM® 7700 Sequence Detection System (Applied Biosystems, Forster 
City, CA, USA). Samples were incubated at 50°C for 2 min, 95°C for 10 min, and 40 
cycles of 95°C for 15 sec and 60°C for 1 min. Threshold cycle (Ct) values were set in 
the linear phase of exponential amplification. ΔΔCt values were calculated by the 
equation ΔΔCt= ΔCtuntreated-ΔCttreated, where ΔCt is the difference in Ct values 
between ET-1 and the household gene β-actin. The relative quantity of ET-1 
mRNA expression in treated samples compared with untreated samples (Xn) can be 
calculated by the formula Xn= 2(meanΔΔCt), according to the instructions of Applied 
Biosystems (ABI Prism7700 Sequence Detection System, User Bulletin #2).  
 
 
Measurement of cytokine-induced ET-1 excretion 
 
Confluent cell monolayers were exposed to 10 U/ml IL-2, 10 ng/ml IL-1β or 10 
ng/ml TNFα. After different time-intervals (0, 6, 12, and 24 hours), medium was 
harvested and ET-1 concentrations were determined using an ET-1 ELISA kit 
(Assay Designs, Ann Arbor, MI, USA), according to the manufacturers’ 
instructions. To correct ET-1 excretion values for differences in protein content in 
the different wells, cells were lyzed in Hanks’ balanced salt solution/0.1% triton X-
100 and protein concentrations were determined using the Bio-Rad protein assay.  
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Data analysis 
 
Data were analyzed using GraphPad Prism version 4.02 for windows (GraphPad 
software, San Diego, CA, USA). Data are given as mean ± S.E.M. Mean values were 
considered to be significantly different, when p<0.05 by use of one-way ANOVA 
followed by Bonferroni’s multiple comparison test.  
 
 
RESULTS 
 
ET-1 and ET-receptor expression 
 
RT-PCR was performed to analyze ET-1 mRNA expression in the rat epithelial 
cell lines of intestinal (IEC-6) and renal (NRK-52E and GERP) origin. Figure 3.1 
shows that all three cell lines investigated express ET-1 mRNA. Negative control 
reactions, performed in the absence of the reverse transcriptase enzyme, did not 
result in the amplification of a PCR product specific for ET-1.  
 
A C(-)B(-)A(-)CB
 
 
 
 
 
 
 
 
 
Figure 3.1 
ET-1 mRNA expression in IEC-6, GERP, and 
NRK-52E cells. Total RNA was isolated from 
IEC-6 (A), GERP (B), and NRK-52E (C) cells, 
and ET-1 mRNA expression was analyzed using 
RT-PCR. For negative controls (-), reverse 
transcriptase reactions were performed in the 
absence of the reverse transcriptase enzyme. In 
all three cell lines, a 443 base pair product 
specific for ET-1 mRNA expression is formed by 
RT-PCR.  
 
In addition, the three cell lines were characterized for ET-1 and ET-receptor 
protein expression. Figure 3.2 shows the green immunofluorescent staining of ET-
1, and the ET-A and ET-B receptor on IEC-6, NRK-52E, and GERP cells. Cells 
were counterstained with a lectin marker and, as a negative control, cells were 
stained with the secondary fluorescent antibodies only. Immunocytochemistry 
showed expression of ET-1 in the cytoplasm of all three cell lines. Also, the ET-A 
receptor was expressed intracellularly, where it showed a punctate staining 
pattern. The ET-B receptor was localized in the plasma membrane of IEC-6 cells 
and NRK-52E cells. In GERP cells, staining of the plasma membrane was less clear. 
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In addition, a bright nuclear staining was observed in the three cell lines with this 
antibody. However, when other antibodies against the ET-B receptor were used, 
different staining patterns were observed (figure 3.3). In contrast to the membrane 
staining, the nuclear staining was not found with the other two antibodies, 
suggesting that a nuclear expression of the ET-B receptor is likely non-specific.  
IEC-6
NRK-52E
GERP
ET-1 ET-BET-A Control
 
Figure 3.2 
Immunofluorescent staining of ET-1, the ET-A, and ET-B receptor in IEC-6, GERP, and NRK-52E cells. 
Confluent monolayers of IEC-6, GERP, or NRK-52E cells were incubated with an antibody for ET-1, the ET-A 
receptor, or the ET-B receptor, followed by staining with a secondary green fluorescent antibody. For ET-B 
receptor staining the antibody of Alomone Labs was used. Controls were incubated with the secondary green 
fluorescent antibody alone. Cells were counterstained with a red fluorescent Lectin GS-II marker.  
 
 
Figure 3.3 
ET-B receptor staining of IEC-6 cells with 
three different antibodies. IEC-6 cells were 
immunofluorescently stained with an ET-B 
antibody from Alomone Labs (A), Abcam (B), or 
Calbiochem (C). Cells were counterstained with 
a red fluorescent Lectin GS-II marker. The three 
ET-B antibodies give different staining patterns.  
A B C
 
 
To confirm the expression of the ET-B receptor in the plasma membrane, total 
membrane fractions were isolated from the IEC-6, NRK-52E, and GERP cells and 
ET-B expression was analyzed by immunoblotting (figure 3.4). In all three cell 
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lines, a band characteristic for ET-B receptor expression was observed at a 
molecular mass of approximately 49 kD.  
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Figure 3.4 
ET-B receptor expression in membranes of 
GERP, NRK-52E, and IEC-6 cells. ET-B 
expression was determined in total membrane 
fractions by Western blot analysis. The protein 
lane of the negative control, containing the total 
membrane fraction of NRK-52E cells, was 
incubated with the antibody against ET-B 
(Alomone Labs) together with the ET-B control 
peptide, according to the manufacturers’ 
instructions. For all three cell lines, a band 
specific for ET-B expression in the membrane is 
detected at approximately 49 kD. 
 
Effects of cytokines on ET-1 excretion 
 
Upon cytokine exposure, ET-1 may be released from epithelial cells. We assessed 
the effects of three different cytokines on ET-1 expression and release. For this 
purpose, IEC-6 cells were exposed to 10 U/ml IL-2, 10 ng/ml TNFα, or 10 ng/ml IL-
1β. It was shown previously that these cytokine concentrations effectively induced 
ET-1 excretion from epithelial cell lines in culture (Endo et al., 1992; Ohta et al., 
1990; Shigematsu et al., 1998). After different time-intervals, ET-1 mRNA 
expression and ET-1 levels in the medium were determined. The effects of the 
three cytokines on ET-1 mRNA expression are shown in figure 3.5. Exposure of 
IEC-6 cells to IL-2 did not affect ET-1 mRNA expression. However, TNFα and IL-
1β significantly enhanced ET-1 mRNA expression in IEC-6 cells (p<0.01; n=5-15).  
Figure 3.6 shows the effects of cytokine exposure on ET-1 excretion from IEC-6 
cells. In accordance with the effects on ET-1 mRNA expression, exposure to IL-2 
did not influence ET-1 excretion. On the other hand, TNFα significantly enhanced 
the excretion of ET-1 from IEC-6 cells by 100% (p<0.001; n=6). Also, IL-1β 
exposure resulted in an induction of ET-1 excretion (p<0.001; n=6). Measurement 
of ET-1 excretion after different time-intervals revealed that ET-1 excretion was 
already maximally induced by TNFα and IL-1β 6 hours after the start of cytokine 
exposure and remained at this level for at least 24 hours (data not shown).  
ET-1 excretion was studied in the other two cell lines as well. In NRK-52E cells, 
TNFα and IL-1β treatment resulted in an upregulation of ET-1 excretion during 24 
hours of 33% and 74%, respectively (n=2). In GERP cells, ET-1 excretion was very 
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low (70 pg ET-1/mg protein during 24 hours; n=2). Accurate measurement of the 
effects of cytokines on ET-1 excretion from these cells was not possible, since basal 
ET-1 excretion values in GERP cells were around the lowest level of detection.  
 
Figure 3.5 
ET-1 mRNA expression in IEC-6 cells after 
incubation with IL-2, IL-1β, or TNFα. 
Confluent IEC-6 cell monolayers were incubated 
in medium in the absence of any effectors or with 
10 U/ml IL-2, 10 ng/ml IL-1β, or 10 ng/ml 
TNFα. After 1 to 24 hours incubation, RNA was 
isolated from the cells and ET-1 expression was 
determined using qRT-PCR. Data are shown as 
ΔΔCt values, calculated as ΔCtuntreated-ΔCttreated, 
where ΔCt is the difference in Ct values between 
ET-1 and the household gene β-actin. One-way 
ANOVA analysis shows that both IL-1β and 
TNFα upregulate ET-1 mRNA expression 
(*p<0.01; n=5-15), while IL-2 does not have an 
effect.  
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Figure 3.6 
ET-1 protein expression in IEC-6 cells after 
incubation with IL-2, IL-1β, or TNFα. ET-1 
excretion was measured 6 to 24 hours after 
incubation using an ET-1 ELISA method. Data 
are expressed as the amount ET-1 excretion 
compared with untreated cells, set at 100%. One-
way ANOVA analysis shows that both IL-1β and 
TNFα upregulate ET-1 protein excretion 
(*p<0.001; n=6), while IL-2 does not have an 
effect.  
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DISCUSSION 
 
In the present study, ET-1 was investigated in two kidney proximal tubular cell 
lines and one small intestinal cell line from rat origin. The two proximal tubular 
cell lines were selected, since ET-1 regulates important transport processes in this 
part of the nephron. The expression of ET-1 in the small intestine is not as 
abundant as in the colon (Firth et al., 1992; Takahashi et al., 1990), but the IEC-6 
cell line was selected because of the similar actions that ET-1 provokes in 
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regulating reabsorption and secretion processes in the intestine as compared to the 
renal proximal tubule. The present study shows that all three cell lines investigated 
express ET-1 mRNA as well as ET-1 protein. It is generally believed that ET-1 is 
stored in intracellular vesicles, and that it can be rapidly excreted from endothelial 
cells upon exposure to stimuli (Harrison et al., 1995; Russell et al., 1998; 
Yanagisawa et al., 1988). Our findings confirm the existence of an intracellular 
storage capacity for ET-1 in epithelial cells as well.  
In addition to ET-1, all three cell lines express the ET-A and the ET-B receptor. 
It was shown previously that the IEC-6 cell line expresses both receptors at the 
mRNA level (Shigematsu et al., 1998). Here, we have shown a predominant 
intracellular localization of the ET-A receptor in all three cell lines. In our IEC-6 
and NRK-52E cells, intracellular ET-A receptor expression may be the result of ET-
1 binding after endogenous ET-1 release. The ET-A receptor is internalized into 
vesicles upon binding with ET-1, from where it can recycle to the plasma 
membrane, resulting in long-lasting actions of ET-1 due to a high-affinity binding 
(with a Km of approximately 475 pM in rats) to the A-type receptor (Abe et al., 
2000; Bremnes et al., 2000; Lin et al., 1991). This binding, however, can not explain 
the vesicular localization of the ET-A receptor in GERP cells, since the amounts of 
ET-1 excreted by GERP cells were much lower (approx. 7 pM). A punctate staining 
pattern, indicative for the presence of the ET-1-ET-A receptor complex in vesicle-
like structures, though, was less clear in these cells. In contrast to the ET-A 
receptor, the ET-B receptor is internalized and degraded by lysosomes upon 
binding to ET-1. For this reason, binding of ET-1 to the ET-B receptor usually 
results in a transient response and this forms a clearance pathway for ET-1 (Abe et 
al., 2000; Bremnes et al., 2000; Oksche et al., 2000).  
Immunocytochemistry demonstrated expression of the ET-B receptor on the 
plasma membrane, which was confirmed by immunoblotting analysis using total 
membrane fractions. Remarkably, we found a nuclear staining of the ET-B receptor 
of which its significance is not clear, because nuclear staining was not observed 
with all antibodies used. This indicates that this staining pattern is probably non-
specific and caution should be taken with the interpretation of these data, although 
others showed previously ET-B receptor expression in the nucleus of cardiac cells 
(Bkaily et al., 2002; Boivin et al., 2003).  
All three cell lines investigated express ET-1, but ELISA analysis showed that 
ET-1 excretion levels under non-stimulated conditions are very low in GERP cells. 
These low levels in medium from cultured GERP cells most likely reflect a low rate 
of excretion under non-stimulated conditions. In contrast, IEC-6 and NRK-52E 
cells excreted measurable amounts of ET-1. ET-1 release results from continuous 
endogenous production of ET-1. Factors present in the culture medium, like 
 ET-1 and ET-receptors in rat epithelial cells 65
growth factors present in fetal calf serum (Shigematsu et al., 1998), may stimulate 
endogenous ET-1 excretion.  
ET-1 production is also influenced by other compounds, including cytokines 
released during inflammatory processes. Previous studies using different cell types 
and species showed that inflammatory cytokines like TNFα, IL-1β, and IL-2 can 
induce ET-1 expression and excretion (Corder et al., 1995; Endo et al., 1992; 
Herman et al., 1999; Kohan, 1992; Ohta et al., 1990). Also in our IEC-6 and NRK-
52E cell lines, ET-1 excretion was induced by exposure to TNFα and IL-1β. In IEC-
6 cells, TNFα was most potent in stimulating both ET-1 mRNA and protein 
expression, while in NRK-52E cells, IL-1β showed the strongest effects. Besides the 
induction of ET-1, these findings indicate that receptors for TNFα and IL-1β are 
likely to be expressed in these cells.  
In contrast to IL-1β and TNFα, IL-2 was without any effects in the IEC-6 cells. 
These findings are in contrast with Shigematsu et al. (1998), who reported an 
upregulation of ET-1 mRNA and ET-1 excretion in IEC-6 cells upon stimulation 
with IL-2. Although we cannot fully explain this difference, the lack of an effect in 
our study may in part be explained by the induction of IEC-6 cell proliferation 
upon IL-2 stimulation. Shigematsu et al. (1998) presented ET-1 excretion as a 
concentration, while we corrected ET-1 excretion levels for differences in protein 
content.  
Because ET-1 has important functions in renal and intestinal epithelial cells and 
many pathological conditions in these organs are associated with enhanced ET-1 
levels, these cell lines may form suitable models for studying the role of ET-1 in 
physiological and pathological processes. In the small intestine, endotoxin 
exposure, for example, increases ET-1 release and causes intestinal damage (Miura 
et al., 1996). The endotoxin itself, but also other factors, like stimulated cytokine 
production, may be responsible for enhanced ET-1 release from vascular 
endothelial and mucosal epithelial cells, resulting in disturbances of the local 
microcirculation, muscular contraction, and secretion and reabsorption processes. 
Our IEC-6 cell line forms a useful model to study the sequence of events leading to 
endotoxin-induced intestinal damage and the role of ET-1 in this process. For 
studying the role of ET-1 in renal function and disease, the NRK-52E cell line may 
be suitable. Radiocontrast agent-induced nephropathy, transplant rejection, acute 
and chronic renal failure are all associated with high ET-1 levels (Kohan, 1997; 
Naicker et al., 2001) and studies in the NRK-52E cell line may clarify the role of 
ET-1 in these disease processes. In transplant rejection, for example, T-cells and 
antigen-presenting cells infiltrate the kidney, after which cytokine release may 
result in locally enhanced ET-1 production, and disturbed kidney functioning 
(Naicker et al., 2001). In contrast, the GERP cell line seems to be less suitable as an 
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in vitro model to study ET-1 function and its role in renal pathophysiology, since 
ET-1 excretion from these cells is very low. Moreover, immunostaining showed a 
less clear expression of the ET-B and the ET-A receptors.  
The ET/ET-receptor system has an important contribution to the renal and 
intestinal functions in physiological and pathological conditions. Evidently, 
multiple cell types are involved of which only one has been studied in more detail 
for both organs in the present study. Complex interactions with other cell types 
present in vivo are lacking. Therefore, additional organ or in vivo models are 
necessary to completely unravel the functions of ET-1 and its role in renal and 
intestinal disease. Furthermore, signaling pathways and protein expression profiles 
present in cells in culture may differ from the in vivo situation, which needs to be 
investigated in further detail.  
In summary, we characterized three rat cell lines of intestinal (IEC-6) and renal 
(NRK-52E and GERP) origin for ET-1 and ET-receptor expression and induction of 
ET-1 excretion. We showed that the three epithelial cell lines express ET-1 and its 
ET-A and ET-B receptors. Basal ET-1 excretion levels from GERP cells were very 
low, while NRK-52E and IEC-6 excreted measurable amounts of ET-1. In NRK-52E 
and IEC-6 cells, the inflammatory cytokines TNFα and IL-1β induced ET-1 
excretion. These latter two cell lines appear to be useful models to study ET-1-
mediated processes.  
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ABSTRACT 
 
In this study, we tested the effects of four different endothelin-1 (ET-1) gene 
silencing approaches in renal proximal tubular cells (NRK-52E) and intestinal cells 
(IEC-6). Cells were transfected either with antisense oligodeoxynucleotides 
(ODNs) using lipofectin, with a baculovirus expressing short interfering RNA 
(siRNA) against ET-1, or with an siRNA-expressing DNA vector using 
lipofectamine 2000 or electroporation. The different methods caused varying 
degrees of transfection, with the highest, nearly 100%, efficiency obtained in NRK-
52E cells using electroporation. Despite an effective transfection, a specific 
inhibition of ET-1 excretion was not observed. Before ET-1 can be silenced in 
vitro, still many factors that determine the success or failure of gene silencing 
should be controlled.  
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INTRODUCTION 
 
This chapter describes different in vitro approaches to silence endothelin-1 (ET-
1) expression. We showed previously that proximal tubule cells derived from rat 
kidney (NRK-52E cells) excrete measurable amounts of ET-1. Also epithelial cells 
derived from rat intestine (IEC-6 cells), an organ in which, similar to the kidney, 
ET-1 is involved in several transport processes and diseases, excrete measurable 
amounts of ET-1. In both cell lines, excretion is induced by the inflammatory 
cytokines tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β) (van de Water 
et al., 2006a). Here, we studied transfection of NRK-52E and IEC-6 cells with 
antisense oligodeoxynucleotides (ODNs) using lipofectin, with an short interfering 
RNA (siRNA)-expressing DNA vector using lipofectamine 2000 or electroporation, 
and transduction of cells with an siRNA-expressing baculovirus.  
 
 
MATERIALS AND METHODS 
 
Cell culture 
 
IEC-6 and NRK-52E cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). NRK-52E cells are of proximal tubular origin 
derived from rat kidney (de Larco et al., 1978). IEC-6 cells are of intestinal origin 
and have the characteristics of undifferentiated small intestinal crypt cells 
(Quaroni et al., 1979). Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with glutamax (DMEM-glutamax; Invitrogen, Breda, The 
Netherlands) and 5% fetal bovine serum (MP Biomedicals, Irvine, CA, USA) and 
grown in a humidified atmosphere of 5% CO2 at 37°C.  
 
 
Antisense ODN sequences 
 
To test the effects of antisense ODNs on ET-1 excretion, two antisense ODN 
sequences containing a phosphorothioate modified backbone against rat prepro-
ET-1 were selected. The sequences were 5’-atcacgggaaaataatccat-3’ for sequence 1 
(PS1) and 5’-tccattctgcaaagggatca-3’ for sequence 2 (PS2). Antisense ODNs were 
dissolved in milliQ prior to use.  
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Construction siRNA expression vectors 
 
For siRNA purposes, three sense and antisense sequences against rat prepro-ET-1 
with a hairpin loop-linker and additional restriction sites were cloned into the 
pSUPERbasic vector (OligoEngine, Seattle, WA, USA). The following ET-1 target 
sequences were used; sequence A: 5’-gcccttctaggtctaagcg-3’, sequence B: 5’-
cagatgccagtgtgctcac-3’, and sequence C: 5’-agacaagaagtgctggaat-3’. Sequence A and 
B were cloned into the BglII and HindIII sites, and sequence C was cloned into the 
BglII and XhoI sites of the pSUPERbasic vector, according to the manufacturers’ 
instructions (OligoEngine, Seattle, WA, USA). As a control, an siRNA sequence 
against a different protein, rat Mrp4 (target sequence: 5’-gagaggtgtcaggagctgt-3’), 
was cloned into the BglII and HindIII site of the pSUPERbasic vector.  
 
 
Construction GFP-expressing vector 
 
To control for transfection efficiency, green fluorescent protein (GFP) was 
cloned into the pSUPERbasic vector. For this purpose, GFP-polyA was amplified 
from the pCINeo/IRES/GFP vector (Trouet et al., 1997) with a forward primer that 
contains a BglII site (5’-gggggagatctatggccacaaccatgagcaag-3’) and a reverse primer 
that contains a XhoI site (5’-gggggctcgagtaccacatttgtagaggttttacttgc-3’). This 
fragment was cloned into the BglII and XhoI site behind the H1 promoter of the 
pSUPERbasic vector, according to the manufacturers’ instructions.  
 
 
Construction and production of siRNA-expressing baculovirus 
 
A baculoviral system was modified to express siRNA against ET-1, or against 
Mrp4 as a control, and a vesicular stomatitis virus G (VSV-G) protein on its viral 
envelop to increase infection efficiency. For this purpose, the VSV-G gene was 
amplified with a forward primer containing the XhoI site (5’-
tggctcgaggccatgaagtgccttttgtacttagc-3’) and a reverse primer containing the NheI 
site (5’-gagatgaaccgacttggaaagtaagctagcact-3’). This fragment was cloned into the 
XhoI and NheI sites behind the p10 promoter of the pFastbacDual vector 
(Invitrogen, Breda, The Netherlands) containing the H,K-ATPase α-subunit behind 
the polyhedron promoter (Koenderink et al., 1999). The H,K-ATPase α-subunit 
was largely removed with PspOMI and SpeI and replaced with the H1 promoter 
and the different siRNA sequences from the pSUPERbasic vector (XbaI and EaeI). 
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The CMV promoter and enhanced yellow fluorescent protein (EYFP) that 
contained the cytochrome oxidase 8 presequence (Dr. R. Rizzuto, University of 
Padova, Italy) fragment (BglII, XbaI) were cloned into the BamHI and XbaI sites of 
the VSV-G containing pFastbacDual vector.  
Competent DH10bac Escherichia coli cells (Invitrogen, Breda, The Netherlands) 
harboring the baculovirus genome (bacmid) and a transposition helper vector were 
transformed with the pFastbacdual transfer vector containing different cDNAs. 
Upon transition between the Tn7 sites in the transfer vector and the bacmid, 
recombinant bacmids were selected and isolated (Luckow et al., 1993). 
Subsequently, insect Sf9 cells were transfected with recombinant bacmids using 
cellfectin reagent (Invitrogen, Breda, The Netherlands). After 3 days, the 
recombinant baculoviruses were harvested and used to infect Sf9 cells at a 
multiplicity of infection of 0.1. Four to six days after infection, the amplified 
viruses were harvested.  
Amplified viruses were purified by centrifugation on a 25% (w/v) sucrose 
gradient. Briefly, virus was centrifuged on 0.25 mg/ml sucrose in 5 mM NaCl, 10 
mM ethylenediaminetetraacetic acid (EDTA) at 4°C and 100,000g for 75 min. 
Pellets were resuspended in phosphate-buffered saline (PBS) and centrifuged for 
another 75 min. Finally, the purified virus was resuspended in PBS and stored at 
4°C until further use.  
 
 
Measurement of ET-1 excretion 
 
To analyze ET-1 excretion, experiments were performed in phenol red free 
DMEM (Invitrogen, Breda, The Netherlands). Medium was harvested and after 
adding protease inhibitors (0.1 mM phenylmethylsulfonylfluoride, 5 μg/ml 
aprotinin, 5 μg/ml leupeptin, and 1 μg/ml pepstatin), samples were stored at -80°C 
till further analysis. ET-1 concentrations were determined using an ET-1 ELISA kit 
(Assay Designs, Ann Arbor, MI, USA), according to the manufacturers’ 
instructions. To correct ET-1 excretion levels for differences in protein content, 
cells were lyzed in Hanks’ balanced salt solution (Invitrogen, Breda, The 
Netherlands) supplemented with 0.1% triton X-100 and protease inhibitors. 
Protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad 
Laboratories, München, Germany). In approach 4, ET-1 excretion levels were 
corrected for differences in DNA content. For this purpose, cells were lyzed in 
tris(hydroxymethyl)-aminomethane/EDTA/0.1% triton X-100 buffer, and DNA 
concentrations were determined using the Quant-iT™ PicoGreen dsDNA assay 
(Invitrogen, Breda, The Netherlands), according to the manufacturers’ instructions.  
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Approach 1 
 
Transfection of IEC-6 cells with antisense ODNs using lipofectin 
IEC-6 cells (passage 9) were seeded at a density of 1x105 cells/2 cm2 in a 24-well 
plate (Greiner Bio-One, Alphen a/d Rijn, The Netherlands). At 90% confluency, 
cells were transfected with 50 or 200 nM of PS1 or PS2 in Optimem (Invitrogen, 
Breda, The Netherlands) using lipofectin, according to the manufacturers’ 
instructions (Invitrogen, Breda, The Netherlands). The ratio of DNA:lipofectin 
used was 1:3. As a control, cells were either untreated or treated with lipofectin 
alone. After 4 hours of incubation, the medium was refreshed with phenol red free 
DMEM, and after another incubation period of 29 hours, medium and cells were 
harvested. ET-1 excretion levels and protein contents were analyzed as described 
above. Transfection efficiency was analyzed using a tetramethyl rhodamine 
isothiocyanate (TRITC)-labeled antisense ODN (PS2), and confocal microscopy.  
 
 
Approach 2 
 
Transfection of NRK-52E cells with an siRNA vector using lipofectamine 2000 
NRK-52E cells (passage 34) were seeded at a density of 1x105 cells/2 cm2 in a 24-
well plate. At 60% confluency, cells were transfected with 1 μg/ml pSUPERbasic 
vector expressing siRNAET-1 sequence A in Optimem using lipofectamine 2000 
(Invitrogen, Breda, The Netherlands), according to the manufacturers’ instructions. 
The ratio of DNA:lipofectamine 2000 used was 1:2. As a control, cells were either 
untreated or treated with lipofectamine 2000. After 6 hours of incubation, medium 
was replaced by phenol red free DMEM in the absence or presence of 10 ng/ml IL-
1β (Sigma, Zwijndrecht, The Netherlands). Medium was refreshed every 24 hours 
and collected on day 1 and 2 after transfection. ET-1 excretion was analyzed and 
corrected for differences in protein content. To control for transfection efficiency, 
cells were transfected with a GFP-expressing pSUPERbasic vector, and GFP 
expression was analyzed using fluorescence microscopy.  
 
 
Approach 3 
 
Infection of IEC-6 cells with an siRNA-expressing baculovirus 
IEC-6 cells (passage 35) were seeded at a density of 1x105 cells/2 cm2 in a 24-well 
plate. One day after seeding, sub-confluent cells were exposed to 6 μl purified 
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baculovirus expressing siRNAET-1 sequence A, B, or C for 6 hours. As a control, cells 
were infected with a baculovirus expressing EYFP or siRNA against Mrp4. After 6 
hours, cells were incubated in the absence or presence of 10 ng/ml TNFα (Sigma, 
Zwijndrecht, The Netherlands) for 72 hours. Medium was refreshed every 24 
hours, and after 72 hours medium and cell samples were collected and analyzed for 
ET-1 excretion and protein content. To control for infection efficiency, GFP 
expression was analyzed using fluorescence microscopy.  
 
 
Approach 4 
 
Transfection of NRK-52E cells with an siRNA vector using electroporation 
NRK-52E cells (passage 13) were electroporated with 2 μg DNA of the 
pSUPERbasic vector expressing siRNAET-1 sequence A, B, or C per 1x105 cells. 
Electroporation was performed in DMEM at 960 μF and 0.3 kV. As a control, cells 
were electroporated in the absence of DNA or in the presence of the pSUPERbasic 
vector without insert or expressing siRNA against a different protein (siRNAMrp4). 
After electroporation, cells were seeded at a density of 1x105 cells/2 cm2 in a 24-
well plate and cultured for 72 hours in medium in the presence or absence of 10 
ng/ml IL-1β. Medium was refreshed every 24 hours, and after 72 hours, samples 
were collected and ET-1 excretion and DNA content were analyzed. ET-1 
excretion levels were corrected for differences in DNA content, since we 
discovered prior to this experiment, which was performed latest in time, that 
measurement of DNA was more sensitive than the measurement of protein, 
making this a more reliable method. To control for transfection efficiency, cells 
were electroporated with a GFP-expressing pSUPERbasic vector, and GFP 
expression was analyzed using fluorescence microscopy.  
 
 
Data analysis 
 
Data were analyzed using GraphPad Prism version 4.02 for windows (GraphPad 
software, San Diego, CA, USA). Data are given as mean ± S.E.M. Mean values were 
considered to be significantly different, when p<0.05 by use of one-way ANOVA 
followed by Bonferroni’s multiple comparison test.  
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RESULTS 
 
Approach 1 
 
Transfection of IEC-6 cells with antisense ODNs using lipofectin 
To test the effects of antisense ODNs on ET-1 excretion, cells were transfected 
with two different ODN sequences against ET-1. One of the sequences tested (PS1) 
was previously shown to be effective in reducing ET-1 expression in a rat cardiac 
allograft model and a vasospasm study (Onoda et al., 1996; Yamaguchi et al., 2002). 
The effects of both antisense ODN sequences were tested in IEC-6 cells using 
lipofectin as a transfection agent, since transfection with a fluorescently labeled 
antisense ODN and lipofectin resulted in effective cellular delivery (figure 4.1A). 
Figure 4.1B shows that, despite efficient transfection, both antisense ODN 
sequences did not affect ET-1 excretion levels until 29 hours after transfection.  
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Figure 4.1 
Transfection efficiency and ET-1 excretion from IEC-6 cells after transfection with a TRITC-labeled 
antisense ODN (PS2) (A) or with antisense ODN PS1 and PS2 (B) using lipofectin. As a control, cells were 
untreated or exposed to the lipofectin alone. Lipofectin A and B correspond with 50 and 200 nM ODN, 
respectively. After transfection, medium was replaced and collected 29 hours later for ET-1 excretion analysis. 
ET-1 excretion levels were corrected for differences in protein content and expressed as mean ± S.E.M. (n=3). 
No differences in ET-1 excretion between the different treatment groups were observed.  
 
 
 In vitro silencing of endothelin-1 77
Approach 2 
 
Transfection of NRK-52E cells with an siRNA vector using lipofectamine 2000 
To test the effects of siRNA against ET-1, NRK-52E cells were transfected with 
the pSUPERbasic vector expressing siRNAET-1 sequence A. Previous experiments 
with the GFP-expressing pSUPERbasic vector in both IEC-6 and NRK-52E cells 
and different liposome-mediated transfection methods showed that transfection of 
NRK-52E cells using lipofectamine 2000 resulted in the highest (around 40%) 
transfection efficiency (figure 4.2A). Figure 4.2B shows that this approach did not 
reduce ET-1 excretion within 24 or 48 hours after transfection. ET-1 excretion 0 to 
24 hours after transfection was much higher than ET-1 excretion from 24 to 48 
hours. After 48 hours, treatment with the siRNA-expressing pSUPERbasic vector 
in combination with IL-1β induced excretion of ET-1 (p<0.01).  
 
Figure 4.2 
Transfection efficiency and ET-1 excretion 
from NRK-52E cells after transfection with 
the GFP-expressing pSUPERbasic vector (A) 
and the pSUPERbasic vector expressing 
siRNAET-1 sequence A (B) using lipofectamine 
2000 (B). As a control, cells were untreated or 
treated with the transfection reagent alone. After 
transfection, medium was replaced, and cells 
were incubated in the absence or presence of 10 
ng/ml IL-1β. Medium was collected over 24 
hours at 24 or 48 hours after transfection and 
analyzed for ET-1 levels. ET-1 excretion levels 
were corrected for differences in protein content 
and expressed as mean ± S.E.M. (n=3). No 
reduction in ET-1 expression was observed. 
Significantly different from lipofectamine 2000 
treated cells in the absence of IL-1β, *p<0.05; 
Significantly different from all other treatment 
groups, **p<0.01.  
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Approach 3 
 
Infection of IEC-6 cells with an siRNA-expressing baculovirus 
To enhance cellular delivery, a modified baculovirus expressing siRNA was 
developed. This virus expressed the VSV-G protein on its viral envelope, which 
may facilitate efficient viral infection of mammalian cells.  
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Figure 4.3 
Infection efficiency of GERP and IEC-6 cells 
with a EYFP-expressing baculovirus (A) and 
ET-1 excretion from IEC-6 cells after infection 
with the VSV-G baculovirus expressing 
siRNAET-1 sequence A, B, or C (B). As a 
control, cells were infected with the baculovirus 
expressing EYFP or expressing siRNA against 
Mrp4 (siRNAMrp4). After 6 hours of infection, 
medium was replaced every 24 hours, and cells 
were incubated in the presence or absence of 10 
ng/ml TNFα. After 72 hours, medium was 
collected and analyzed for ET-1 excretion. ET-1 
excretion levels were corrected for differences in 
protein content and expressed as the mean of two 
experiments.  
 
A pilot study in our lab showed efficient infection of an epithelial cell line 
derived from rat kidney, the GERP cell line, using this method (figure 4.3A). These 
cells, however, could not be used for the measurement of ET-1 gene silencing, 
since basal ET-1 excretion levels are very low in these cells (van de Water et al., 
2006a). Although promising, exposure of NRK-52E cells to this virus did not result 
in EYFP expression at all, and in IEC-6 cells infection efficiency was around 10% 
(figure 4.3A). In contrast to the other GFP control vectors used, the modified 
baculovirus uses the cytomegalovirus promoter to transcribe EYFP, while for 
siRNA expression transcription is mediated via the H1 promoter. Since these 
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promoters may show different transcription activities, effects of the modified 
baculovirus were tested, despite a low infection efficiency observed with the 
EYFP-expressing virus.  
Figure 4.3B shows that siRNA sequence A, B, and C did not inhibit ET-1 
expression in the absence of TNFα in IEC-6 cells. When cells were exposed to 
TNFα, ET-1 excretion was induced in untreated cells, which was reduced after 
siRNA infection, indicating that a gene silencing effect might have occurred. This 
effect, however, was not specific, since the other infection conditions (EYFP and 
siRNAMrp4) showed similar effects.  
 
 
Approach 4 
 
Transfection of NRK-52E cells with an siRNA vector using electroporation 
In addition to liposome-mediated uptake of siRNA, the transfection efficiency of 
a non-endocytic delivery method was tested.  
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Figure 4.4 
Transfection efficiency and ET-1 excretion of NRK-52E cells after electroporation with the GFP-
expressing pSUPERbasic vector (A) and the pSUPERbasic vector expressing siRNAET-1 sequences (B). As 
a control, cells were electroporated in the absence of DNA, with the vector without insert (pSUPER) or the 
vector expressing siRNA against Mrp4 (siRNAMrp4). Medium was replaced 6 hours after electroporation, and 
cells were incubated in the absence or presence of 10 ng/ml IL-1β. Medium was refreshed every 24 hours, and 
after 72 hours, medium and cell samples were collected and analyzed for ET-1 levels and DNA content. Data are 
expressed as mean ± S.E.M. (n=3-4). Treatments showing no column were not determined. IL-1β significantly 
upregulated ET-1 excretion (p<0.001). In addition, some siRNA treatments were different from untreated cells 
or cells treated with the vector without insert, *p<0.05.  
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Figure 4.4A shows that electroporation of NRK-52E cells with the GFP-
expressing pSUPERbasic vector was very successful, resulting in a transfection 
efficiency of about 90 to 100%. To test the effects of gene silencing on ET-1 
excretion, cells were electroporated and exposed to the pSUPERbasic vector 
expressing siRNAET-1 sequences. Figure 4.4B shows that IL-1β induces ET-1 
excretion (p<0.001). Exposure to any of the three siRNA sequences against ET-1 
did not reduce the excretion. Remarkably, exposure to the pSUPERbasic vector 
expressing siRNA against Mrp4 reduced ET-1 excretion.  
 
 
DISCUSSION 
 
In the present study, we investigated the effects of several antisense- and siRNA-
mediated approaches against ET-1 expression in rat epithelial cell lines. Some of 
our methods tested resulted in efficient transfection of cells. In IEC-6 cells, 
transfection with fluorescently labeled antisense ODNs was efficient, while cellular 
delivery of siRNA-expressing vectors was unsuccessful. Possibly, promoter and 
transcription activity of our siRNA expression vectors are very low in these cells, 
resulting in low GFP and siRNA expression levels. Therefore, the application of 
antisense ODNs or synthetic siRNA duplexes might be more successful than vector 
based approaches in IEC-6 cells in future experiments. In NRK-52E cells, infection 
with the baculovirus was unsuccessful. In contrast, delivery of the GFP-expressing 
pSUPERbasic vector resulted in almost complete transfection using 
electroporation. This latter approach may be an efficient and relatively simple 
method for silencing gene expression in NRK-52E cells in future experiments.  
In the different approaches, specific silencing of ET-1 was not observed. 
Different factors may have limited the rate of success in our first attempts to 
silence ET-1 expression, including toxicity due to transfection, half-life of ET-1, 
time-frame of measurement, antisense or siRNA sequence, stability of the antisense 
ODN, and transcription efficiency of the DNA vector. Table 4.1 presents a general 
overview of several factors that may influence effective gene silencing in vitro, and 
issues that should be considered in the development of in vitro gene silencing 
methods.  
In future experiments, the choice of delivery method should be considered 
carefully, since transfection itself can cause cellular toxicity. Transfection or 
transduction dependent toxicity is likely of minor importance in vivo, since no 
additional methods are necessary for successful delivery of sequences to the kidney 
(Juliano et al., 1999; van de Water et al., 2006b).  
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Table 4.1  
Summary of issues that should be considered in the development of in vitro gene silencing methods  
 
Factors  Success rate 
  
Transfection efficiency Depends on factors like cell type, cell confluency, method used, and 
antisense/siRNA and transfectant concentrations used.  
Toxicity due to transfection Depends on factors like cell type, method used, antisense/siRNA and 
transfectant concentrations used, and time of exposure to transfectant.  
Half-life protein of interest Depends on synthesis rate and degradation of protein.  
Time-frame of measurement Depends on half-life of protein of interest, required time for mRNA 
binding, silencing and transcription in the case of siRNA expression 
vectors after transfection.  
Antisense or siRNA sequence For antisense ODNs approximately 1 out of 10 sequences is effective, 
for siRNA approximately 1 out of 2-3. Issues like accessibility of 
mRNA affect rate of success.  
Off-target effects The probability of off-target effects may be prevented by rational 
selection of antisense or siRNA sequences.  
Stability of the sequence In case of antisense and siRNA duplexes, chemical modifications 
improve stability and nuclease resistance. Expression vectors are 
relatively stable.  
Concentrations used Compared with antisense ODNs, the IC50 for siRNA is approximately 
100-fold lower.  
Desired effect (transient/stable) Antisense and siRNA duplexes can only be used for transient silencing. 
When stable silencing or induction/repression of siRNA expression is 
desired, siRNA expression vectors can be used.  
 
The half-life of ET-1 and time-frame of measurement may have influenced our 
results and should be considered in future experiments. Besides the presence of an 
intracellular storage capacity for ET-1, transcription of prepro-ET-1 is rapidly 
induced after exposure to stimuli (Shigematsu et al., 1998; van de Water et al., 
2006a). In a previous study with antisense ODNs against prepro-ET-1, effects were 
rapidly observed (within 20 min) and lasted for a couple of days (Onoda et al., 
1996), indicating that the intracellular storage capacity might be small and depleted 
upon stimulation. To our knowledge, very little is known about the half-life of ET-
1 in cell culture. After excretion, ET-1 may bind to its receptors present on the cell 
surface. ET-1 bound to the ET-A receptor is internalized and recycled to the 
plasma membrane, while ET-1 bound to the ET-B receptor is degraded (Abe et al., 
2000; Bremnes et al., 2000). These factors may influence the half-life of ET-1 and 
the amount of ET-1 in culture medium available for measurement. This may be cell 
type dependent and, therefore, different time-frames should be tested in future 
experiments. In our settings, some methodological inadequacies may have 
complicated the measurement of silencing effects on ET-1 excretion as well. First, 
sufficiently high amounts of ET-1 have to be excreted into medium to be 
detectable, making collection of medium over a long (for example 24 hours) time-
frame necessary. Second, although the antibodies used in our ELISA method do not 
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cross-react with the other ET isoforms, they do not detect the precursor, big-ET-1, 
either.  
Another factor to take into account is the nucleotide sequences used. Several 
recommendations for enhancement of the probability of success exist for the 
selection of suitable sequences (Agrawal et al., 2000; Stein, 2001; Tuschl et al., 
2004), which are based on sequence motifs associated with successful silencing, 
with less side effects, and on chemical compositions with desirable properties. 
Nevertheless, these recommendations do not fully guarantee a silencing effect, 
since other factors, like RNA folding and accessibility of RNA to antisense or 
siRNA sequences, determine the rate of success as well. Therefore, different 
sequences should be tested. In addition, appropriate controls should be selected to 
ensure specific silencing. Usually mismatched, scrambled, or sequences in the sense 
orientation are used as controls.  
Stability of antisense ODNs and transcription efficiency of siRNA expression 
vectors might also have influenced our data. Unmodified phosphodiester backbone 
ODNs are rapidly degraded by nucleases. To overcome this problem, chemically 
modified ODNs have been developed. We tested the relatively stable 
phosphorothioate ODNs, in which one of the non-bridging oxygens in the 
phosphodiester backbone is replaced by sulphur. In our siRNA experiments, vector 
transcription, folding of the transcript, and activation of the siRNA pathway should 
take place in advance of gene silencing. Transfection of NRK-52E cells with the 
GFP-expressing pSUPERbasic vector showed that, at least in these cells, activation 
of the H1 promoter results in effective transcription.  
In summary, we tested four different approaches to silence ET-1 expression in 
vitro. We obtained high transfection efficiencies, with the most successful method 
being electroporation in NRK-52E cells. A specific down-regulation of ET-1 
excretion, however, was not observed. Although the application of ET-1 silencing 
by antisense or siRNA seems a new and promising method to prevent ET-1-
induced renal injury, these data show the complexity of ET-1 silencing methods 
and the factors that determine their success.  
 
 
Reference List 
 
Abe, Y., Nakayama, K., Yamanaka, A., Sakurai, T., Goto, K. (2000). Subtype-specific trafficking of 
endothelin receptors. J. Biol. Chem. 275:8664-8671. 
Agrawal, S., Kandimalla, E. R. (2000). Antisense therapeutics: is it as simple as complementary base 
recognition? Mol. Med. Today 6:72-81. 
Bremnes, T., Paasche, J. D., Mehlum, A., Sandberg, C., Bremnes, B., Attramadal, H. (2000). Regulation and 
intracellular trafficking pathways of the endothelin receptors. J. Biol. Chem. 275:17596-17604. 
 In vitro silencing of endothelin-1 83
de Larco, J. E., Todaro, G. J. (1978). Epithelioid and fibroblastic rat kidney cell clones: epidermal growth 
factor (EGF) receptors and the effect of mouse sarcoma virus transformation. J. Cell Physiol. 94:335-342. 
Juliano, R. L., Alahari, S., Yoo, H., Kole, R., Cho, M. (1999). Antisense pharmacodynamics: critical issues in 
the transport and delivery of antisense oligonucleotides. Pharm. Res. 16:494-502. 
Koenderink, J. B., Swarts, H. G., Hermsen, H. P., De Pont, J. J. (1999). The beta-subunits of Na+,K+-ATPase 
and gastric H+,K+-ATPase have a high preference for their own alpha-subunit and affect the K+ affinity 
of these enzymes. J. Biol. Chem. 274:11604-11610. 
Luckow, V. A., Lee, S. C., Barry, G. F., Olins, P. O. (1993). Efficient generation of infectious recombinant 
baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome 
propagated in Escherichia coli. J. Virol. 67:4566-4579. 
Onoda, K., Ono, S., Ogihara, K., Shiota, T., Asari, S., Ohmoto, T., Ninomiya, Y. (1996). Inhibition of vascular 
contraction by intracisternal administration of preproendothelin-1 mRNA antisense oligoDNA in a rat 
experimental vasospasm model. J. Neurosurg. 85:846-852. 
Quaroni, A., Wands, J., Trelstad, R. L., Isselbacher, K. J. (1979). Epithelioid cell cultures from rat small 
intestine. Characterization by morphologic and immunologic criteria. J. Cell Biol. 80:248-265. 
Shigematsu, T., Miura, S., Hirokawa, M., Hokari, R., Higuchi, H., Watanabe, N., Tsuzuki, Y., Kimura, H., 
Tada, S., Nakatsumi, R. C., Saito, H., Ishii, H. (1998). Induction of endothelin-1 synthesis by IL-2 and its 
modulation of rat intestinal epithelial cell growth. Am. J. Physiol. 275:G556-G563. 
Stein, C. A. (2001). The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. 
Invest. 108:641-644. 
Trouet, D., Nilius, B., Voets, T., Droogmans, G., Eggermont, J. (1997). Use of a bicistronic GFP-expression 
vector to characterise ion channels after transfection in mammalian cells. Pflugers Arch. 434:632-638. 
Tuschl, T., Elbashir, S., Harborth, J., Weber, K. (2004). The siRNA user guide- Selection of siRNA duplexes 
from the target mRNA sequence. http://www.rockefeller.edu/labheads/tuschl/sirna.html 
van de Water, F. M., Russel, F. G., Masereeuw, R. (2006a). Regulation and expression of endothelin-1 (ET-1) 
and ET-receptors in rat epithelial cells of renal and intestinal origin. Pharm. Res. 54:429-435. 
van de Water, F. M., Boerman, O. C., Wouterse, A. C., Peters, J. G., Russel, F. G., Masereeuw, R. (2006b). 
Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses 
gene function in renal proximal tubules. Drug Metab. Dispos. 34:1393-1397. 
Yamaguchi, A., Miniati, D. N., Hirata, K., Hoyt, E. G., Robbins, R. C. (2002). Ex vivo blockade of 
endothelin-1 inhibits graft coronary artery disease in a rodent cardiac allograft model. J. Heart Lung 
Transplant. 21:417-424. 
  84
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
hapter 5
Characterization of P-glycoprotein and 
multidrug resistance proteins in rat kidney 
and intestinal cell lines
Femke M. van de Water
Johanna M. Boleij
Janny G.P. Peters
Frans G.M. Russel
Rosalinde Masereeuw
European Journal of Pharmaceutical Sciences 30(1): 36-44, 2007
Department of Pharmacology and Toxicology, Nijmegen Centre for Molecular Life 
Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
 Chapter 5 86
ABSTRACT 
 
The activity of P-glycoprotein (Pgp/MDR1/ABCB1) and multidrug resistance 
proteins (MRP/ABCC) influence the pharmacokinetics and bioavailability of many 
drugs. Few suitable cell lines for the study of drug transport exist. Additional non-
human cell lines may help clarify species differences and contribute to the current 
knowledge of drug transport. The aim of the present study was to characterize 
three rat epithelial cell lines for transporter expression and activity.  
Transporter expression was assessed in intestinal IEC-6 and renal GERP and 
NRK-52E cells using RT-PCR and Western blot analysis. Pgp and Mrp transport 
activity were analyzed by measuring calcein accumulation and glutathione-S-
bimane efflux, respectively.  
The three cell lines showed Pgp expression and Pgp-dependent transport, both 
decreasing with culture time after reaching confluency. Besides Pgp, cells 
expressed Mrp1, Mrp3, Mrp4, and Mrp5, while Mrp2 and Mrp6 were absent. In 
addition, they showed temperature- and Mrp-dependent efflux of glutathione-S-
bimane. Exposure to a panel of different inhibitors showed that this efflux was 
probably mediated by Mrp4.  
In conclusion, the three rat epithelial cell lines investigated showed Pgp and 
Mrp expression and transport. Mrp dependent transport was most likely mediated 
by Mrp4. In future, these cell lines may be used as in vitro models to study drug 
transport.  
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INTRODUCTION 
 
Several ATP-binding cassette (ABC) proteins play an important role in the 
defense of the body against xenobiotics, their metabolites, and waste products by 
excreting these compounds into bile, the intestinal lumen, or the urine. Important 
members of these ABC transporters are the multidrug resistance 1/P-glycoprotein 
(MDR1/Pgp) and the multidrug resistance proteins (MRPs). P-glycoprotein 
(ABCB1) transports a broad range of uncharged and cationic compounds. In the 
intestine, Pgp limits the bioavailability of many drugs and other compounds by 
transporting them from enterocytes back into the intestinal lumen. In the 
hepatocyte and the kidney proximal tubule, Pgp contributes to the excretion of 
drugs into the bile and urine, respectively. For reviews about Pgp see (Ambudkar 
et al., 1999; Chan et al., 2004).  
The multidrug resistance proteins belong to the ABCC subfamily and to date 
nine different MRPs (MRP1-9) have been identified. They excrete a broad range of 
organic anionic drugs and metabolites, like glutathione and glucuronide conjugates, 
out of the cell. For reviews about the MRP transporters see (Kruh et al., 2003; van 
de Water et al., 2005). Of the different MRPs, MRP2 and MRP4 are expressed on 
the brush-border membrane (BBM) of the kidney proximal tubule, thereby playing 
an important role in the urinary excretion of organic anionic compounds 
(Masereeuw et al., 2003; Schaub et al., 1997; van Aubel et al., 2002). Furthermore, 
MRP2 is involved in the biliary excretion of organic anionic conjugates and 
restricted uptake of some unconjugated organic anionic compounds from the 
intestinal lumen (Mottino et al., 2000; Paulusma et al., 1996; van Aubel et al., 
2000).  
A few suitable cell lines exist for studying intestinal transport and renal 
excretion. These cell lines, used in the pharmaceutical industry and research, are 
often cell lines overexpressing the human transporter. Pgp function in renal 
proximal tubule cells, for example, is often studied in LLC-PK1 cells stably 
transfected with the human MDR1 gene (van Helvoort et al., 1996). MDCKII cells 
transfected with human MRP2 and Caco-2 cells, a human colon carcinoma cell line 
which functionally expresses Pgp and MRP2, are two other well established models 
to study transport function in kidney and intestinal cells, respectively (Evers et al., 
1998; Hirohashi et al., 2000; Terlouw et al., 2001).  
Species differences in transporter expression and function exist. Rodents, for 
example, have two different Mdr1 genes leading to drug resistance, Mdr1a and 
Mdr1b, while humans have only one MDR1 isoform (Chen et al., 1986; Deuchars 
et al., 1992). Several studies showed that species differences in this gene cause 
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differences in drug resistance profiles and sensitivity to modulators of this 
transporter (Tang-Wai et al., 1995; Yasuda et al., 2002). When, for example, drug-
sensitive Chinese hamster cells were transfected with mouse mdr1 or human 
MDR1, striking species differences in resistance to the Pgp substrates colchicine 
and actinomycin D were observed (Tang-Wai et al., 1995). The characterization of 
additional non-human in vitro models may contribute to a better knowledge of 
drug transport function in different species. Moreover, they may help in the 
extrapolation of in vitro data to in vivo animal models used in pharmaceutical 
research. Since first clinical trials in men are based on studies in laboratory 
animals, recognition of species differences in an early stage of drug development 
may also be valuable for the prediction of differences in drug excretion profiles.  
A disadvantage of the currently used cDNA transfectants overexpressing a 
transporter is that regulatory pathways present in vivo, transcriptional regulation, 
and the interplay between different transporters may be absent. In this respect, 
non-transfected cell lines may provide a more physiological model in the study to 
the regulation and function of drug transport.  
The aim of the present study was to develop and characterize new in vitro 
models in which drug transport can be studied. To this end, we investigated the 
expression and transport activity of several members of the ABC family of 
transporters in three rat epithelial cell lines of intestinal (IEC-6) and renal (GERP 
and NRK-52E) origin. Our results show that, although to a different extent, these 
three cell lines express Pgp and several Mrp transporters. Furthermore, they show 
Pgp- and Mrp-dependent transport activity. In future research, these rat epithelial 
cell lines may be used as in vitro models to study drug transport and help in the 
interpolation of in vitro to laboratory animal research.  
 
 
MATERIALS AND METHODS 
 
Cell culture 
 
NRK-52E and IEC-6 cells were obtained from the American Type Culture 
Collection (Manassas, VA, USA). NRK-52E cells are of proximal tubular origin 
derived from rat kidney (de Larco et al., 1978). IEC-6 cells are of intestinal origin 
and have the characteristics of undifferentiated small intestinal crypt cells 
(Quaroni et al., 1979). IEC-6 (passage 10-30) and NRK-52E cells (passage 7-26) 
were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 
glutamax (DMEM-glutamax; Invitrogen, Breda, The Netherlands) and 5% fetal 
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bovine serum (MP Biomedicals, Irvine, CA, USA). The GERP cell line, a 
spontaneously immortalized epithelial cell line isolated from the rat kidney 
proximal tubule by Dr. G. Schaaf, was a kind gift of the department of Veterinary 
Pharmacology, Pharmacy and Toxicology of the University of Utrecht, The 
Netherlands. GERP cells (passage 49-81) were cultured in collagen-coated culture 
flasks in DMEM-glutamax supplemented with 5% fetal bovine serum and 10 mg/l 
insulin, 5.5 mg/l transferrin, and 67.0 μg/l selenium (Invitrogen, Breda, The 
Netherlands). All cells were grown in a humidified atmosphere of 5% CO2 and 
37°C and subcultured every 3 or 4 days, when 90% confluent.  
 
 
RT-PCR analysis 
 
For Mdr1 and Mrp1-6 mRNA expression analysis, total RNA was extracted from 
cultured cells or from rat kidney cortex using TRIzol reagent according to the 
manufacturers’ instructions (Invitrogen, Breda, The Netherlands). Before reverse 
transcription, concentrations of total RNA were measured with the GeneQuant pro 
(Amersham International, Little Chalfont, UK) and RNA integrity was analyzed 
under UV light by visualization of 28S- and 18S-rRNA bands on a 1.5% agarose gel 
containing ethidium bromide.  
Total intact RNA (2 μg) was reverse transcribed using a pd(N)6 random hexamer 
primer (Amersham International, Little Chalfont, UK) and M-MLV reverse 
transcriptase, according to the manufacturers’ instructions (Invitrogen, Breda, The 
Netherlands). Transcription reactions without the reverse transcriptase enzyme 
were performed for negative controls in subsequent PCR reactions.  
PCR amplification was performed in a 50 μl reaction mixture containing cDNA 
sample, 200 nM of each primer, 1.25 U Taq DNA polymerase, 200 μM dATP, 200 
μM dGTP, 200 μM dCTP , 200 μM dTTP, and 1.5 mM MgCl2 (Invitrogen, Breda, 
The Netherlands). Primers were selected against rat Mdr1a/b and Mrp1-6, checked 
for specificity, dimer and loop formation and obtained from Biolegio (Nijmegen, 
The Netherlands). Table 5.1 shows the forward and reverse primer sequences used 
to detect Mdr1a/b and Mrp1-6 and predicted band sizes of the PCR products. PCR 
reaction mixtures were heated at 94°C for 5 min followed by 35 cycles, each 
consisting of incubation for 1 min at 94°C followed by 1 min at 50°C (Mrp4 and 
Mrp5), 57°C (Mdr1a/b), 60°C (Mrp 2, Mrp3, and Mrp6) or 65°C (Mrp1) and 1 min 
at 72°C. After termination of the last cycle, samples were incubated at 72°C for 4 
min and chilled at 4°C. Amplified PCR products were electrophoresed on a 1.5% 
agarose gel containing ethidium bromide. The products were then visualized under 
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UV light and images were saved digitally with a Gel DocTM 2000 Gel 
Documentation System (Bio-Rad Laboratories, Hercules, CA, USA).  
 
Table 5.1 
Primer sequences used for RT-PCR analysis of Mdr1 and six different Mrp transporters 
 
Primer Forward primer (5'-3') Reverse primer (5'-3') Predicted band size
Mdr1a/b (Abcb1) ggaccatcaatgtgaggtat gtagacaagcggtgagctat 397 bp 
Mrp1 (Abcc1) gctgggaaatcatctctcaccctgg tctgcacactcatggttcagcttg 285 bp 
Mrp2 (Abcc2) Ctggtgtggattcccttgg caaaaccaggagccatgtgc 253 bp 
Mrp3 (Abcc3) Acctcacaccctgtttccag cacacacaggagccagaaga 356 bp 
Mrp4 (Abcc4) taaaatggacactgaactagc aatggtgagaacagtgca 202 bp 
Mrp5 (Abcc5) Gtattgcccagctacctctg gatgggcaatggtcagcatg 228 bp 
Mrp6 (Abcc6) Tcccaagctcctcagtctgt aaggagctgccacaggtaga 361 bp 
bp= base pairs 
 
Immunoblot analysis 
 
For immunoblot analysis of Pgp expression, cells were harvested and lyzed with 
0.1% triton X-100 supplemented with protease inhibitors (0.1 mM 
phenylmethylsulfonylfluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin and 1 μg/ml 
pepstatin). For the determination of Mrp2 and Mrp4 protein expression, total 
membrane fractions were isolated. Briefly, cells were shaken for 1 hour in 0.5 mM 
sodium phosphate, 0.1 mM ethylenediaminetetraacetic acid (pH=7.0) 
supplemented with protease inhibitors and centrifuged for 5 min at 200g. The 
supernatant was ultra-centrifuged at 100,000g for 1 hour. After centrifugation, the 
pelleted total membrane fractions were dissolved in 10 mM tris(hydroxymethyl)-
aminomethane (Tris), 250 mM sucrose (pH=7.4) buffer and stored at -80°C till 
further analysis. As a control, Mrp expression was analyzed in Wistar Hannover 
(WH) and rats lacking Mrp2 expression (TR- rats). For this purpose, BBM fractions 
were isolated from kidney cortex of WH and TR- rats as described previously 
(Biber et al., 1981).  
After cell lysis or isolation of total membrane or BBM fractions, protein contents 
were measured using the Bio-Rad protein assay, which is a modified Bradford assay 
(Bradford, 1976), according to the manufacturers’ instructions (Bio-Rad 
Laboratories, München, Germany). Equivalent amounts of protein were dissolved 
in Laemmli’s sample buffer supplemented with 100 mM dithiothreitol and heated 
for 10 min at 65°C. Proteins were separated on a 6% SDS-polyacrylamide gel and 
transferred to a Hybond-C pure nitrocellulose membrane (Amersham, 
Buckinghamshire, UK). Transfer of proteins was confirmed by the reversible 
staining of the membrane with Ponceau Red. Subsequently, the blot membrane 
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was blocked for 60 min with 5% non-fat dry milk powder dissolved in Tris-
buffered saline supplemented with 0.3% Tween-20 (TBS-T). The membrane was 
incubated at 4°C for 16 hours with a monoclonal rat Mrp2 antibody (M2III-6, 
Alexis Biochemicals, San Diego, CA, USA), a polyclonal human MRP4 antibody 
(van Aubel et al., 2002), or the C219 monoclonal antibody against Pgp 
(DakoCytomation B.V., Heverlee, Belgium) diluted in TBS-T. After two times of 
washing in TBS-T for 10 min, the membrane was blocked for another 30 min as 
described above and incubated at room temperature for 60 min with an affinity-
purified horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse 
antibody (Sigma immunochemicals, St. Louis, MO, USA) diluted in TBS-T. Finally, 
the blot was washed twice in TBS-T for 10 min, and proteins were visualized with 
enhanced chemiluminescence (Pierce, Rockford, IL, USA).  
 
 
Analysis of Pgp transport activity 
 
The transport activity of Pgp was determined with the calcein accumulation 
assay. To this end, cells were seeded at a density of 1x105 cells/2 cm2 in a 24-well 
plate (Greiner Bio-One, Alphen a/d Rijn, The Netherlands) and grown for different 
time intervals (4 to 7 days) till analysis. On the day of analysis, cells were washed 
twice with Hanks’ balanced salt solution (Invitrogen, Breda, The Netherlands) 
supplemented with 10 mM Hepes (pH=7.4; HBSS+) at 37°C. After washing, cells 
were incubated at 37°C for 1 hour with 1 μM calcein-acetoxymethylester (calcein-
AM; Invitrogen, Breda, The Netherlands) in 500 μl HBSS+ in the absence or 
presence of 5 μM of the Pgp inhibitor PSC833 (Valspodar; kindly provided by 
Novartis Pharma, Basel, Switzerland). After washing twice with HBSS+, cells were 
lyzed with 0.1% triton X-100 in HBSS+, and cellular calcein fluorescence was 
measured using a Perkin-Elmer LS50 luminescence spectrophotometer 
(Beaconsfield, Buckinghamshire, UK). Excitation and emission wavelengths were 
set to 488 and 518 nm respectively, and the band widths were set to 2.5 nm. Pgp 
transport activity was calculated by dividing the cellular fluorescence in the 
presence of PSC833 by the cellular fluorescence measured in the absence of 
PSC833.  
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Functional analysis of multidrug resistance protein  
 
For the assessment of Mrp transport activity, the efflux of the Mrp substrate 
glutathione-S-bimane (GS-B) was analyzed. To this end, cells were seeded at a 
density of 1x105 cells/2 cm2 in a 24-well plate and grown for 4 days. Efflux studies 
were performed as described earlier by Terlouw et al. (2001), with some 
modifications. Briefly, cells were washed twice with HBSS+ at room temperature. 
After washing, cells were preloaded with 5 μM monochlorobimane (MCB; 
Invitrogen, Breda, The Netherlands) in 300 μl HBSS+ for 60 min at 10°C in the 
presence or absence of inhibitors. Inhibitors used were chlorodinitrobenzene 
(CDNB; 5 μM), MK571 (3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-
dimethyl-amino-3-oxopropyl)-thio}-methyl]thio)propanoic acid); 50 μM; Alexis 
biochemicals, Lausen, Switzerland), indocyanine green (100 and 200 μM), 
progesterone (100 and 200 μM), prostaglandin E1 (10 and 25 μg/ml), bromphenol 
blue (100 and 200 μM), and PSC833 (5 and 25 μM; Novartis Pharma, Basel, 
Switzerland). These inhibitors were purchased from Sigma (Zwijndrecht, The 
Netherlands), unless mentioned otherwise. After preloading, cells were washed 
twice with ice-cold HBSS+. The measurement was started by incubating cells with 
500 μl HBSS+ at 37°C or 10°C in the presence or absence of inhibitors. After 
specified time-intervals, between 0 and 30 min, the apical medium was taken and 
cells were lyzed in 500 μl 0.1% triton X-100 in HBSS+. The fluorescence in the 
apical medium and cell lysates was measured using a Perkin-Elmer LS50 
luminescence spectrophotometer with excitation and emission wavelengths set to 
393 and 475 nm, respectively. The band widths were set to 5 nm. The percentage 
GS-B efflux was calculated by dividing the fluorescence in the apical medium by 
the total fluorescence (apical medium + cell) multiplied by 100. The inhibition of 
GS-B efflux is expressed as a percentage of the GS-B efflux in the absence of 
inhibitors set to 100%.  
 
 
Data analysis 
 
Data are given as mean ± S.E.M. Data were analyzed using GraphPad Prism 
version 4.02 for windows (GraphPad software, San Diego CA, USA). Mean values 
were considered to be significantly different, when p<0.05 by use of one-way or 
two-way ANOVA followed by Bonferroni’s multiple comparison test.  
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RESULTS 
 
Pgp and Mrp1-6 mRNA expression 
 
The mRNA expression of Pgp and Mrp1-6 was investigated in IEC-6, GERP, and 
NRK-52E cells using RT-PCR analysis. RNA isolated from rat kidney cortex was 
used as a positive control. Figure 5.1 shows that all three cell lines express Mdr1, 
Mrp1, Mrp3, Mrp4, and Mrp5 mRNA, while Mrp2 and Mrp6 expressions are not 
detectable. For the analysis of Mdr1 mRNA expression, a primer set was used 
which recognizes both isoforms of the rat Mdr1 gene, Mdr1a and Mdr1b. No 
differentiation was made between the two different Pgp isoforms, because a 
combination of both isoforms results in Mdr1 expression and transport function. In 
addition, the assays used to determine Pgp protein expression and transport 
function do not differentiate between the two isoforms as well.  
 
Figure 5.1 
Mdr1a/b (Pgp) and Mrp1-6 mRNA expression 
in IEC-6, GERP, and NRK-52E cells. Mdr1a/b 
and Mrp1-6 mRNA expression were analyzed in 
IEC-6 (passage 30), GERP (passage 68 and 81), 
and NRK-52E (passage 13 and 26) cells with 
RT-PCR. Rat kidney cortex mRNA was used as 
a positive control.  
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To check for specific PCR product formation, products were separated by 
electrophoresis, and negative RT-PCR reactions were performed in the absence of 
the reverse transcriptase enzyme. The amplified PCR products were all of the 
expected size, as confirmed with a DNA size marker, and no products were formed 
in negative PCR reactions (data not shown).  
 
 
Pgp protein expression and function: effect of culture time 
 
The three rat epithelial cell lines were analyzed for Pgp protein expression and 
transport function after different periods of cell culturing. Protein expression and 
Pgp-dependent transport were measured daily after cultured cells reached 
confluency on day 4 after seeding.  
Figure 5.2 shows the Pgp expression in the three cell lines. In GERP and IEC-6 
cells, a protein band specific for Pgp is detectable at 130 kD. Expression is highest 
just after reaching confluency (day 5) and decreases gradually during longer 
periods of culturing. NRK-52E cells show two protein bands specific for Pgp 
expression. At 170 kD a protein band is detectable of which the intensity decreases 
with culture time, comparable with GERP and IEC-6 cells. The intensity of the 
second protein band at 130 kD, however, gradually increases during time.  
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Figure 5.2 
Representative blot of Pgp protein expression 
in cell lysates of IEC-6, GERP, and NRK-52E 
cells. IEC-6 (passage 18), GERP (passage 68), 
and NRK-52E (passage 16) cells were cultured 
till they formed a confluent monolayer on day 4 
after seeding. Thereafter, Pgp expression was 
followed during five subsequent days (day 4 to 8) 
using Western blot analysis. In GERP and IEC-6 
cells, Pgp expression is detectable at 130 kD. In 
NRK-52E cells, Pgp expression is detectable at 
130 and 170 kD. ND = not determined; MW = 
molecular weight in kD  
 
In agreement with protein expression, Pgp transport function was analyzed 
using the calcein accumulation assay. This assay is a well established model, that 
can be used for the screening of compounds for their interaction with Pgp (Eneroth 
et al., 2001; Liminga et al., 1994; Tiberghien et al., 1996). In the calcein 
accumulation assay, we exposed cells to the non-fluorescent lipophilic Pgp 
substrate calcein-AM, and measured Pgp activity by comparing the cellular 
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accumulation of calcein, a fluorescent metabolite of calcein-AM, in the presence 
and the absence of the Pgp inhibitor PSC833. By comparing the cellular 
fluorescence in the presence and absence of a Pgp inhibitor, confounding by 
esterase activity, the enzyme responsible for the conversion of calcein-AM into 
calcein, is excluded when Pgp activity is compared between different cell lines.  
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Figure 5.3 
Pgp transport activity in IEC-6, GERP, and 
NRK-52E cells. IEC-6 (passage 24), GERP 
(passage 68), or NRK-52E (passage 20) cells 
were cultured till they formed a confluent 
monolayer on day 4 after seeding. Thereafter, 
transport activity was analyzed during four 
subsequent days (day 4 to 7) using the calcein 
accumulation assay. Pgp transport activity was 
determined by calculating the ratio of cellular 
accumulation of fluorescent calcein in the 
presence and absence of the Pgp inhibitor 
PSC833. Data are expressed as mean values ± 
S.E.M. of three wells per experimental group. 
Significantly different from day 4, *p<0.001.  
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Figure 5.3 shows the calcein fluorescence ratios of cells treated with and without 
PSC833. All three cell lines show Pgp-dependent transport activity. The transport 
activity decreases in all three cell lines during prolonged time intervals of 
culturing, which is in accordance with the observed decrease in Pgp protein 
expression in time. In this experiment, highest activities were found in IEC-6 cells. 
Although a decrease in Pgp expression and activity with culture time is consistent, 
Pgp activity might vary in cell cultures with different passage numbers. 
 
 Chapter 5 96
Mrp2 and Mrp4 protein expression 
 
We investigated the protein expressions of Mrp2 and Mrp4 in the three cell lines 
in addition to their mRNA expressions. Figure 5.4 shows a representative Western 
blot of Mrp2 and Mrp4 expression in IEC-6, GERP, and NRK-52E cells. As a 
control, we analyzed expression in isolated BBM fractions from kidney cortex of 
normal WH rats and Mrp2-deficient TR- rats. As expected from the mRNA 
expression results, all three cell lines lack Mrp2 protein as did TR- rats, while WH 
rats do express the transporter protein. Mrp4 protein expression appears as a double 
protein band at 150 kD in all three cell lines, with highest expression levels in 
GERP cells. Furthermore, Mrp4 is expressed in BBM fractions of kidneys of WH 
rats as well as TR- rats.  
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Figure 5.4 
Representative blot of Mrp2 and Mrp4 protein 
expression in total membrane fractions of 
IEC-6 (passage 13), GERP (passage 56 and 
81), and NRK-52E (passage 13 and 17) cells. 
As a control, expression was analyzed in BBM 
fractions of kidney cortex of a WH rat and a TR- 
rat. Mrp2 expression is detectable in kidney 
cortex of WH rats at 175 kD. Mrp4 expression is 
detectable in all three cell lines and in rat kidney 
cortex at 150 kD. MW = molecular weight in kD  
 
GS-B efflux 
 
Mrp-dependent transport was studied in our three cell lines by using the 
glutathione conjugate GS-B as a model substrate. For this purpose, cells were 
exposed to the non-fluorescent compound MCB, which diffuses into the cell and 
conjugates to glutathione. Subsequently, the cellular efflux of the fluorescent Mrp 
substrate formed, GS-B, was measured (Terlouw et al., 2001). GS-B efflux was 
measured at 37°C and 10°C and in the presence of two MRP inhibitors, CDNB and 
MK571. Figure 5.5 shows that in all three cell lines at 37°C, approximately 95% of 
the GS-B formed is excreted from the cells within 30 min. This efflux is highly 
temperature-dependent, since at 10°C the efflux is inhibited by 91, 92 and 90% in 
the IEC-6, GERP, and NRK-52E cell line, respectively (p<0.0001). In addition, Mrp 
inhibitors reduce the efflux of GS-B in all three cell lines (p<0.001). Clear 
inhibition is found after 10 min, with an inhibition of 33, 45, and 32% in IEC-6, 
GERP, and NRK-52E cells, respectively by CDNB (5 μM). When cells are exposed 
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to 50 μM MK571, GS-B efflux is inhibited with 67, 82, and 64% in IEC-6, GERP, 
and NRK-52E cells, respectively.  
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Figure 5.5 
Time-dependent efflux of GS-B in IEC-6, GERP, 
and NRK-52E cells. After loading IEC-6 (passage 10-
24), GERP (passage 49-74), or NRK-52E (passage 7-
17) cells with 5 μM MCB in the absence and presence 
of additional inhibitors, the efflux of GS-B was 
measured at 37°C (control; ■), 10°C (◊), or in the 
presence of 5 μM CDNB (∆) or 50 μM MK571 (▼). 
The percentage of efflux is expressed as the ratio of the 
fluorescence intensity in the supernatant and the total 
fluorescence intensity (supernatant + cellular 
fluorescence), multiplied by 100. Values are shown as 
mean ± S.E.M. of multiple cell cultures (n=6-12). 
Statistical comparisons were performed by two-way 
ANOVA followed by Bonferroni’s multiple comparison 
test. In all cell lines, efflux in the presence of inhibitors 
or at 10°C was significantly different from controls 
(p<0.001).  
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Inhibition of GS-B efflux 
 
To study the efflux of GS-B in more detail, we used GERP cells and tested the 
effects of different inhibitors. Cells were exposed to a panel of different 
compounds, and inhibition of GS-B efflux was measured after 8 min, a time-point 
at approximately 50% of efflux in controls. Figure 5.6 shows that indocyanine 
green, progesterone, and bromphenol blue inhibit GS-B efflux significantly 
(p<0.001). Prostaglandin E1 inhibits GS-B efflux at the highest concentration 
measured (25 μg/ml; p<0.01), while exposure to the Pgp inhibitor PSC833 does not 
interfere with GS-B efflux. 
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Figure 5.6 
Effects of different inhibitors on GS-B efflux 
in GERP cells. After loading GERP cells 
(passage 62-66) with 5 μM MCB in the presence 
or absence of additional inhibitors, the efflux of 
GS-B was determined after 8 min. Inhibition of 
GS-B transport was calculated by comparing the 
percentage of efflux in the presence of inhibitors 
with the efflux in control cells. Inhibitors tested 
were indocyanine green (ICG, 100 and 200 μM), 
progesterone (PROG, 100 and 200 μM), 
prostaglandin E1 (PGE1, 10 and 25 μg/ml), 
bromphenol blue (BPB, 100 and 200 μM), and 
PSC833 (PSC, 5 and 25 μM). Values are shown 
as mean ± S.E.M. of multiple cell cultures (n=6-
15). Statistical comparisons were performed by 
one-way ANOVA followed by Bonferroni’s 
multiple comparison test. Significantly different 
from control, *p<0.01, **p<0.001.  
 
DISCUSSION 
 
The results of the present study show that the three rat epithelial cell lines 
investigated all express Pgp and show Pgp-dependent transport activity. Both 
decrease during time of culturing after cells have formed a confluent monolayer. 
This is in agreement with previous findings in the human cell line Caco-2 (Goto et 
al., 2003). In contrast to IEC-6 and GERP cells, NRK-52E cells express two protein 
bands specific for Pgp. The intensity of the 170 kD protein band decreases during 
time, while the intensity of the 130 kD band increases. Most probably, the 170 kD 
product represents an N-linked glycosylated and phosphorylated form of Pgp 
(Gottesman et al., 1993). Although several studies showed that these post-
translational modifications are not essential for multidrug transport activity 
(Germann et al., 1996; Gribar et al., 2000), the 170 kD isoform seems to be 
responsible for the Pgp transport activity in NRK-52E cells. When comparing Pgp 
expression and function (figures 5.2 and 5.3), highest expression was observed on 
day 5, while Pgp activity was highest on day 4 after seeding. This discrepancy may 
be attributed to the fact that expressed P-gp is not always fully functional (Hosoya 
et al., 1996) and the process of Pgp degradation after reaching confluency. Upon 
degradation, retrieval of Pgp from the membrane directly causes a decrease in 
transport activity (Kim et al., 1997). This intracellular Pgp, however, is still 
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detectable in the total cell lysates explaining the delayed decrease in Pgp 
expression.  
In addition to Pgp expression and function, we analyzed the expression of 
different Mrp transporters and Mrp-dependent transport. In epithelial cell layers in 
vivo as well as in polarized cells in culture, Mrp1, Mrp3, Mrp5, and Mrp6 are 
expressed in the basolateral membrane (see references in van de Water et al., 
2005). In contrast, Mrp2 is expressed in the apical membrane, where it plays an 
important role in the urinary and biliary excretion of organic anionic compounds 
and a limited uptake of drugs via the intestine in vivo (Masereeuw et al., 2003; 
Mottino et al., 2000; Paulusma et al., 1996; Schaub et al., 1997; van Aubel et al., 
2000). Mrp4 is involved in the urinary excretion of organic anionic compounds and 
is expressed in the apical membrane of the proximal tubule as well (van Aubel et 
al., 2002). In the liver, on the other hand, Mrp4 is expressed in the basolateral 
membrane (Rius et al., 2003). Although a preliminary localization study showed 
that Mrp4 is possibly expressed in the basal cytoplasmic regions of the enterocytes 
of the intestine (Johnson et al., 2006), our data suggest that the transporter is 
expressed in the BBM of IEC-6 cells. All three cell lines investigated express Mrp1, 
Mrp3, Mrp4, and Mrp5, while Mrp2 and Mrp6 are not detectable. This is in good 
agreement with previous findings by Li et al. (2003), who observed expression of 
Mrp1 and Mrp3 in IEC-6 cells, but not of Mrp2. Compared with rat kidney cortex, 
Mdr1 and Mrp5 mRNA expression seem to be higher in the renal cell lines. 
Furthermore, Mrp2 and Mrp6 are absent in the cell lines, while present in intestine 
and kidney in vivo (Kool et al., 1999; Mottino et al., 2000; Schaub et al., 1997). 
However, this is not unique to our cells, but seems to be a general feature of 
cultured epithelial cell lines (Hagmann et al., 1999; Terlouw et al., 2001). Future 
studies should be directed at finding the right conditions to regain Mrp2 activity in 
these cell lines. Although Mrp2 transports a broad range of substrates, it should be 
noticed that in vivo there is considerable overlap in substrate specificity with other 
transporters that can compensate for a lack of Mrp2 (Masereeuw et al., 2003; 
Terlouw et al., 2001).  
The efflux of the glutathione conjugate GS-B was investigated to assess Mrp 
function. In all three cell lines, efflux is highly temperature-dependent, indicating 
that GS-B is actively excreted. Furthermore, GS-B efflux is Mrp-dependent, as 
shown by the inhibition by CDNB and MK571. GS-B was found to be a substrate of 
Mrp2 (Oude Elferink et al., 1993), however, our cell lines do not express Mrp2, 
indicating that GS-B is transported by other transporters. We previously showed 
that GS-B efflux was not different between primary cultures of proximal tubule 
cells isolated from normal rats and TR- rats, indicating that other transporters 
compensate for the lack of Mrp2 (Terlouw et al., 2001). A likely candidate is Mrp4, 
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since this protein, like Mrp2, is expressed on the apical site of renal proximal 
tubule cells and shows an overlap in substrate specificity with Mrp2. In addition, 
both Mrp4 expression and GS-B transport activity were highest in GERP cells.  
To study GS-B efflux in more detail, we tested the effects of a panel of 
compounds on their inhibitory capacities. Although no inhibitors were identified 
yet which are specific for one particular Mrp transporter, it is possible to 
distinguish between several transporters by using a panel of different inhibitors. In 
a previous study, Wielinga et al. (2003) tested the effects of different compounds 
on cyclicGMP efflux from HEK cells and HEK cells overexpressing MRP4 or 
MRP5. They showed that indocyanine green, progesterone, prostaglandin E1, and 
bromphenol blue effectively inhibit the efflux of cyclicGMP. In our rat kidney 
cells indocyanine green, progesterone, and bromphenol blue efficiently inhibit GS-
B efflux as well. Furthermore, prostaglandin E1 inhibits the efflux of GS-B at the 
highest concentration tested (25 μg/ml PGE1). Although others, using inside-out 
membrane vesicles, showed that at 10 μg/ml prostaglandin E1 is an effective 
inhibitor of Mrp4 (Reid et al., 2003), we did not observe an effect of this 
concentration, most probably because the compound is poorly membrane 
permeable (Schuster, 1998). In addition to the different Mrp4 and Mrp5 inhibitors, 
we measured the effects of the specific Pgp inhibitor PSC833. This compound does 
not interfere with GS-B efflux, thereby excluding the involvement of Pgp on the 
transport of GS-B.  
Although we could not conclusively discriminate between Mrp4- and Mrp5-
mediated transport using this panel of inhibitors, the apical efflux measured is in 
favor of Mrp4. However, a contribution of Mrp1, Mrp3 and Mrp5 can not be ruled 
out completely, but since these transporters are localized to the basolateral 
membrane in polarized cultured cells it is unlikely that they have contributed to 
GS-B efflux. Nevertheless, transport of GS-B by Mrp1, Mrp3, or Mrp5 into the 
extracellular space below the monolayer and leakage of the fluorescent compound 
into the apical medium might have occurred. Involvement of other transporters is 
very unlikely, since MK571 is a specific Mrp inhibitor. In support of our findings, 
others showed an enhanced transport of GS-B in Hep G2 cells, which were stably 
transfected with the human MRP4 transporter, compared with control cells (Bai et 
al., 2004).  
In addition to drug transport activity, biotransformation reactions influence the 
bioavailability of drugs to a great extent and should be taken into consideration 
when extrapolating in vitro data to in vivo situations. To date, a few studies on 
biotransformation activities have been performed in our cell lines (Lampen et al., 
1998; Lash et al., 2002). In addition, the present study shows glutathione S-
transferase activity, since the fluorescent GS-B is formed by conjugation of the 
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non-fluorescent compound MCB to glutathione. After glutathione conjugation, GS-
B may have been metabolized further into other fluorescent derivatives by γ-
glutamyltransferase, cysteinylglycinase, and N-acetyltransferase (Miller et al., 
1996). Additional studies on biotransformation activities in these cell lines may 
help in the understanding of the interplay between biotransformation and 
transport activity in these cells. Furthermore, to study vectorial transport of 
organic anionic and cationic compounds across these cell lines, the presence and 
functionality of other organic anion and cation transporters need to be investigated 
as well. In this study, Pgp and Mrp transport function were analyzed by using a 
highly membrane permeable compound and an intracellularly formed conjugate 
metabolite as a substrate, respectively. To study the directional transport of other, 
non-permeable, compounds, these cell lines need to functionally express uptake 
transporters, such as organic cation (OCT) and organic anion (OAT) transporters, 
in addition to the efflux transporters.  
In conclusion, we characterized three rat epithelial cell lines of intestinal (IEC-
6) and renal (NRK-52E and GERP) origin for Pgp and Mrp expression and transport 
function. All three cell lines show expression of Pgp and several of the Mrp 
transporters, but not Mrp2. Furthermore, they show Pgp- and Mrp-dependent 
transport activity, most likely mediated by Mrp4. In addition to other well 
established in vitro models, these rat cell lines may be used in future to study drug 
transport.  
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ABSTRACT 
 
In the kidney proximal tubule, the multidrug resistance protein 2 
(MRP2/ABCC2) mediates the urinary excretion of xenobiotics and metabolic 
wastes. Previous studies with isolated killifish renal tubules showed regulation of 
Mrp2 expression and transport activity by endothelin-1 (ET-1) and several 
nephrotoxic agents. Here, we investigated the role of ligand-activated nuclear 
receptors, previously shown to regulate Mrp2 in mammalian liver.  
The effects of different pregnane xenobiotic receptor (PXR) and farnesoid 
xenobiotic receptor (FXR) ligands on Mrp2-dependent transport were measured in 
isolated killifish tubules using fluorescein methotrexate as a substrate. No effect 
was observed for eight ligands tested, except for the PXR ligand dexamethasone. 
This compound increased Mrp2-mediated transport with a maximum at 1 μM, 
measured after 3 hours. In agreement, Mrp2 expression at the luminal membrane 
was enhanced. Exposure of tubules to dexamethasone in combination with the 
nitric oxide synthase inhibitor, NG-methyl-L-arginine, showed that the effects 
were not mediated via activation of nitric oxide synthase, an element of the ET-1 
signaling pathway. On the other hand, the glucocorticoid receptor blocker, RU-
486, ameliorated the effects of dexamethasone, indicating that dexamethasone 
induced Mrp2 expression and function via activation of the glucocorticoid 
receptor.  
In conclusion, these data suggest that dexamethasone interferes with 
glucocorticoid receptor-mediated processes, rather than with PXR or FXR, 
resulting in an induction of Mrp2 expression and activity in renal proximal tubules.  
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INTRODUCTION 
 
The multidrug resistance protein isoform 2 (MRP2/ABCC2) is expressed at the 
luminal membrane of renal proximal tubule cells, where it mediates ATP-
dependent efflux of anionic xenobiotics and metabolic wastes into the urinary 
space. Previous studies with isolated killifish (Fundulus Heteroclitus) renal tubules 
showed that Mrp2-mediated transport activity is rapidly reduced by endothelin-1 
(ET-1) acting through an ET-B receptor, nitric oxide synthase (NOS), cyclicGMP 
and protein kinase C (Masereeuw et al., 2000; Notenboom et al., 2002; Notenboom 
et al., 2004). A number of tubular nephrotoxicants, including radiocontrast agents, 
aminoglycoside antibiotics and heavy metal salts, activate the same sequence of 
events (Terlouw et al., 2001; Terlouw et al., 2002). In contrast, in the long-term, 
luminal Mrp2 activity and protein expression are increased 24 hours after a 
transient exposure to ET-1 or nephrotoxic agents (Notenboom et al., 2005). This 
can be the result of an induced de novo synthesis of Mrp2, or regulation at the 
post-transcriptional level.  
In support of a transcriptional regulation, increased levels of Mrp2 mRNA were 
found in the kidney after exposure to several toxicants and in chronic renal failure 
(van de Water et al., 2005). In mammalian liver, MRP2 expression is induced 
through activation of nuclear receptors, viz. the pregnane xenobiotic receptor 
(PXR; NR1I2), constitutive androstane receptor (CAR; NR1I3), and farnesoid 
xenobiotic receptor (FXR; NR1H4) (Kast et al., 2002). After binding to their 
ligands, including both endogenous metabolites and xenobiotics, these receptors 
form a heterodimer with the retinoid xenobiotic receptor (RXR; NR2B1). These 
heterodimers bind to response elements in the promoter regions of target genes, 
and regulate transcription activity of many drug metabolizing enzymes and 
transport proteins (Xie et al., 2004). Whether Mrp2 expression in the kidney is 
regulated by these nuclear receptors remains to be elucidated.  
Although the killifish nucleotide sequences of these nuclear receptors have not 
been identified yet, a screen of a teleost fish genome (Fugu Rubripes) showed that 
these fish express analogous ligand-activated nuclear receptors, including FXR and 
PXR, but not CAR (Maglich et al., 2003). In addition, using the cloned zebrafish 
(Danio Rerio) receptor in a promoter assay, Moore et al. (2002) identified several 
ligands for teleost PXR.  
The present study was designed to determine the role of FXR and PXR in the 
regulation of Mrp2 expression and transport activity in killifish renal tubules. We 
first screened a series of compounds known to be activators of mammalian FXR and 
PXR, of which only dexamethasone was able to induce Mrp2-mediated transport. 
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The mechanism of action of dexamethasone was investigated in more detail and 
appeared to be mediated via the glucocorticoid receptor (GR; NR3C1), independent 
of PXR or FXR activation.  
 
 
MATERIALS AND METHODS 
 
Chemicals 
 
Fluorescein methotrexate (FL-MTX) and Alexa Fluor 488-labeled goat anti-
rabbit IgG were obtained from molecular probes (Eugene, OR, USA). 15α-
androstan-17β-ol, chenodeoxycholic acid, clotrimazole, dexamethasone, 
dehydroepiandrosterone, mifepristone (RU-486), NG-methyl-L-arginine acetate salt 
(L-NMMA), n-propyl p-hydroxybenzoate, 5β-pregnane-3,20-dione, pregnenolone-
16α-carbonitrile and modified medium 199 with Earle’s salts were purchased from 
Sigma Chemicals (St. Louis, MO, USA). A rabbit polyclonal antibody against Mrp2 
(k78 Mrp2) was obtained as described previously (van Aubel et al., 1998). All other 
chemicals used were obtained at the highest purity available.  
 
 
Animals and tubule preparation 
 
Isolation of killifish proximal tubules and analysis of Mrp2 expression and 
transport was performed as described previously (Masereeuw et al., 2000; 
Notenboom et al., 2005), with some modifications. Killifish were collected in the 
vicinity of Mount Desert Island, Maine, and maintained at the Mount Desert Island 
Biological Laboratory in tanks with natural flowing seawater. Renal tubular masses 
were isolated in a marine teleost saline based on that of Forster and Taggart, 
containing 140 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 1.0 mM MgCl2 and 20 mM 
tris(hydroxymethyl)aminomethane at pH 8.0 (Forster et al., 1950). Under a 
dissecting microscope each mass was teased with fine forceps to remove adherent 
hematopoietic tissue. Individual killifish proximal tubules were dissected and 
transferred to a well plate containing 2 ml modified medium 199 with Earle’s salts 
supplemented with 30 mM NaCl, 4.2 mM NaHCO3, 1.0 mM L-glutamine, 25.0 mM 
Hepes, 14.75 mM NaOH (pH 7.5, 347 mosmol/kg H2O), 20 mg/ml tetracycline, 10 
μg/ml insulin and 5 μg/ml hydrocortisone (Renfro et al., 1999) and added effectors 
(nuclear receptor ligands or inhibitors). After 3, 6, or 24 hours incubation at 14°C 
and 95% O2/5% CO2, tubules were washed in marine teleost saline and transferred 
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to a foil-covered Teflon chamber (Bionique), containing 1 ml of marine teleost 
saline with 2 μM FL-MTX, a fluorescent Mrp2 substrate, to analyse Mrp2-mediated 
transport. The chamber floor was a 4 x 4 cm glass coverslip to which the tubules 
adhered lightly, and through which the tissue could be viewed by means of an 
inverted microscope. Tubules were incubated at room temperature for 45 min until 
steady state was reached for FL-MTX. Analysis of tubule extracts by HPLC showed 
no metabolic degradation of FL-MTX when incubated with killifish proximal 
tubules for periods of at least 1 hour (Masereeuw et al., 1996). FL-MTX transport 
was visualized using the Olympus Fluoview inverted confocal laser scanning 
microscope.  
 
 
Immunohistochemistry 
 
For the analysis of Mrp2 expression, tubule dissection and incubation with 
effectors were performed as decribed above. After incubation of tubules in M199 
medium with effectors, tubules were stained for Mrp2 (Masereeuw et al., 2000). 
For this purpose, tubules were washed in phosphate-buffered saline (PBS), fixed for 
10 min at room temperature in 2% (v/v) formaldehyde/0.1% (v/v) glutaraldehyde, 
permeabilized in 1% (v/v) triton X-100, and incubated for 90 min with a primary 
antibody against Mrp2 (k78) at 37°C, and for 60 min with the secondary Alexa 
Fluor 488-labeled goat anti-rabbit IgG antibody at 37°C. All dilutions were in PBS, 
and between each procedure step, tubules were washed in PBS. After staining, 
tubules were transferred to a Teflon chamber, containing marine teleost saline, and 
Mrp2 expression was visualized using the Olympus Fluoview inverted confocal 
laser scanning microscope.  
 
 
Confocal microscopy 
 
The chamber containing killifish tubules was mounted on the stage of an 
Olympus FluoView inverted confocal laser scanning microscope and viewed 
through a 40x water immersion objective (numerical aperture 1.15). Excitation was 
provided by the 488 nm line of an argon laser. A 510 nm dichroic filter and a 515 
nm long-pass emission filter were used. Neutral density filters and low laser 
intensity were used to avoid photobleaching. With the photomultiplier gain set to 
give an average luminal fluorescence intensity of 1500 to 3000 (on a scale of 0 to 
4096), tissue autofluorescence was undetectable.  
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To obtain an image, dye-loaded or stained tubules were viewed under reduced, 
transmitted light illumination, and a single proximal tubule with well defined 
lumen and epithelium was selected. The plane of focus was adjusted to cut through 
the center of the tubular lumen, and an image was acquired by averaging four 
scans. Stored images were analyzed using ImageJ 1.34s (NIH, MD, USA). For 
analysis of FL-MTX transport, two or three adjacent cellular and luminal areas 
were selected from each tubule. After subtracting the background fluorescence 
intensity, average luminal and cellular pixel intensities were calculated for each 
tubule. Previous studies showed a linear relationship between fluorescence 
intensity and dye concentration (Miller et al., 1991). Because of uncertainties in 
relating fluorescence to actual dye concentration in cells and tissues with a 
complex geometry, we reported data as a percentage of average measured pixel 
intensity compared to control, rather than by estimated dye concentration.  
For analysis of Mrp2 expression, a grid was placed on top of the confocal images, 
and pixel intensities were measured where the grid crossed the luminal membrane. 
For each tubule, Mrp2 staining intensity was measured by averaging the 
pixelintensities measured for that tubule.  
 
 
Data analysis 
 
Data are given as mean percentage of control fluorescence ± S.E.M. Mean values 
were considered significantly different when p<0.05 using one-way ANOVA 
followed by Bonferroni’s multiple comparison test. Data were analyzed using 
GraphPad Prism version 4.02 for windows (GraphPad software, San Diego CA, 
USA).  
 
 
RESULTS 
 
Effects of FXR and PXR ligands on FL-MTX transport 
 
To investigate the role of nuclear receptor activation in the regulation of Mrp2 
expression and function, Mrp2-mediated transport was measured in isolated 
killifish tubules after exposure to different FXR and PXR ligands. The ligands tested 
were previously shown to be potent PXR or FXR activators in other species or 
activators of the zebrafish PXR ligand binding domain in a reporter assay (Moore et 
al., 2002; Parks et al., 1999).  
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As shown in table 6.1, different exposure times and concentrations of the FXR 
ligand, chenodeoxycholic acid, did not induce FL-MTX transport. Also exposure to 
1 to 50 μM of the PXR ligands 15α-androstan-17β-ol, clotrimazole, 
dehydroepiandrosterone, 5β-pregnane-3,20-dione, pregnenolone-16α-carbonitril, 
and n-propyl p-hydroxybenzoate did not induce Mrp2-mediated transport. In 
contrast, the PXR activator and synthetic glucocorticoid, dexamethasone, potently 
increased Mrp2-mediated transport.  
 
Table 6.1 
Effect of various FXR and PXR activators on Mrp2-mediated transport in killifish tubules 
 
Compound Activator of Exposure Effect on FL-MTX 
  conditions Transport 
Chenodeoxycholic acid FXR 1 μM, 6 hours 0 
  5 μM, 6 hours 0 
  10 μM, 6 hours 0 
  50 μM, 6 hours - -** 
    
15α-androstan-17β-ol PXR 1 μM, 6 hours 0 
  5 μM, 6 hours 0 
  1 μM, 24 hours 0 
  5 μM, 24 hours 0 
    
Clotrimazole PXR 1 μM, 3 hours 0 
  5 μM, 3 hours 0 
    
Dehydroepiandrosterone PXR 1 μM, 6 hours 0 
  5 μM, 6 hours 0 
  10 μM, 6 hours - -** 
  50 μM, 6 hours - -** 
    
Dexamethasone PXR 10 μM, 6 hours  + +** 
  50 μM, 6 hours +* 
    
5β-pregnane-3,20-dione PXR 1 μM, 6 hours 0 
  5 μM, 6 hours - -** 
  1 μM, 24 hours 0 
  5 μM, 24 hours 0 
    
Pregnenolone-16α-carbonitrile PXR 1 μM, 3 hours 0 
  5 μM, 3 hours 0 
    
n-propyl p-hydroxybenzoate PXR 1 μM, 3 hours -* 
  5 μM, 3 hours 0 
  10 μM, 6 hours 0 
  50 μM, 6 hours 0 
Effects of different FXR and PXR ligands on FL-MTX transport. For each ligand, Mrp2-mediated FL-MTX transport was 
analyzed after different periods of exposure to different concentrations. No effect (0), significant inhibition (-), or stimulation 
(+) as compared to control (no compound), * p<0.05, ** p<0.01. 
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Effects of dexamethasone on FL-MTX transport and Mrp2 expression 
 
As shown in figure 6.1, exposure of killifish tubules to different concentrations 
of dexamethasone for 3 hours resulted in an induction of FL-MTX transport at all 
concentrations tested (p<0.01; n=48-231 tubules). This exposure time was chosen, 
because after 3 hours the tubules still showed good viability and transport capacity. 
After longer exposure times, the quality of the tubules was sometimes affected 
(data not shown). Highest stimulation of Mrp2-mediated transport (218 ± 10%) was 
observed at 1 μM dexamethasone.  
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Figure 6.1 
Induction of FL-MTX transport after 3 hours 
incubation with different concentrations of 
dexamethasone. The fluorescence in the lumen 
and cell are shown as a percentage of the 
fluorescence intensity in the control lumen. Mean 
values ± S.E.M. are shown for 48-231 tubules. 
Significantly different from control, *p<0.01.  
Figure 6.2 shows that, in agreement with an increase in transport activity, 
exposure to 1 μM dexamethasone resulted in an enhancement of Mrp2 expression 
in the luminal plasma membrane as determined by immunocytochemistry. After 
treatment with dexamethasone, apical staining was enhanced to 158 ± 9% of 
control (p<0.0001; n=17-20 tubules).  
 
0 μM Dex 1 μM Dex
 
Figure 6.2 
Mrp2 expression in killifish tubules 
after 3 hours exposure to 0 μM or 1 
μM dexamethasone. Arrows indicate 
Mrp2 expression in the brush-border 
membrane of killifish proximal 
tubules. Exposure to dexamethasone 
(Dex) induces Mrp2 expression in the 
membrane.  
 
In addition to being a PXR ligand, dexamethasone is a very potent synthetic 
glucocorticoid. Therefore, we investigated the effects of glucocorticoid receptor 
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inhibition on FL-MTX-mediated transport. Figure 6.3 shows that the 
glucocorticoid receptor blocker, RU-486, reduced the effects of dexamethasone on 
Mrp2-mediated transport by approximately 50% (p<0.001; n=49-231 tubules). 
Exposure of tubules to 1 μM RU-486 in the absence of dexamethasone did not 
affect FL-MTX transport.  
 
 
Figure 6.3 
The effects of dexamethasone and RU-486 on 
FL-MTX transport. Tubules were incubated for 
3 hours in the absence (Control) or presence of 1 
μM dexamethasone (Dex), 1 μM RU-486 or both 
of these drugs. The fluorescence in the lumen and 
cell are shown as a percentage of the 
fluorescence intensity in the control lumen. Mean 
values ± S.E.M. are shown for 49-231 tubules. 
Significantly different from control, *p<0.001; 
Significantly different from dexamethasone, 
##p<0.001.  
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Furthermore, dexamethasone may alter Mrp2 expression and function via 
activation of the ET-1 signaling pathway as observed for nephrotoxic agents. One 
of the early key events in this signaling pathway is activation of NOS. To 
investigate the involvement of this pathway, tubules were exposed to 50 μM of the 
NOS inhibitor L-NMMA. Figure 6.4 shows that L-NMMA did not reduce the 
effects of dexamethasone, indicating that activation of NOS is not involved.  
 
 
Figure 6.4 
The effects of dexamethasone and L-NMMA 
on FL-MTX transport. Tubules were incubated 
for 3 hours in the absence (Control) or presence 
of 1 μM dexamethasone (Dex), 50 μM L-NMMA 
or both compounds. The fluorescence in the 
lumen and cell are shown as a percentage of the 
fluorescence intensity in the control lumen. Mean 
values ± S.E.M. are shown for 26-231 tubules. 
Significantly different from control, *p<0.001.  
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DISCUSSION 
 
The present study shows that PXR and FXR most likely do not play a role in 
controlling Mrp2 expression and function in killifish proximal tubules, since except 
for dexamethasone, none of the receptor activators tested induced Mrp2-mediated 
transport. In contrast to our data, others showed regulation of Mrp2 by both PXR 
and FXR in mammalian hepatocytes (Courtois et al., 1999; Kast et al., 2002). These 
nuclear receptors, however, have been reported to show significant organ and 
species differences in the regulation of transporter gene expression (van de Water 
et al., 2005). In support of a minor role and low expression of PXR in the kidney, 
studies in mammals showed an abundant expression of PXR in the liver and 
intestine (Cheng et al., 2006; Lehmann et al., 1998; Zhang et al., 1999). Moreover, 
comparison of PXR nucleotide sequences between different species showed a high 
conservation of the DNA binding domains, while homology of their ligand binding 
domains is very low (Xie et al., 2004). In zebrafish PXR, for example, the ligand 
binding domain shows a sequence homology of only 50% with other species 
(Moore et al., 2002). This diversity in sequence might explain the large variety in 
ligand specificity and xenobiotic responses observed between different species.  
Since dexamethasone was the only PXR ligand tested that activated Mrp2 
function, the effect of this compound was investigated in more detail. After 
exposure of killifish proximal tubules to different concentrations of dexamethasone 
for 3 hours, Mrp2-mediated transport was induced, as was the expression of Mrp2 
in the apical membrane. The potential activation of the glucocorticoid receptor and 
the ET-1 signaling pathway, as described previously for different nephrotoxicants 
(Notenboom et al., 2005; Terlouw et al., 2002) in the regulation of Mrp2 by 
dexamethasone were investigated.  
Triggering the ET-1 signaling pathway by inducing ET-1 excretion and 
subsequent signaling via the ET-B receptor and NOS seems of minor importance, 
since NOS inhibition did not influence the effects of dexamethasone. In contrast, 
the glucocorticoid receptor blocker, RU-486, inhibited the effects of 
dexamethasone on FL-MTX transport, indicating that signaling via this receptor is, 
at least partly, involved in the effects of dexamethasone on Mrp2. A higher 
concentration of RU-486 to block the glucocorticoid receptor completely was not 
tested, because at higher concentrations RU-486 itself activates PXR (Lehmann et 
al., 1998).  
In contrast to our findings in killifish renal tubules, which showed regulation of 
Mrp2 via glucocorticoid receptor activation, others showed that dexamethasone 
induces Mrp2 in rodent hepatocytes via PXR, independent of glucocorticoid 
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receptor activation (Courtois et al., 1999; Kast et al., 2002). Compared with a 
typically glucocorticoid regulated gene, tyrosine aminotransferase, a higher 
dexamethasone concentration was required for maximal Mrp2 activation, and RU-
486 did not block the effects (Courtois et al., 1999). As described above, these 
apparent contradictory data may be explained by organ and species differences. 
Another explanation might be the concentrations of dexamethasone used, leading 
to activation of more than one signaling pathway. A study in human hepatocytes 
showed a biphasic induction of cytochrome P450 form 3A4 (CYP3A4) expression 
by dexamethasone (Pascussi et al., 2001). While at low concentrations activation of 
the glucocorticoid receptor caused a 3 to 4 times increase in CYP3A4 expression, 
PXR was activated at higher concentrations (>10 μM), leading to a 15 to 30 times 
induction (Pascussi et al., 2001). A similar biphasic mechanism might control Mrp2 
in some organs or species as well.  
The glucocorticoid-dependent response on Mrp2 expression may be mediated by 
binding of the activated receptor to glucocorticoid responsive elements present on 
the 5’-flanking region of the Mrp2 gene (Kauffmann et al., 1998). In addition, 
glucocorticoid signaling may indirectly influence Mrp2 expression by inducing the 
expression of PXR and RXR (Pascussi et al., 2000).  
Moreover, in contrast to other species, the glucocorticoid receptor in teleost fish 
is encoded by two separate genes, probably resulting from gene duplication during 
evolution (Bury et al., 2003; Greenwood et al., 2003). Although these receptors and 
their alternative splice variants seem to have similar dexamethasone-binding 
affinities, variations in affinity for the natural glucocorticoid cortisol and variations 
in gene activation are observed between the different glucocorticoid receptor 
subtypes. Besides, the synthetic glucocorticoid dexamethasone has a much higher 
binding affinity for the glucocorticoid receptor than its natural ligand cortisol, 
which should be taken into consideration when interpreting experiments in which 
dexamethasone is used as a ligand in the study to glucocorticoid-mediated 
processes (Stolte et al., 2006). Evidently, the signaling pathways involved in the 
induction of Mrp2 need to be investigated in more detail.  
In summary, the present study showed regulation of Mrp2 expression and 
function by dexamethasone, while other PXR and FXR ligands did not induce 
Mrp2 function. Although involvement of PXR receptor activation can not be ruled 
out completely, the effects of dexamethasone are likely mediated via interference 
with the glucocorticoid signaling pathway.  
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ABSTRACT 
 
Different gene silencing methods, like antisense and short interfering RNA 
(siRNA), are widely used as experimental tools to inhibit gene expression. In the 
present study, the in vivo behavior of siRNA in rats and siRNA-mediated silencing 
of genes in the renal proximal tubule were investigated. To study the 
biodistribution of siRNA, rats were injected i.v. with radiolabeled siRNA or 
radiolabel alone (control), and scintigraphic images were acquired at different 
time-intervals post-injection. The siRNA preferentially accumulated in the kidneys 
and was excreted in the urine. One hour after injection, the amount of siRNA 
present in both kidneys (1.7 ± 0.3% of injected dose/g tissue) was on average 40 
times higher than in other tissues (liver, brain, intestine, muscle, lung, spleen, and 
blood). Besides the biodistribution, the effect of siRNA on multidrug resistance 
protein isoform 2 (Mrp2/Abcc2; siRNAMrp2) in renal proximal tubules was 
investigated. Mrp2 function was assessed by measuring the excretion of its 
fluorescent substrate calcein in the isolated perfused rat kidney. Four days after 
administration, siRNAMrp2 reduced the urinary calcein excretion rate significantly 
(35% inhibition over the period 80 to 150 min of perfusion). This down-regulation 
was specific, because another siRNA sequence directed against a different 
transporter in the proximal tubule, Mrp4 (Abcc4; siRNAMrp4), did not alter the 
Mrp2-mediated excretion of calcein. In conclusion, siRNA accumulates 
spontaneously in the kidney after i.v. injection, where it selectively suppresses 
gene function in the proximal tubules. Therefore, i.v. administered siRNA provides 
a novel experimental and potential therapeutic tool for gene silencing in the 
kidney.  
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INTRODUCTION 
 
Various gene silencing methods, like antisense oligonucleotides and short 
interfering RNA (siRNA), are widely used as experimental tools to inhibit the 
expression of genes. During the last few decades, antisense oligonucleotides have 
been used to study gene function by silencing gene expression in vitro and in vivo. 
In addition, several antisense oligonucleotides have entered into clinical trials, and 
in 1998 the first antisense drug, fomivirsen, was approved by the U.S. Food and 
Drug Administration (Marwick, 1998). Because of the potential application of 
antisense oligonucleotides as therapeutic agents, several research groups 
investigated the biodistribution and pharmacokinetics of antisense oligonucleotides 
(reviewed by Levin, 1999). After i.v. administration, antisense oligonucleotides are 
rapidly cleared from the plasma and distributed to the peripheral tissues. In rats, 
phosphorothioate antisense oligonucleotides are mainly taken up by the kidney 
(Bijsterbosch et al., 1997; Lendvai et al., 2005). Studies on the intra-renal 
distribution of antisense oligonucleotides showed that oligonucleotide uptake is 
most prominent in the proximal tubule (Carome et al., 1997; Oberbauer et al., 
1995). This specific uptake takes place via filtration by the glomeruli, followed by 
tubular reabsorption, as well as by direct uptake at the capillary side of the tubules 
(Sawai et al., 1996).  
More recently, siRNA was discovered as a promising gene silencing tool in 
research and in the clinic. The molecular mechanism of RNA interference was first 
described by Fire et al. (1998), who observed a sequence-specific gene silencing at 
the post-transcriptional level in the nematode Caenorhabditis Elegans after 
exposure to double-stranded RNA (dsRNA). In the RNA interference pathway, 
long dsRNA sequences are cleaved by the enzyme dicer into short 21-base pair 
stretches of dsRNA, the siRNA. These siRNA duplexes associate with a multi-
protein complex known as the RNA-induced silencing complex. After unwinding, 
siRNA strands bind to complementary mRNA, causing a targeted degradation of 
mRNA and, thus, a translational block. The finding that exposure to siRNA 
duplexes shorter than 30 base pairs circumvent activation of the interferon 
pathway and overall suppression of gene expression enabled the successful use of 
this technique in mammalian cells (Elbashir et al., 2001; Tuschl et al., 2002). 
Compared with antisense oligonucleotides, siRNA duplexes seem to be more 
resistant to biodegradation in cell culture and more efficient in silencing gene 
expression (Bertrand et al., 2002; Grunweller et al., 2003).  
Besides the applications of siRNA in vitro, a great interest exists to apply this 
technique as an experimental or therapeutic tool in vivo. To achieve this, different 
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experimental methods have been used to enhance effective delivery of siRNA to 
the target organs. For example, hydrodynamic injection of siRNAs and cationic 
liposome-mediated delivery of siRNA in mice were effective in silencing gene 
expression in different organs in vivo (Lewis et al., 2002; Sioud et al., 2003; Song et 
al., 2003; Sorensen et al., 2003). However, despite the successful silencing of genes 
by siRNA in vivo, the effective delivery of siRNA to the target organs still forms a 
major obstacle, and little is known about the in vivo behavior of synthetic siRNA 
duplexes.  
The objective of the present study was to investigate whether siRNA duplexes, 
like antisense oligonucleotides, are delivered spontaneously to the kidney and 
whether siRNA can silence genes in vivo. Our results showed that siRNA 
accumulates rapidly in rat kidneys after i.v. injection. In addition, we showed 
effective silencing of a transporter gene in the kidney proximal tubule.  
 
 
MATERIALS AND METHODS 
 
siRNA sequences and preparation 
 
To investigate the in vivo behavior of siRNA, the biodistribution of a duplex 
RNA containing two phosphodiester (PO/PO) RNA strands and a dTdT overhang 
was studied. The siRNA sequence was directed against rat multidrug resistance 
protein 4 (Mrp4; siRNAMrp4) and contained a 3’-amino C7 linker on the antisense 
strand for radioactive labeling of the siRNA duplex. To measure the functional 
effects of siRNA, the same siRNAMrp4 sequence without 3’-amino C7 linker and a 
siRNA sequence against rat Mrp2 (siRNAMrp2) were used. The DNA target 
sequences were 5’-aacatggcctactcctacctg-3’ for siRNAMrp2 and 5’-
aagagaggtgtcaggagctgt-3’ for siRNAMrp4. To avoid formation of higher aggregates, 
siRNA duplexes were prepared by dissolving the duplexes in siRNA suspension 
buffer, followed by heating at 90°C for 1 min and incubation at 37°C for 1 hour, 
according to the manufacturers’ instructions (Qiagen, Venlo, The Netherlands). 
 
 
Radiolabeling of siRNA 
 
Duplex 3’-amino siRNAMrp4 was conjugated with cDTPA (Sigma, St. Louis, MO, 
USA) and subsequently labeled with Indium-111 (111In; half-life 2.8 days) under 
strict RNase-free conditions. All the solutions were supplemented with 0.2% (v/v) 
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diethylpyrocarbonate (Fluka, Buchs, Switzerland). All the solutions and pipet tips 
were autoclaved. The siRNA (20 nmol) was solubilized in 10 μl suspension buffer 
and prepared as described above. The pH of the solution was adjusted to pH 8.2 by 
adding 10 μl 0.2 M NaHCO3. A 50-fold molar excess of cDTPA solubilized in 36 μl 
dimethylsulfoxide was added to the siRNA solution, and the reaction mixture was 
incubated for 45 min at room temperature. The reaction was stopped by adding 180 
μl of 0.1 M citrate buffer, pH 5.0, and the fraction mixture was dialyzed extensively 
against 0.1 M citrate buffer, pH 5.0, in a Slide-A-Lyzer with a molecular cutoff of 
3,000 Da (Pierce, Rockford, IL, USA). The siRNA-DTPA conjugate was stored in 
aliquots at -20°C until use.  
For radiolabeling, we used 10 nmol siRNA-DTPA conjugate in 100 μl of 0.1 M 
citrate buffer, pH 5.0. Next, 500 μCi 111InCl3 (Tyco Medical, Petten, The 
Netherlands) was added, and the mixture was incubated for 30 min at room 
temperature. The 111In-labeled DTPA-siRNA was purified by gel filtration on a 
disposable G25M sephadex column (PD10, Pharmacia, Woerden, The Netherlands) 
eluted with phosphate-buffered saline (PBS). The specific activity of the final 
preparation was 30 μCi/nmol. The radiochemical purity of the preparation was 
tested by eluting a sample of the preparation on a PD10 column and exceeded 95%.  
 
 
In vivo experiments 
 
The Animal Experimental Committee of the Radboud University Nijmegen 
approved all procedures involving animals. Specific pathogen free-bred male 
Wistar Hannover (WH) rats (10 to 12 weeks) were obtained from Harlan (CPB, 
Zeist, The Netherlands). WH rats and Mrp2 transport deficient (TR-) rats (de Vries 
et al., 1989) were housed under routine laboratory conditions at the Central 
Animal Facility Nijmegen.  
 
 
Biodistribution of radiolabeled siRNA 
 
To study the biodistribution of 111In-labeled DTPA-siRNA, three rats were 
injected i.v. with 50 μCi 111In-labeled DTPA-siRNA diluted in 200 μl of PBS. A 
control group of three rats was injected i.v. with 50 μCi 111In-labeled DTPA. The 
rats were placed on a gamma camera (Siemens Orbitor, Hoffmann Estates, IL, USA) 
equipped with a medium energy collimator, and scintigraphic images were 
acquired at 5, 30, and 60 min post-injection. Rats were euthanized at 1 hour post-
 Chapter 7 124
injection, and the biodistribution of the radiolabel was determined. A blood sample 
was drawn by cardiac puncture, and normal tissues (muscle, lung, spleen, kidney, 
liver, small intestines, and brain) were dissected, weighed, and counted in a gamma 
counter (Wizard; Pharmacia-LKB, Uppsala, Sweden). To correct for radioactive 
decay, injection standards were counted simultaneously. The activity in samples 
was expressed as a percentage of the injected dose per gram tissue (% ID/g).  
 
 
Functional assessment of siRNA treatment 
 
To investigate the effects of siRNAMrp2 and siRNAMrp4 on Mrp2 transport 
function, male WH rats were injected in the tail vein with 7 nmol (100 μg) 
siRNAMrp2 or siRNAMrp4 dissolved in 150 μl of siRNA suspension buffer. Dependent 
on the experimental settings, rats were euthanized 3 or 4 days post-injection. Rat 
kidneys were isolated and perfused with calcein-acetoxymethylester (calcein-AM), 
a lipophilic compound which is converted into calcein intracellulary. 
Subsequently, the urinary excretion of calcein, a fluorescent substrate of Mrp2, was 
determined. The isolation of rat kidneys and in vitro perfusion were performed as 
described previously in detail (Masereeuw et al., 2003). TR- rats, lacking Mrp2 
expression, were used to compare siRNA effects on Mrp2 transport function.  
 
 
Data analysis 
 
Data were analyzed using GraphPad Prism version 4.02 for windows (GraphPad 
software, San Diego CA, USA). Data are given as mean ± S.E.M. Mean values were 
considered to be significantly different, when p<0.05 by use of a student’s t test, 
one-way or two-way ANOVA, both followed by Bonferroni’s multiple comparison 
test.  
 
 
RESULTS 
 
Biodistribution of siRNA 
 
The in vivo distribution of siRNA was studied in rats after i.v. injection of 
radiolabeled siRNA. As a control, rats were injected with the radiolabel alone. 
Figure 7.1 shows the scintigraphic images of rats acquired after i.v. injection with 
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radiolabeled siRNA or radiolabel. After an initial rapid distribution phase, 
radioactivity is cleared from the circulation via the kidneys and excreted into the 
urine. Compared with control (111In-DTPA), higher concentrations of 111In-DTPA-
siRNA were found in both kidneys, indicating that the kidney selectively takes up 
siRNA after i.v. administration. In figure 7.1, one kidney of a rat injected with 
111In-DTPA-siRNA shows a very high accumulation of siRNA compared with the 
other kidneys. This kidney was not included in the biodistribution shown in figure 
7.2. 
 
 
Figure 7.1 
Scintigraphic images of the uptake of radiolabeled siRNA. Rats (n=3 for each treatment group) were injected 
i.v. with either 111In-DTPA (control) or 111In-DTPA-siRNAMrp4, and the biodistribution of radiolabel was 
followed on a gamma camera for 1 hour.  
 
Rats were euthanized 1 hour after i.v. injection, and the radioactivity per organ 
was determined by calculating the percentage of injected dose per gram tissue (% 
ID/g) recovered in each organ. Figure 7.2 shows that a relatively high 
concentration of radiolabeled siRNA is found in the kidneys. Here 1.7 ± 0.3% ID/g 
is present 1 hour after injection. Accumulation of siRNA in the kidneys is almost 
three times as high as radiolabel alone (0.6 ± 0.1% ID/g). One hour after injection, 
the radioactivity present in the circulation is somewhat lower in siRNA-treated 
rats (0.07 ± 0.01 %ID/g) compared with control rats (0.10 ± 0.01% ID/g). There is 
no selective uptake of siRNA in the muscles, lungs, spleen, liver, intestines and 
brain. In support, the concentration of radiolabel in these organs is very low 
(<0.07% ID/g).  
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Figure 7.2 
Biodistribution of radiolabeled siRNA. Rats 
were injected i.v. with either 111In-DTPA 
(control) or 111In-DTPA-siRNA (siRNA). One 
hour after injection, rats were sacrificed, and the 
distribution of the radiolabel was determined in 
different tissues. Radioactivity for each organ 
was calculated as percentage of injected dose per 
gram tissue (% ID/g). Data are expressed as mean 
± S.E.M. of three animals per treatment group, 
except for the kidneys (n=5 for siRNA-treated 
rats and n=6 for control rats). Statistical 
comparisons between control and siRNA group 
were performed by student’s t tests. Significantly 
different from controls, *p<0.05, **p<0.0001.  
 
 
Functional assessment of siRNA treatment  
 
The effects of siRNA duplexes were tested through assessment of the 
Abcc2/Mrp2 function. As a control, siRNA against rat Mrp4 (Abcc4) was used. 
MRP2 and MRP4 are members of the MRP family (MRP1-9), belonging to the 
subfamily C of the ATP-binding cassette transporters. These two transport proteins 
are expressed in the brush-border membrane of the kidney proximal tubule 
(Schaub et al., 1997; van Aubel et al., 2002), where they excrete a broad range of 
organic anionic compounds into the urine (van de Water et al., 2005). We showed 
previously that Mrp2 function can be monitored using an isolated perfused rat 
kidney model and calcein as a substrate (Masereeuw et al., 2003). Isolated kidneys 
were perfused with medium containing calcein-AM, which was converted 
intracellularly by esterases into the fluorescent Mrp2 substrate calcein. In TR- rats, 
the urinary calcein excretion was found to be highly impaired because of the lack 
of a functional Mrp2 (Masereeuw et al., 2003).  
Four days after exposure of rats to a single dose of siRNAMrp2, a significant 
inhibition of the calcein excretion was found as compared to normal WH rats, 
indicating a reduced Mrp2 function (figure 7.3). With the excretion in Mrp2-
deficient TR- rats set as a baseline, a 35% inhibition of Mrp2 function was observed 
in siRNAMrp2-treated rats over the period 80 to 150 min of perfusion. Inhibition of 
calcein excretion was already observed 3 days post-injection (p<0.001 at t = 60-70 
min, data not shown), but the functional knockdown of Mrp2 was highest 4 days 
after injection. Injection of rats with siRNAMrp4 did not significantly reduce Mrp2 
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function. This shows that other siRNA sequences, which are not complementary to 
Mrp2 mRNA, do not result in a non-specific silencing of Mrp2.  
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Figure 7.3 
Renal excretion rate of calcein as a function of time in isolated perfused rat kidneys. A concentration of 100 
nM of the hydrophobic, non-fluorescent compound calcein-AM was added to normal perfusion medium, and 
secretion of the fluorescent calcein into urine was measured in WH rats that were untreated (●, n=16), treated for 
4 days with siRNAMrp2 (■, n=5), treated with siRNAMrp4 (▲, n=6), or in TR- rats (▼, n=4). Data are given as 
mean ± S.E.M. Statistical comparisons were performed by two-way ANOVA. Significantly different from 
untreated WH rats, *p<0.001.  
 
Besides the effects of siRNA on Mrp2 transport function, general functional 
parameters of the kidney were monitored during the perfusion experiment. Table 
7.1 presents the mean glomerular filtration rate, diuresis, fractional reabsorption of 
water, and perfusion pressure for the different experimental groups.  
 
Table 7.1 
Functional parameters of isolated perfused kidneys of control rats (no additional treatment), after 4 days 
of treatment with siRNAMrp2, siRNAMrp4, and in TR- rats 
 
Parameter Control (n=16) siRNAMrp2 (n=4) siRNAMrp4 (n=6) TR- (n=4) 
GFR (μl/min) 280 ± 20 270 ± 30 240 ± 20 430* ± 40 
diuresis (μl/min) 18 ± 1 16 ± 1 16 ± 1 28* ± 3 
FRwater (%) 93.7 ± 0.2 94.0 ± 0.5 93.2 ± 0.6 93.5 ± 0.2 
RPP (mmHg) 82 ± 1 81 ± 1 80 ± 2 95* ± 5 
Values are presented as mean ± S.E.M. over the period 30 to 120 min. Kidneys were perfused for 150 min as described under 
Materials and methods. GFR = glomerular filtration rate, FR = fractional reabsorption, RPP = renal perfusion pressure. 
Statistical comparisons were performed by one-way ANOVA. Significantly different from control rat kidney, * p<0.01.  
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Administration of both siRNA sequences did not affect these parameters. In 
contrast, glomerular filtration rate and diuresis were increased in TR- rats 
compared with controls (p<0.01). This is most probably the result of a somewhat 
higher renal perfusion pressure during the experiments. Nevertheless, renal 
function of TR- rats was good during the experimental time-period, which is in 
agreement with our previous findings for these rats (Masereeuw et al., 2003).  
 
 
DISCUSSION 
 
A new promising tool to silence gene expression in vivo is siRNA, but little is 
known about the distribution of siRNA duplexes. Thus far, successful delivery of 
siRNA in mammals in vivo was investigated in mice using techniques like 
hydrodynamic injection via the tail vein. However, i.v. injection of siRNA under 
these conditions in humans is not feasible. Therefore, the analysis of the 
biodistribution of siRNA and exploration of other delivery methods may contribute 
to a more effective use of siRNA.  
The present study clearly demonstrates that after i.v. administration of even 
small amounts, siRNA preferentially accumulates in the kidney. After tail-vein 
injection, the sequences rapidly distributed throughout the body, and a large 
amount was delivered to the kidneys and excreted into the urine. One hour after 
injection, the amount of siRNA present in the kidneys was about 40 times higher 
than in the other organs. Although the biodistribution was studied with an siRNA 
sequence against Mrp4, we expect to find a similar biodistribution pattern with 
siRNA duplexes against any other gene. The functional down-regulation of Mrp2 
in the kidney is in support of this.  
Braasch et al. (2004) showed previously the biodistribution of siRNA in mice at 0 
to 72 hours after i.v. injection. In contrast to our findings, they found that 125I-
labeled siRNA accumulated in the liver in addition to the kidney. This difference 
may be caused by the siRNA sequence and the radiolabeling method used and/or 
by interspecies differences. Because of its hydrophilic character, the DTPA-linker 
we used for radioactive labeling of siRNA is easily filtered by the glomerulus, after 
which the complexes are specifically taken up by the renal proximal tubules. In 
accordance with Braasch et al. (2004), we detected very low siRNA concentrations 
in the brain, most likely reflecting a poor ability of siRNA to penetrate the blood-
brain barrier.  
The siRNA biodistribution pattern is similar to that found after i.v. injection of 
antisense oligonucleotides (Bijsterbosch et al., 1997; Lendvai et al., 2005), which is 
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most likely independent of the sequence studied (Rifai et al., 1996). For siRNA 
duplexes, the intra-renal distribution has not been investigated yet. However, 
because of the high reabsorption capacity of the proximal tubule, duplexes may, 
like antisense oligonucleotides, accumulate in this part of the nephron. Previous 
studies showed that antisense oligonucleotides predominantly accumulate in the 
proximal tubule cells after i.v. administration (Carome et al., 1997; Oberbauer et 
al., 1995). Uptake in these cells takes place via the capillary side and via 
reabsorption of antisense oligonucleotides from the tubular lumen. Compared with 
the capillary side, uptake on the luminal side is much more efficient (Sawai et al., 
1996). The uptake on both sides is saturable, indicating the involvement of 
receptor-mediated processes (Rappaport et al., 1995; Sawai et al., 1996). Although 
the receptors responsible for the uptake on both sides of the proximal tubule have 
not been identified yet, different groups showed the presence of oligonucleotide 
receptor proteins (Bijsterbosch et al., 1997; Rappaport et al., 1995; Sawai et al., 
1996). In addition, two receptors expressed on the brush-border membrane of 
proximal tubule cells, cubulin and megalin, may play a role in the reabsorption of 
oligonucleotides from the glomerular filtrate (Birn et al., 2000; Sawai et al., 1996; 
Zhai et al., 2000).  
Besides the application of synthetic siRNA duplexes of 21 nucleotides, RNA 
silencing can be induced by siRNA-expressing viral and non-viral vectors. Because 
of their different physical properties, biodistribution patterns of these vectors may 
be different from those of short 21-nucleotide siRNA duplexes. With a few 
successful exceptions, the kidney has been difficult to transduce with the various 
vectors available (Favre et al., 2000). DNA vectors can transduce proximal tubular 
cells by filtration through the glomerulus and reabsorption by the proximal tubule. 
DNA complexes that are unable to pass the glomerular basement membrane are 
most likely not effective to transduce proximal tubular cells via the basolateral site 
(Favre et al., 2000; Foglieni et al., 2000).  
A research area in which siRNA can provide a useful tool in the characterization 
of gene function and the development of new therapies is that of drug transport 
proteins. Mrp2 and P-glycoprotein (MDR1/ABCB1), for example, play an 
important role in the excretion of many compounds, and multidrug resistance in 
cancer is associated with high expression levels of these transporters. Also, siRNA 
can be useful in the identification of new substrates of these transporters, as well as 
in therapy. An excellent overview about the application of siRNA in the study of 
drug transport proteins has been published recently by Tian et al. (2005).  
The present study shows that after i.v. administration, siRNA accumulation in 
the kidney was sufficient to knock down transporter gene function. The i.v. 
administration of siRNAMrp2 resulted in a specific inhibition of Mrp2 function. We 
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used an isolated rat kidney model perfused with calcein-AM to study Mrp2 
function. This lipophilic compound diffuses into the cells, where it is converted by 
esterases into calcein. This  fluorescent compound is excreted into urine by Mrp2 
and not by Mrp4, and can be used as a model substrate to monitor Mrp2 function. 
We showed previously that calcein is an excellent model substrate for monitoring 
Mrp2 function in the isolated perfused rat kidney (Masereeuw et al., 2003), but we 
cannot exclude completely the involvement of other Mrp, viz. Mrp1, Mrp3, Mrp5, 
and Mrp6, in calcein excretion. In contrast to Mrp2 and Mrp4, Mrp1, Mrp3, Mrp5, 
and Mrp6 are localized in the basolateral membrane, of which only Mrp6 is 
expressed in the proximal tubule. Therefore, changes in Mrp1, Mrp3, and Mrp5 
expression may not have influenced the urinary calcein excretion. Mrp6 might 
contribute to overall renal calcein handling; however, the substrate specificity of 
Mrp6 is very narrow. So far, calcein has not been identified as an Mrp6 substrate. 
In addition, exposure to siRNAMrp4 did not affect calcein excretion, suggesting that 
there were no aspecific effects on other Mrp transporters.  
The effects of siRNA on protein expression largely depend on siRNA 
concentrations and stability, as well as the turnover rate of the protein of interest. 
Compared with antisense oligonucleotides, siRNA duplexes are relatively stable, 
and degradation of siRNA in serum is slow (Bertrand et al., 2002; Braasch et al., 
2004). Expression of Mrp2 in the apical membrane of the proximal tubule is 
dependent on de novo protein synthesis, insertion into the apical membrane, and 
retrieval from the membrane followed by degradation. Jones et al. (2005) 
investigated the rate of Mrp2 protein synthesis and degradation in rat liver. Using 
in vivo metabolic labeling and autoradiography, they estimated the degradation 
half-life of Mrp2 as 27 hours. With a half-life of 27 hours for Mrp2, siRNA 
silencing effects on this protein should be detectable within several days after 
siRNA administration. Using the isolated perfused rat kidney model, we observed a 
clear inhibition of Mrp2 function on day 3 and day 4 after injection. Unfortunately, 
we did not detect an inhibition of transporter expression after administration of 
siRNA using real-time RT-PCR or semiquantitative Western blot analysis (data not 
shown). Although mRNA and protein expression must be down-regulated as well, 
in our hands these two methods were not sensitive enough to significantly detect 
small changes in expression levels.  
To test whether siRNA administration does not alter kidney function, different 
parameters were analyzed during the perfusion experiments. In siRNA-treated rats, 
basic renal functional parameters, like glomerular filtration rate, diuresis, fractional 
reabsorption of water, and renal perfusion pressure, were not different from 
control values, indicating that siRNA administration is safe and without side 
effects.  
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The use of siRNA has an advantage over the use of chemical inhibitors to reduce 
Mrp2 transport function because it shows a specific down-regulation. To date, no 
inhibitors have been identified that exclusively affect Mrp2. In addition, chemical 
inhibitors may have side effects. The spontaneous accumulation of siRNA duplexes 
in the kidney after i.v. administration has potential therapeutic implications. The 
i.v. administration of siRNA duplexes seems a simple but effective method in 
research and therapy to silence gene expression in the kidney. A more site-directed 
administration, like injection of siRNA into the renal artery, may even further 
enhance the accumulation of siRNA duplexes in the kidney.  
In summary, the present study shows that after i.v. injection in rats, siRNA 
duplexes are distributed throughout the body within minutes. Most of the i.v. 
administered siRNA accumulates rapidly in the kidneys and is excreted via the 
urine over time. Moreover, we show for the first time successful suppression of 
Mrp2 in the renal proximal tubule. Therefore, i.v. administration of siRNA 
duplexes provides a novel research and potential therapeutic tool for gene silencing 
in the kidney.  
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GENERAL DISCUSSION 
 
The reabsorptive and excretory capacity of the kidney has an important 
influence on the systemic concentration of drugs. The multidrug resistance 
proteins (MRP/ABCC) and the multidrug resistance 1/P-glycoprotein (MDR1/Pgp) 
expressed in the kidney proximal tubule play a critical role in the urinary efflux of 
a wide variety of drugs and toxicants. During altered physiological circumstances, 
adaptations in these transporters are required to avoid systemic toxicity as well as 
renal tubular injury.  
Previously, our group found that Mrp2 and Pgp expression and transport 
function are regulated by the vasoactive hormone endothelin-1 (ET-1) in killifish 
(Fundulus Heteroclitus) renal tubules (Masereeuw et al., 2000). Exposure of these 
tubules to ET-1 rapidly reduced Mrp2- and Pgp-mediated transport via the 
activation of an ET-1 signaling cascade (Masereeuw et al., 2000; Notenboom et al., 
2002; Notenboom et al., 2004). Furthermore, exposure to nephrotoxic compounds 
induced ET-1 excretion, causing a similar sequence of events (Terlouw et al., 2001; 
Terlouw et al., 2002). Although transport is enhanced after long-term exposure and 
after a short-term exposure followed by a recovery period (Notenboom et al., 2005; 
Terlouw et al., 2002), an initial decrease in transport activity may have detrimental 
effects on the proximal tubule as a result of the accumulation of potentially toxic 
compounds. We hypothesized that renal toxicity may be prevented or diminished 
by silencing of enhanced ET-1 expression after exposure to nephrotoxic agents.  
In this thesis, we investigated several aspects of ET-1, ATP-binding cassette drug 
transporters, and gene silencing in order to develop in vitro and in vivo models to 
study the effects of ET-1 gene silencing on drug transport and renal toxicity. 
Experiments were performed in three experimental models: rat epithelial cell lines, 
isolated killifish tubules and an in vivo rat model. Each of these models have their 
own merits to investigate the effects of ET-1 gene silencing on Mrp2- or Pgp-
mediated drug transport in future. Furthermore, they may be useful for studying 
other ET-1-mediated processes and regulation of Mrp- and Pgp-mediated drug 
transport. Here, we discuss the advantages and disadvantages of these three 
research models.  
 
 
Epithelial cell lines 
 
Three rat epithelial cell lines of renal (NRK-52E and GERP) and intestinal (IEC-
6) origin were selected. Although this thesis concentrates on the kidney, we 
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characterized an intestinal cell line in addition to two renal cell lines. Comparable 
to the kidney, the intestine has a major function in many drug transport processes, 
and ET-1 plays a role in various intestinal diseases (Miura et al., 1996; Wolfard et 
al., 2002). Moreover, this cell line was previously shown to express Mrp1 and 
Mrp3, as well as ET-1 and its receptors (Li et al., 2003; Shigematsu et al., 1998).  
The three rat epithelial cell lines showed expression of Pgp and several Mrp 
transporters. Mrp2, which was found to be regulated by ET-1 in killifish renal 
tubules (Masereeuw et al., 2000), however, was absent. In addition to transporter 
expression, we showed Pgp- and Mrp-dependent transport activity. In these cell 
lines, transport of the glutathione conjugate, glutathione-S-bimane, seemed to be 
mediated via Mrp4 (Chapter 5). ET-1 and the ET-receptors were also found to be 
expressed in the three cell lines. ET-1 excretion from GERP cells was hardly 
detectable, but IEC-6 and NRK-52E cells showed high excretion levels, induced by 
exposure to inflammatory cytokines (Chapter 3).  
Although they lack Mrp2, the NRK-52E cell line and IEC-6 cell line may 
provide suitable models to study the effects of ET-1 silencing on Pgp transport 
activity and, eventually, on other ET-1-mediated signaling pathways. In addition, 
the three cell lines may be useful for the study of Pgp- and Mrp-dependent 
transport processes. To study the vectorial transport of drugs, these cells need to be 
characterized further for the presence of other transporters, like organic anion 
(OAT) and cation (OCT) uptake transporters.  
In a first attempt to silence ET-1 expression in vitro, we tested different 
antisense and siRNA-mediated gene silencing approaches. Despite successful 
transfection, we did not observe a specific silencing of ET-1 expression (Chapter 4). 
Effectiveness of ET-1 gene silencing depends on many factors, like transfection 
efficiency, half-life of ET-1, time-frame of measurement, and sequence. Eventually, 
other approaches, in which these factors could be controlled, may be successful in 
silencing ET-1 expression in future.  
Before the effects of ET-1 silencing on transport function can be studied in these 
cell lines, the regulation of Pgp expression and activity by ET-1 and 
nephrotoxicants should be investigated. ET-1 regulates Pgp expression in other 
research models (Hartz et al., 2004; Masereeuw et al., 2000), but this has not yet 
been described in the cell lines studied in this thesis.  
An advantage of cell lines over the use of in vivo animal models is that a 
relatively large amount of data can be obtained rapidly. The effects of different 
antisense oligodeoxynucleotides (ODNs) or short interfering RNA (siRNA) 
duplexes, as well as the effects of many other factors, can be screened relatively 
easy. Antisense ODNs or siRNA duplexes found to be effective in vitro, however, 
do not guarantee to be effective in vivo and vice versa. Moreover, transfection is 
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required for the cellular delivery of antisense ODNs or siRNA in vitro. In the in 
vivo situation, however, additional transfection methods do not seem to be 
necessary for an effective cellular uptake and gene silencing effect (Juliano et al., 
1999).  
A disadvantage of cell lines over the use of in vivo animal models is that these 
cell lines are not useful for the study of the role of ET-1 in renal injury. For the 
study of the beneficial effects of ET-1 silencing on drug-induced renal injury a 
more physiological in vivo model may be more appropriate.  
 
 
Killifish model 
 
Isolated killifish renal tubules are a unique model, in which renal transepithelial 
transport processes can be studied. Killifish kidneys contain a high proportion of 
proximal tubules, which show expression of transporters, like Pgp and Mrp2, with 
many transport characteristics comparable to those found in mammalian cells. In 
addition, they form, in contrast to mammalian renal tubules, closed, fluid filled 
compartments after isolation. By determining the accumulation of fluorescent 
substrates, like FL-MTX for Mrp2 and NDB-CSA for Pgp, in this fluid filled 
compartment, transepithelial transport activity can be quantified (Masereeuw et 
al., 1996; Schramm et al., 1995).  
In previous studies by our lab, the signaling pathway that regulates Mrp2- and 
Pgp-dependent transport activity after exposure to ET-1 or nephrotoxic agents was 
revealed in isolated killifish proximal tubules (Masereeuw et al., 2000). To learn 
more about the regulation of Mrp2 expression and activity, we investigated the 
potential role of nuclear receptors in this process. Expression and transport activity 
were affected by dexamethasone via activation of the glucocorticoid receptor. 
Exposure to different ligands of the pregnane xenobiotic receptor (PXR) and the 
farnesoid xenobiotic receptor (FXR) did not reveal a role for these receptors in the 
regulation of Mrp2 in killifish renal tubules (Chapter 6). In future, the regulation of 
transporter expression and the ET-1 signaling pathway may be investigated further 
in this model.  
The killifish model is suitable to study ET-1 silencing effects on drug transport 
in future, since all components of the ET-1 signaling pathway are functionally 
present. Currently, however, there are still some practical problems in the 
application of antisense ODNs or siRNA in this model. The full genome of the 
killifish has not been sequenced yet, and the nucleotide sequence coding for ET-1 
in this species is still unknown. Until then, other fish, of which the ET-1 sequence 
is known, like the zebrafish (Danio Rerio), may provide a suitable alternative 
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(Miller et al., 2000). Pilot studies in our lab showed that, similar to killifish, 
exposure of zebrafish renal tubules to ET-1 reduced Mrp2-mediated transport 
(Masereeuw, unpublished data).  
When the ET-1 sequence in killifish will be identified, isolated tubules can be 
transfected with antisense ODNs or siRNA duplexes in order to study the effects of 
ET-1 silencing on transport activity. Transfection of isolated killifish tubules 
appears possible, since successful transfection with rat Oat1 and Oct2 was shown 
earlier (Sweet et al., 1999; Sweet et al., 2000). In these studies, tubules remained 
viable and transport activity was measurable up to several days after transfection.  
For the direct measurement of ET-1 silencing effects on ET-1 protein excretion, 
a new method needs to be developed for the detection of killifish ET-1. Accurate 
and quantitative measurement of silencing effects on ET-1 mRNA expression in 
transporting tubules may be very complicated, since small amounts of non-
transporting tubules and remnants of hematopoietic tissue are always present in 
the tubule preparations.  
To study the role of ET-1 and ET-1 silencing in nephrotoxicant-induced renal 
injury, an in vivo model is more appropriate. In an in vivo fish model, whole 
animals can be injected with antisense ODNs or siRNA duplexes. After exposure to 
nephrotoxic agents, renal injury can be determined by histological examination. 
Recently, a zebrafish model was developed for the quantification and analysis of 
renal function in vivo (Hentschel et al., 2005). In this model, gene silencing effects 
on renal function after exposure to nephrotoxic agents can be measured.  
Also for other research purposes, fish can be used as efficient research models in 
gene silencing experiments. The antisense technology is, for example, frequently 
applied in zebrafish embryos as an effective silencing tool in the study to gene 
function and in developmental biology (Chen et al., 2004; Nasevicius et al., 2001). 
Furthermore, siRNA was found to be effective in fish embryos and can be used as a 
silencing tool to study gene function in fish as well (Boonanuntanasarn et al., 
2003).  
 
 
Rat in vivo model 
 
In rats, renal Mrp2 transport function can be studied in an isolated perfused 
kidney model (Masereeuw et al., 2003). In this model, long-term exposure to 
gentamicin was previously shown to induce Mrp2-mediated excretion, which 
could be ameliorated by the dual ET-receptor antagonist bosentan, indicating that 
long-term signaling of ET-1 via the ET-B receptor observed in killifish is present in 
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rat as well. In contrast, a short-term regulation of transport by gentamicin was not 
observed (Notenboom et al., 2006).  
A good in vivo model should be able to test the concept of ET-1 silencing on 
drug transport, overall renal function, and injury after nephrotoxicant exposure. 
The rat kidney proximal tubule is a suitable target for the application of antisense 
or siRNA in vivo. Previous studies showed that antisense ODNs accumulate 
spontaneously in the renal proximal tubule after intravenous administration 
(Bijsterbosch et al., 1997; Carome et al., 1997; Oberbauer et al., 1995). We observed 
a preferential accumulation of siRNA duplexes in the kidney as well. To determine 
whether gene function in the kidney proximal tubule could be silenced, rats were 
injected with siRNA duplexes against Mrp2. Silencing effects on this transporter 
could then be easily determined using the isolated perfused rat kidney model. 
Mrp2 function was inhibited after intravenous injection with siRNA against Mrp2, 
indicating that siRNA duplexes likely accumulate in the proximal tubular part of 
the kidney (Chapter 7).  
Other delivery methods, like hydrodynamic injection or injection of siRNA via 
the renal artery followed by electroporation, were successful in silencing renal 
gene expression in vivo as well (Hamar et al., 2004; Takabatake et al., 2005). 
Besides synthetic siRNA, in vivo gene silencing can be established using siRNA-
expressing vectors or viral systems. Pilot studies in our lab showed tubular 
expression of green fluorescent protein (GFP) after direct injection of GFP-
expressing lentivirus and baculovirus particles in rat renal cortex (Heemskerk and 
Huls, unpublished data). Possibly this method is effective in the renal delivery of 
an siRNA-expressing virus as well.  
In this thesis, we did not yet investigate the effects of ET-1 silencing in vivo. 
SiRNA is a relatively new method and the potential in vivo applications of this 
technique are still unexplored. Having shown renal accumulation of siRNA and 
silencing of gene function, the application of this technique in vivo seems 
promising. In future experiments, our rat model can be used to study the effects of 
ET-1 silencing on nephrotoxicant-induced renal injury and Mrp2 transport 
function. The effects of ET-1 gene silencing may be compared with the use of the 
ET-receptor antagonist bosentan, or with other, more specific, ET-receptor 
antagonists.  
 
 
Future perspective: ET-1 gene silencing as a potential therapy? 
 
The different experimental models described in this thesis may contribute to the 
development of an ET-1 gene silencing approach, which may be effective in the 
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prevention or treatment of nephrotoxicant-induced renal injury. To be an effective 
therapy against the short-term reduction in Mrp2 and Pgp transport activity 
observed in killifish, antisense or siRNA treatment should be started before 
nephrotoxicant exposure. In situations in which nephrotoxicant exposure is 
predictable, for example when using radiocontrast agents in diagnostics and 
aminoglycoside antibiotics in therapy, pretreatment with gene silencing methods 
may be useful.  
The rapid inhibition of drug transport observed in killifish, however, did not 
seem to be present in mammals (Notenboom et al., 2006). Nevertheless, exposure to 
nephrotoxic agents has long-term consequences, which are mediated via ET-1 as 
well (Notenboom et al., 2005; Notenboom et al., 2006). Although upregulation of 
transport observed after long-term exposure seems to serve a protective function, 
long-term exposure to nephrotoxic compounds still may cause injury. Moreover, 
many renal disease conditions are associated with enhanced ET-1 levels (Kohan, 
1997; Naicker et al., 2001). Therefore, silencing of ET-1 expression may also be 
beneficial in the treatment or prevention of renal injury after long-term exposure 
to nephrotoxic agents.  
Before antisense or siRNA can be applied as a therapy against nephrotoxicant-
induced renal injury, additional optimalisation studies are necessary. Although 
widely used as a gene silencing tool in vitro, the use of antisense and siRNA in 
human therapy is limited. For antisense ODNs, a few clinical trials have been 
reported (Agrawal et al., 2000; Kurreck, 2003). Most of these sequences are directed 
against abnormal or non-human genes, like mutated genes in cancer and viral 
genes, or they do not require intravenous administration for effective delivery. In 
these situations, targeting problems play a minor role in their therapeutic 
effectiveness. Targeted silencing of endogenous genes where intravenous 
administration is required, however, appears far more problematic and less 
effective. For siRNA, the potential therapeutic applications were not investigated 
yet, but probably studies in laboratory animals and clinical trials in humans will 
increase in the next few years. Similar to antisense, targeting problems will likely 
limit the effective therapeutic use of siRNA to a great extent. Also off-target effects 
like immunogenicity, aspecific silencing and induction of stress response genes and 
genes involved in apoptosis are to be expected with certain siRNA sequences and 
should be investigated very carefully (reviewed in Paroo et al., 2004; Sioud, 2004; 
Stein et al., 2005).  
Because of the many problems that may arise when using siRNA as a therapy, 
the application of ET-1 gene silencing in the treatment of nephrotoxicant-induced 
renal disease in human is still far future. In this case, targeted delivery may form 
one of the major obstacles, since local and site-directed silencing of ET-1 is crucial. 
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Silencing of ET-1 in other parts of the body, like the systemic circulation, may 
have detrimental effects. Therefore, intravenous administration may not be the 
delivery method of choice and other, safer delivery methods need to be developed.  
In conclusion, we characterized several in vitro and in vivo models for various 
aspects of ET-1 expression and excretion, transport activity, regulation of drug 
transport, and gene silencing. Each of these models has its own merits and they 
may be useful in future for the study of the effects of ET-1 gene silencing on drug 
transport activity and drug-induced renal injury. Moreover, they may aid in the 
development of a therapy against drug-induced or ET-1-mediated renal injury. 
Antisense- or siRNA-mediated treatment of renal injury in human, however, is still 
far future, and major problems have to be solved.  
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SUMMARY 
 
The kidney has a detoxification function by excreting many xenobiotics, their 
metabolites, and metabolic waste products into the urine. Transporters expressed in 
the renal proximal tubule, like the multidrug resistance 1/P-glycoprotein 
(MDR1/Pgp) and several members of the family of the multidrug resistance 
proteins (MRP/ABCC), MRP2 and MRP4 (Schaub et al., 1997; Thiebaut et al., 1987; 
van Aubel et al., 2002), play an important role in this detoxification process. In our 
lab, the vasoactive hormone endothelin-1 (ET-1) was found to regulate Pgp and 
Mrp2 transport activity in the proximal tubule of the kidney (Masereeuw et al., 
2000). Exposure to nephrotoxic agents induced ET-1 production, leading to a rapid 
decrease in transport activity. As a result, a diminished urinary efflux of potentially 
toxic drugs and metabolic waste products may cause renal injury. Also via other 
signaling pathways, excessive ET-1 formation may cause renal injury, and many 
renal diseases are associated with elevated ET-1 levels (Kohan, 1997; Naicker et al., 
2001). As described in chapter 1, we hypothesized that inhibition of increased ET-1 
production in the renal proximal tubule may protect against drug-induced injury. 
Compared with the classical pharmacological approach using ET-receptor 
antagonists, gene silencing of ET-1 with antisense oligodeoxynucleotides (ODNs) 
or short interfering RNA (siRNA) may provide a more site-directed therapy with 
less side effects to be expected.  
The aim of this thesis was to develop in vitro and in vivo models, in which the 
effects of ET-1 gene silencing on Pgp and Mrp2 transport and renal injury can be 
studied. For this purpose, we investigated some aspects regarding ET-1 expression 
and excretion, activity and regulation of drug transport, and gene silencing by 
antisense and siRNA in three different experimental models. Experiments were 
performed in rat epithelial cell lines, in isolated killifish renal tubules, and in rats 
in vivo. These models may be used for the further development of appropriate in 
vitro and in vivo research tools, to study the effects of ET-1 gene silencing on 
Mrp2- and Pgp-mediated transport and renal injury.  
In chapter 2, an overview of the current knowledge on the function and 
regulation of renal MRPs is given. To date, nine structurally and functionally 
related MRP family members (MRP1-9) have been identified. The MRPs expressed 
in the kidney play a critical role in the renal elimination of a wide variety of 
organic anionic drugs and toxicants, and, in particular, of their negatively charged 
conjugation products (e.g. glutathione, glucuronide and sulfate conjugates). During 
altered physiological circumstances, adaptations in these transporters are required 
to avoid systemic toxicity as well as renal tubular damage. Hormones, protein 
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kinases, nuclear receptors, and disease conditions play a key role in these events, 
and their effects on MRP transporter expression and function are discussed in this 
chapter.  
Chapter 3 describes the characterization of three rat epithelial cell lines for ET-1 
and ET-receptor expression, as well as inducibility of ET-1 by inflammatory 
cytokines. In order to study ET-1 function and its role in pathophysiological 
processes in vitro, experiments were performed in two renal (NRK-52E and GERP) 
cell lines, and one intestinal (IEC-6) cell line. The intestinal cell line was used, 
since ET-1 has many functions in the intestine similar to the kidney. Furthermore, 
various intestinal diseases are associated with high ET-1 levels. All three cell lines 
showed expression of ET-1, the ET-A, and the ET-B receptor. Exposure to the 
inflammatory cytokines tumor necrosis factor α and interleukin-1β induced ET-1 
excretion from IEC-6 and NRK-52E cells, while interleukin-2 did not. ET-1 
excretion from GERP cells was hardly detectable.  
Having shown ET-1 expression and induction by cytokines in NRK-52E an IEC-
6 cells, a first attempt to silence ET-1 expression in vitro was made in chapter 4. 
Renal NRK-52E cells or intestinal IEC-6 cells were exposed to antisense ODNs or 
siRNA-expressing vectors using different approaches. The four methods tested 
caused varying degrees of transfection, with highest, nearly 100%, efficiencies 
obtained with a green fluorescent protein-expressing vector in NRK-52E cells using 
electroporation. Despite an effective transfection, a reduction of ET-1 excretion 
was not observed. The data presented in this chapter show the complexity of 
silencing ET-1 expression in vitro, and some of the factors that determine the 
success of gene silencing are discussed.  
In addition to ET-1, the three rat cell lines were characterized for drug 
transporter expression and functionality, to investigate whether these cell lines 
may be suitable to study drug transport. Currently, a few cell lines, which often 
overexpress a human transporter, exist for drug transport studies. Our rat epithelial 
cell lines provide a more physiological model that may aid in the extrapolation of 
in vitro experiments to laboratory animal research, and possibly to clarify species 
differences. Chapter 5 describes Pgp and Mrp expression, and transport activity in 
NRK-52E, GERP, and IEC-6 cells. The three rat epithelial cell lines showed Pgp 
expression and transport activity, both decreasing with culture time after reaching 
confluency. Besides Pgp, cells expressed Mrp1, Mrp3, Mrp4, and Mrp5, while Mrp2 
and Mrp6 were absent. Cellular excretion of glutathione-S-bimane was 
temperature- and Mrp-dependent. Exposure to a panel of different inhibitors 
showed that the efflux of this compound was probably mediated by Mrp4.  
In chapter 6, isolated killifish renal proximal tubules were used. Previously, the 
ET-1- and nephrotoxicant-induced signaling mechanisms, leading to altered Mrp2 
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and Pgp expression and function, were elucidated using this experimental model 
(Masereeuw et al., 2000; Terlouw et al., 2001). Here the role of ligand activated 
nuclear receptors in the regulation of Mrp2 expression and function was 
investigated. Except for dexamethasone, different ligands of the pregnane 
xenobiotic receptor (PXR) and farnesoid xenobiotic receptor (FXR), two nuclear 
receptors previously shown to regulate Mrp2 in mammalian liver (Kast et al., 
2002), did not induce Mrp2-mediated transport in isolated killifish renal tubules. 
Since the other ligands were without effects, activation of PXR by dexamethasone 
did not seem to be involved in the regulation of Mrp2. Dexamethasone also did not 
interfere with the ET-1 signaling pathway, since an inhibitor of nitric oxide 
synthase, an element of this pathway, did not alter the effects of dexamethasone. In 
contrast, the glucocorticoid receptor blocker, RU-486, ameliorated the effects of 
dexamethasone, indicating that dexamethasone induced Mrp2 expression and 
function via interference with the glucocorticoid receptor.  
In chapter 7, the potential in vivo application of siRNA was investigated in the 
rat. Antisense ODNs were previously shown to accumulate spontaneously in the 
renal proximal tubule after intravenous administration (Bijsterbosch et al., 1997; 
Carome et al., 1997; Oberbauer et al., 1995). Although its potential therapeutic 
applications seem very promising, not much is yet known about the in vivo 
behavior of siRNA duplexes. We showed that, like antisense ODNs, intravenously 
administered siRNA duplexes preferentially accumulate in the kidney. A single 
intravenous injection of siRNA duplexes directed against Mrp2 was sufficient to 
selectively silence Mrp2 transport function in the renal proximal tubule.  
Chapter 8 discusses the advantages and disadvantages of the three different 
experimental models investigated in this thesis and their potential applications. 
The rat epithelial cell lines are potentially useful models for the study of ET-1 
function and drug transport. In order to study vectorial transport of drugs, 
however, cells need to be characterized further for uptake transporters. For the 
analysis of the effects of ET-1 gene silencing on drug transport, the regulation of 
drug transport by ET-1 and nephrotoxicants still needs to be investigated in these 
cell lines. Killifish tubules are a unique model to study ET-1 signaling events and 
regulation of Mrp2- and Pgp-mediated transport, since all components of the ET-1 
signaling pathway are functionally present. When the ET-1 sequence has been 
identified in this species, the effects of ET-1 silencing can be studied as well. The in 
vivo rat model may be used to study the effects of ET-1 gene silencing on Mrp2 
transport activity and renal injury in future experiments. The effects of ET-1 
silencing may be compared with other therapeutic strategies, like the application of 
ET-receptor antagonists.  
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SAMENVATTING 
 
De nier heeft een belangrijke ontgiftingsfunctie door lichaamsvreemde stoffen 
(xenobiotica), hun afbraakproducten en metabole afvalstoffen in de urine uit te 
scheiden. Bij dit proces zijn verschillende transporteiwitten, zoals het 
multidrugresistentie-1/P-glycoproteïne (MDR1/Pgp) en enkele leden van de 
familie van de multidrugresistentie-proteïnes (MRP/ABCC), MRP2 en MRP4, 
betrokken. Deze transporteiwitten komen tot expressie in de proximale tubulus 
van de nier (Schaub et al., 1997; Thiebaut et al., 1987; van Aubel et al., 2002). 
Eerdere studies in ons lab met proximale tubuli van de killifish (tandkarper) 
toonden aan dat het vaatactieve hormoon, endotheline-1 (ET-1), de activiteit van 
Pgp en Mrp2 reguleert (Masereeuw et al., 2000). Blootstelling aan nierschadelijke 
stoffen leidde tot een verhoogde productie van ET-1, hetgeen een snelle 
vermindering van transportactiviteit tot gevolg had. Hierdoor zou een verminderde 
uitscheiding van schadelijke stoffen en afvalproducten kunnen leiden tot 
nierschade. Ook via andere signaaltransductieroutes kan ET-1 nierschade 
veroorzaken en veel nierziekten gaan gepaard met verhoogde ET-1-bloedspiegels 
(Kohan, 1997; Naicker et al., 2001). In hoofdstuk 1 veronderstelden we dat het 
tegengaan van een verhoogde productie van ET-1 in de proximale tubulus van de 
nier mogelijk kan beschermen tegen nierschade ten gevolge van blootstelling aan 
schadelijke stoffen. Vergeleken met de klassieke farmacologische benadering, 
waarin ET-receptorantagonisten worden gebruikt, kan uitschakeling van ET-1-
expressie met behulp van antisense oligodeoxynucleotiden (ODNs) of kort-
interfererend (‘short interfering’) RNA (siRNA) een betere doelgerichte therapie 
vormen met minder bijwerkingen.  
Het doel van dit proefschrift was in vitro- en in vivo-modellen te ontwikkelen 
waarin de effecten van ET-1-geninhibitie op Pgp- en Mrp2-afhankelijk transport 
en nierschade bestudeerd kunnen worden. Hiertoe zijn enkele aspecten van ET-1-
expressie en -excretie, de activiteit en regulatie van Pgp- en Mrp-transporteiwitten 
in de nier, en remming van genexpressie door antisense en siRNA onderzocht in 
drie verschillende modellen. De experimenten zijn uitgevoerd in epitheliale 
cellijnen van de rat, in geïsoleerde nierbuisjes van de killifish en in de rat in vivo. 
Deze modellen kunnen verder worden ontwikkeld om de effecten van 
uitschakeling van ET-1-genexpressie op Mrp2- en Pgp-afhankelijk transport en 
nierschade nader te bestuderen.  
In hoofdstuk 2 wordt een overzicht gegeven van de literatuur met betrekking tot 
de transportactiviteit en regulatie van de MRP-eiwitten in de nier. Tot nu toe zijn 
er negen verschillende MRP-eiwitten (MRP1-9) geïdentificeerd die structureel en 
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functioneel aan elkaar verwant zijn. De MRPs die in de nier tot expressie komen 
spelen een belangrijke rol in de uitscheiding van een breed scala aan organische 
anionen en, in het bijzonder, van negatief geladen conjugaten van 
lichaamsvreemde stoffen (onder meer glutathion-, glucuronide- en 
sulfaatconjugaten). Wanneer fysiologische omstandigheden veranderen, zijn 
aanpassingen in de expressie en activiteit van deze transporteiwitten nodig om 
toxiciteit en schade in de nier en de rest van het lichaam te voorkomen. 
Hormonen, proteïnekinasen, nucleaire receptoren en verscheidene ziektecondities 
hebben allen een effect op MRP-expressie en -functie. De invloed van deze 
factoren wordt besproken in hoofdstuk 2.  
Hoofdstuk 3 beschrijft de karakterisering van drie epitheliale cellijnen van de rat 
op aanwezigheid van ET-1 en de ET-receptoren. Tevens wordt hierin de activatie 
van ET-1-productie door inflammatoire cytokinen beschreven. Om de functie van 
ET-1 en diens rol in pathologische processen in vitro te kunnen bestuderen, zijn 
experimenten in twee niercellijnen (NRK-52E en GERP) en een darmcellijn (IEC-
6) uitgevoerd. Omdat vele ET-1-functies in de darm vergelijkbaar zijn met die in de 
nieren, en enkele darmziekten geassocieerd zijn met hoge ET-1-bloedspiegels, is 
eveneens een darmcellijn getest. De drie cellijnen bleken ET-1 en de ET-A- en ET-
B-receptor tot expressie te brengen. Blootstelling aan de ontstekingsmediatoren, 
tumornecrosefactor-α en interleukine-1β, leidde tot een verhoogde uitscheiding 
van ET-1 in IEC-6- en NRK-52E-cellen, terwijl interleukine-2 geen effect had. In 
GERP-cellen was ET-1-uitscheiding nagenoeg niet detecteerbaar.  
Nadat was aangetoond dat NRK-52E- en IEC-6-cellen ET-1 tot expressie 
brengen, zijn in hoofdstuk 4 enkele pogingen om ET-1-expressie in vitro uit te 
schakelen beschreven. Verschillende methoden, waarin gebruik werd gemaakt van 
antisense ODNs of vectoren die siRNA tot expressie brengen, zijn getest in NRK-
52E- en IEC-6-cellen. Deze methoden leidden tot een verschillende mate van 
transfectie. De hoogste efficiëntie, van bijna 100%, werd bereikt met een 
expressievector in NRK-52E-cellen met behulp van electroporatie. Desondanks 
leidde geen van de gebruikte methoden tot een specifieke remming van de 
uitscheiding van ET-1. Onze eerste pogingen om ET-1 uit te schakelen tonen de 
complexiteit van ET-1-geninhibitie in vitro aan en enkele factoren die het al dan 
niet slagen van geninhibitie bepalen worden beschreven in dit hoofdstuk.  
Naast ET-1, zijn de drie rattencellijnen gekarakteriseerd ten aanzien van 
expressie en functie van transporteiwitten, om te onderzoeken of deze cellijnen 
gebruikt kunnen worden om Mrp- en Pgp-afhankelijke transportprocessen te 
bestuderen. Momenteel bestaan er maar enkele cellijnen die geschikt zijn voor het 
onderzoek naar geneesmiddeltransport. Veelal gaat het om zoogdiercellijnen 
waarin een (meestal humane) transporter tot overexpressie is gebracht. Onze 
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epitheliale rattencellijnen vormen daarentegen een meer fysiologisch model en zij 
kunnen bijdragen aan het oplossen van de extrapolatieproblemen van in vitro- naar 
proefdieronderzoek en mogelijk speciesverschillen verklaren. Hoofdstuk 5 
beschrijft de Pgp- en Mrp-expressie en transportactiviteit in NRK-52E-, GERP- en 
IEC-6-cellen. In alle drie de cellijnen komt Pgp tot expressie en zowel expressie als 
transportactiviteit nemen af nadat de cellen een confluente laag hebben gevormd. 
Ook Mrp1, Mrp3, Mrp4 en Mrp5 komen tot expressie, terwijl Mrp2 en Mrp6 
afwezig zijn. Het transport van het glutathionconjugaat, glutathion-S-bimane, in 
deze cellen bleek temperatuur- en Mrp-afhankelijk. Een combinatie van 
verschillende remmers toonde aan dat dit transport waarschijnlijk gemedieerd is 
door Mrp4.  
In hoofdstuk 6 zijn geïsoleerde proximale tubuli van de killifish gebruikt. In dit 
model was eerder aangetoond dat nierschadelijke stoffen en ET-1 de expressie van 
Mrp2 en Pgp beïnvloeden via activatie van een ET-1-gemedieerde 
signaaltransductieroute (Masereeuw et al., 2000; Terlouw et al., 2001). Wij hebben 
de rol van ligand-geactiveerde nucleaire receptoren op de regulatie van Mrp2 
onderzocht. De pregnane-xenobiotic-receptor (PXR) en farnesoïd-xenobiotic-
receptor (FXR) zijn bekende activatoren van Mrp2-expressie in de lever van 
zoogdieren (Kast et al., 2002). Behalve dexamethason, veroorzaakte geen van de 
geteste PXR- en FXR-liganden een verhoging van Mrp2-afhankelijk transport in de 
niertubuli van de killifish. Het effect van dexamethason bleek niet van invloed op 
de ET-1-signaalcascade, omdat een remmer van het stikstofoxidesynthase, een 
onderdeel van deze cascade, de effecten van dexamethason niet veranderde. 
Echter, toevoeging van de glucocorticoïdreceptorblokker, RU-486, resulteerde in 
een minder sterk effect van dexamethason op Mrp2-gemedieerd transport. Deze 
resultaten tonen aan dat dexamethason de expressie en functie van Mrp2 activeert 
door te interfereren met de glucocorticoïdreceptor.  
In hoofdstuk 7 is de mogelijke in vivo-toepassing van siRNA bestudeerd in de 
rat. Eerder onderzoek liet zien dat antisense ODNs na intraveneuze toediening 
spontaan in de proximale tubuluscellen van de nier ophopen (Bijsterbosch et al., 
1997; Carome et al., 1997; Oberbauer et al., 1995). Omdat de therapeutische 
toepassingen van siRNA veelbelovend zijn, maar er nog niet veel over het in vivo-
gedrag bekend is, hebben we de biodistributie van siRNA in de rat bestudeerd. Net 
als antisense ODNs, hopen intraveneus toegediende siRNA-duplexen op in de nier. 
Een enkele intraveneuze injectie van siRNA bleek voldoende om de functie van 
Mrp2 in de nier specifiek te remmen.  
In hoofdstuk 8 worden de voor- en nadelen van de drie gebruikte 
onderzoeksmodellen en hun mogelijke toepassingen besproken. De epitheliale 
rattencellijnen vormen een bruikbaar model om zowel de functie van ET-1 als Pgp- 
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en Mrp-afhankelijk transport te bestuderen. Om het vectoriële transport van 
stoffen te kunnen bestuderen, moeten deze cellijnen echter verder 
gekarakteriseerd worden op onder andere de aanwezigheid van transporteiwitten 
voor de opname van xenobiotica. Bovendien moet de regulatie van transport door 
ET-1 en nierschadelijke stoffen in deze cellijnen nader worden onderzocht. De 
killifish is zeer geschikt om de ET-1-signaaltransductie en de regulatie van Mrp2- 
en Pgp-afhankelijk transport verder te onderzoeken, omdat alle elementen van de 
signaaltransductieroute functioneel aanwezig zijn. Als de nucleotidesequentie van 
ET-1 in killifish bekend is, kan het bovendien gebruikt worden om de effecten van 
ET-1-geninhibitie te bestuderen. Het in vivo-rattenmodel kan gebruikt worden om 
de effecten van ET-1-geninhibitie op Mrp2-transportactiviteit en nierschade verder 
te bestuderen. De effecten kunnen vervolgens vergeleken worden met andere 
therapeutische toepassingen, zoals het gebruik van ET-receptorantagonisten.  
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Sylvia Notenboom, met jou naast me in het U-tje heb ik een ontzettend leuke 
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of opgeofferd wegens schimmel! De vele leuke momenten samen zijn onvergetelijk 
en er gaan er vast nog veel meer volgen.  
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